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Vaccination has important clinical potential in the immunotherapy of both infectious 
disease and cancer.  The central aim of the studies reported in this thesis has been the 
development of vaccination strategies that will be effective for therapeutic 
applications in cancer.  Using ovalbumin antigen in a mouse model, we have 
examined a combination of recently developed adjuvants referred to as CASAC 
(combined adjuvants for synergistic stimulation of cellular immunity) to optimise the 
efficacy of vaccination induced T cell mediated immunity. These studies have 
examined the effect of repeated rounds of vaccination with one, or alternating cycles 
of two different helper peptides. The hypothesis was that repeated stimulation of the 
same clonal population of CD4+ T helper cells with a single MHC class II peptide 
could induce anergy, exhaustion, clonal deletion and/or stimulation of regulatory T-
cells, resulting in reduced and shorter lived immunity.  These studies have also 
examined the effect of inclusion of other immune regulatory components, and in 
particular a cocktail of cytokines generated by phytohemagglutinin stimulation of 
human peripheral blood mononuclear cells (referred to as IRX-2).  Another 
important issue for vaccination mediated immune therapy that was addressed is the 
age-associated loss of immunological competence (immunesenescence).  
A comparative analysis is reported of the magnitude and duration of responses to 
vaccination with a single MHC class-I presented peptide in combination with the 
same or alternating MHC class-II presented peptides. In addition, we have quantified 
the number of antigen specific CD8 T cells, their effector and memory subsets and in 
vivo antigen specific cytolytic activity to examine the effect of CASAC vaccination 
alone or in combination with IRX-2. The induction of immunological responses in 
young and aged immune backgrounds was also examined. 
Vaccinations with ovalbumin peptides in the CASAC adjuvant have shown higher 
percentages and numbers of antigen specific CD8 T cells with improved cytolytic 
activity when helper functions are stimulated by two different class-II peptides used 
in alternating cycles of vaccination, rather than repeated stimulation by the same 
class-II peptide. This conclusion can be confirmed with a repeated experiment. 
Analysis of T cells with a regulatory (Treg) phenotype (CD4+CD25+Foxp3+) showed 
that their expansion was reduced with the alternating T-helper peptide vaccination 
regimen. The addition of IRX-2 to the CASAC vaccination regimen was found to 
enhance the in vivo antigen specific cytolytic activity.  This was particularly 
significant in the aged mice which were found to have increased levels of Tregs.
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This thesis describes studies aimed at enhancing the generation of CD8 T-cell 
responses by peptide vaccination, using a number of novel vaccination regimens. 
Peptide vaccination has the potential to be of therapeutic value for the treatment of 
cancer and chronic infectious diseases but would require the right combination of 
adjuvants, timing, induction of suitable helper functions, etc., without the stimulation 
of immune suppressive functions. In this chapter, previously published studies that 




Vaccination is the administration of antigenic material to produce immunity against 
certain diseases. There are also emerging vaccination strategies for the induction of 
antigen specific tolerance, but they are not the subject of this review. Antigens used 
in vaccinations range from live viruses or bacteria to peptides of proteins associated 
with the disease target. Edward Jenner marked the beginning of vaccination by using 
cowpox to give protection against smallpox in humans in 1796. Injecting the 
harmless form of a disease organism, Jenner utilized the specificity and memory of 
the acquired immune response to lay the foundation to modern vaccination 
strategies1. The two main types of cancer vaccination are prophylactic and 
therapeutic cancer vaccines. The latter are substantially more challenging, as the 
disease would have co-existed for a long time with the immune system and have 
finally escaped immune surveillance. At this stage, almost by definition, tumour 
tolerance would have been induced2, 3.  
A previously published study by Chan et al. (2006), showed an example of tumour 
escape by acute myeloid leukaemia (AML) cells by downregulation of the B7.1. 
Downregulation of B7.1 molecule, a co-stimulatory molecule required for activation 
of CD8 T-cells, enabled the tumour to escape the immunesurveillance4. The modern 
history of cancer vaccination started in the 1970s when Hanna et al., showed tumour 
regression in vaccinated guinea pigs, using irradiated hepatocellular carcinoma cells 
and bacillus Calmette-Guérin (BCG) as an adjuvant5, 6. BCG, an attenuated 
Mycobacterium bovis was a vaccine first used in humans in 1921 to confer immunity 
towards tuberculosis7. BCG contains pathogen-associated molecular patterns that 
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stimulate the innate immune system and thus provide Th1 responses that lead to 
improved generation of cytotoxic T-cells, providing the protective immunological 
responses in the vaccinated guinea pigs. BCG is currently studied for its efficacy as 
an adjuvant used in vaccinations against autologous tumour cells in a number of 
clinical studies. For instance, a Phase III study of the benefits of BCG as an adjuvant 
(Patented as OncoVax®) in 2005 showed statistically significant 5-year survival and 
recurrence free survival in Stage II colon cancer patients8. In various forms of 
tumour cell vaccination, tumour cells maybe rendered replication incompetent (e.g. 
by ionizing irradiation) and administered alone or in combination with different 
adjuvants (e.g. BCG). Alternatively, the tumour cells may be genetically modified to 
express immune stimulatory cytokines such GM-CSF, IL-2, IL-12, etc., or co-
stimulatory ligands such as B7.1 (CD80), B7.2 (CD86) and 4-1BBL (CD137)9-12. All 
such modifications enhance the immunogenicity of the tumours and achieve better 
immune stimulation, resulting in improved tumour rejection by the immune system.  
Peptide vaccination and peptide loaded dendritic cell-based immune therapy of 
cancer has also been attempted13 and Bakker et al., in 1995 generated anti-melanoma 
cytotoxic T-cells by presentation of melanoma tumour associated antigens14 on 
dendritic cells (DC). Immature monocyte-derived DC were loaded with Tumour 
associated antigen 15 peptides and then used in an autologous transplant to induce 
antigen-specific T-cell responses16. Immature DC were also injected into adjuvant 
pre-treated sites in mice and were found to be more effective than ex-vivo matured 
DC. This strategy showed that the injected DC acquired a lymph node migratory 
capacity comparable to ex-vivo matured DC17. TAA such as MAGE-A3 and NY-
ESO-1 have been utilised in peptide vaccinations in combination with a range of 
different adjuvants for several clinical trials in melanoma, non-small cell lung cancer 
(NSCLC) and ovarian carcinoma18-20. This subset of TAA, which are normally 
expressed in the testis and tumour cells, are also known as cancer testis antigens and 
expressed by a range of tumours. MAGE-A3 for example is found in lung cancer 
(35-50%), bladder cancer (35%), head and neck cancer (49%) and melanoma (74%), 
while it is absent in normal healthy cells18. Cancer vaccination strategies also include 
DNA vaccines where vectors (usually plasmids) encoding TAA are delivered to 
muscles as a strategy for the expression of TAA at high levels in sites away from the 
tumour (i.e. less immune suppressed environment) in combination with adjuvants, 
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e.g. super antigens expressed by pathogens (e.g. fragments of tetanus toxoid). In an 
example of this strategy, Chaise et al., demonstrated in 2008 that vaccination with a 
plasmid containing the gene encoding Wilms tumour antigen (WT1), fused to the 
first domain of tetanus toxin (DOM), could induce in a transgenic mouse expressing 
human HLA-A2 the activation of cytotoxic T-cells that were able to kill HLA-A2+  
human leukemic blasts in-vitro21. Genes for TAA were also introduced into viral 
vectors such as modified vaccinia Ankara (MVA) virus in combination with co-
stimulatory factors as a DNA vaccine that generated tumour-specific immune 
responses and antitumor activity22. This approach was shown by Hodge et al. to 
induce the rejection of murine colon adenocarcinoma cells expressing human 
carcinoembryonic antigen (MC-38-CEA) following vaccination with MVA 
expressing CEA and a Triad of co-stimulatory molecules (TRICOM which includes 
B7.1, ICAM-1 and LFA-3)22. Cancer vaccination strategies are still largely in 
clinical trials, but there has been a variety of approved immunotherapy methods (see 
Table 1.1). The presence of a variety of approved immune therapies and vaccination 
for cancer indicates its potential therapeutic value2.  
Other notable immunotherapy products are Ipilimumab and Provenge. Ipilimumab, a 
monoclonal antibody against CTLA-4 (an inhibitory receptor for T-cell generation) 
has been extensively reviewed23 and shown to have therapeutic benefits in metastatic 
melanoma24. Sipuleucel-T (Provenge) on the other hand, is an autologous cellular 
immunotherapy approved by the American Food and Drug Association (FDA) for 
the treatment of metastatic castration-resistant prostate cancer25. It's efficacy against 
metastatic prostate cancer has been proven in a clinical trial where there was a 
reduction of 22% in the risk of death, representing a 4.1 months improvement in the 
median survival26.  




Table 1.1: Approved Immune therapies for cancer: Abbreviations: AML, acute 
myelogenous leukaemia; BCG, bacillus Calmette-Guérin; CLL, chronic lymphocytic 
leukaemia; DLI, donor lymphocyte infusion; FAP, familial adenomatous polyposis; 
HBV, hepatitis B virus; HPV, human papilloma virus; MALT, mucosal-associated 
lymphoid tissue; MTX, methotrexate; NHL, non-Hodgkin’s lymphoma; NSAID, 
nonsteroidal anti-inflammatory drug; RCC, renal cell carcinoma; VIN, vulvar 









The immune system can be divided into the innate immune system which encompass 
a system that does not require a specifically acquired immunity against a certain 
antigen, and the adaptive immune system which encompasses specifically acquired 
immunity against antigens or pathogens. The innate immune system is the frontline 
of the body’s defence system against bacteria and virus infections. It works by toll-
like receptors recognising certain pathogen-associated molecular patterns27. This 
recognition allows up-regulation of transcription factors such as NF-κB, IRF3, IRF5, 
etc, which eventually lead to the production of inflammatory cytokines and other 
effector molecules. 
After the onset of innate immunity, the secondary line of defence, adaptive immunity, 
takes over in the form of specifically acquired immunity. This is composed of B-cell 
mediated humoral immunity, involving the production of antibodies and the antigen 
specific cellular immunity which involves the activation of cytotoxic T-cells. B-cells 
produces about 108-109 B-cell receptor (BCR) on their cell surface and each B-cell 
when matured and terminally differentiated will only produce a single type of 
antibody which in turn will only recognize one specific antigen28. When a pathogen 
enters the body, it will be presented to a very large array of B-cells expressing about 
105 different antibody molecules making a very diverse variety of antibody 
molecules. The recognition of a pathogen by B-cell receptor molecule triggers the 
expansion of the B-cell clone to produce a high enough concentration of a given 
antibody to ensure effective eradication of infection. The complex of antibody and 
antigen activates phagocytosis when the antibody is detected by the antibody 
receptors on phagocytes. This complex would also lead to NK cell antibody-
dependant cell-mediated cytotoxicity (ADCC). Single antibody detection is not 
sufficient to elicit a response and it would require multiple antibodies to bind and 
trigger phagocytosis by cross-linking the surface receptors for antibodies. However, 
in immunotherapy especially with monoclonal antibodies, the efficacy of these 
antibodies are higher as they have been specifically selected for increased binding to 
pathogens. This eventually leads to the eradication of the pathogen1.  
Antibody mediated responses have played a crucial part in development of 
immunotherapy and now represent well established treatments for different types of 
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diseases including cancer. For instance Rituximab, a widely used monoclonal 
antibody, targets CD20 which is expressed on the surface of B cells, including non-
Hodgkin’s lymphoma (NHL) cells. When used in combination with 
cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), Rituximab 
therapy induces 76% complete remissions contrasted to 63% for CHOP treatment 
alone. However, antibody mediated rejection of solid tumours are less efficient, 
unless the antibody is engineered to induce more efficient ADCC which involves 
NK and macrophage mediated lysis of the antibody decorated target cells. One such 
example is cetuximab which targets colorectal cancer expressing high epidermal 
growth factor receptor (EGFR)29. Therefore based on our basic understanding of the 
immune system, we and many others predict that a much more effective tumour 
rejection response could be induced by the activation of cell mediated immunity. 
Cell mediated immunity could be induced by activating the host’s immune system 
with different vaccination regimens.  
Cell mediated, antigen specific, immunity is manifested by the activation of T-cells 
which are cytotoxic cells that are able to recognize and eradicate cells that are 
infected by intracellular organisms such as viruses. T-cells differentiate in the 
thymus and are capable of recognizing cells by the presence of foreign antigen 
derived peptides in the context of their own MHC molecule1. T-cell immunity differs 
from humoral immunity as they are capable of screening cells with their T-cell 
receptors (TCR) for the recognition of antigen in the context of major 
histocompatibility complex (MHC)1. The two major groups of MHC molecules are 
the MHC Class I which is recognized by CD8+ effector T-cells and the MHC Class 
II molecule which is recognized by CD4+ helper T-cells1. Antigens are taken up by 
the professional antigen presenting cells (e.g. dendritic cells) and are processed to 
small fragments which are then presented by the MHC molecules. This will be 
further elaborated in section 1.3. In addition to presentation of antigen on MHC 
molecules, other co-stimulatory factors are also required for activation of cytotoxic 
T-cells. Two main factors which are involved in the activation of T-cells are the B7.1 
and B7.2 co-stimulatory molecules which bind to the activatory receptor CD28 and 
inhibitory receptor CTLA-4 on T-cells. B7 family members of co-stimulators were 
first characterized to activate T-cell proliferation and to up-regulate the expression of 
IL-2 mRNA30. B7-CD28 interaction stimulates the proliferation and the activation of 
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cytotoxic resting T-cells31. However, it wasn’t until 1993 when the B7 family was 
shown to have distinct members, B7.l and B7.232. About the same time, it was also 
shown that B7.1 and B7.2 can bind not only to the activatory receptor CD28, but 
also to Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), the activation of which 
induces T-cell apoptosis33 (Figure 1.1). 
T-cell receptors are different from B-cell immunoglobulins (antibodies) in terms of 
recognition of foreign antigens. Antibodies are capable of recognizing pathogens and 
their immunogenic products within the body. Antibodies are secreted as soluble 
molecules which patrol the extracellular spaces of the body. T-cells receptors 
however recognizes composite ligands made up of short sequences of peptide bound 
to a self MHC complex. These interactions enable killing of cells infected with 
intracellular pathogens because they carry foreign antigenic peptides on their 
surface34.  
 
Figure 1.1 Antigen presentation: Presentation of antigen and the requirement of 
co-stimulatory factors to activate T-cells. Abbreviations: APC, Antigen presenting 
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In the human body, there are also two types of T-cells subdivided by their TCR due 
to the presence of 4 loci of TCR which are α, β, γ and δ. The majority of T-cells 
expresses a variable alpha chain, a variable beta chain, a constant alpha chain and a 
constant beta chain termed αβ T-cells because of the αβ heterodimers found on their 
cell surface (Figure 1.2 a and b). The other T-cell type, named γδ T-cells, constitute a 
minority group of T-cells (about 10% of total T-cells). The γδ T-cells are 
predominant until birth when the αβ T-cells takes over. In our studies, we will be 
focusing only on αβ T-cells. However, it is noted that a number of studies have 
shown efficacy for γδ T-cells activated with zoledronate to treat metastatic solid 
tumours in combination with other therapies in the clinic35. 
 
Figure 1.2 T-cell receptors: a) A schematic representation of αβ. Protein 
crystallographs of αβ T-cell receptor (b) which shows similarity to δγ T-cell receptor 
(c) (Adapted from Figure 3-12 and 3-29, Immunobiology, 6/e Garland Science 
2005)28  
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1.3 MHC Class I and Class II antigen presentation for activation of CD4+ and 
CD8+ T-cells 
Histocompatibility genes H-1, H-2 and H-3 were first characterized in 
transplantation studies when numerous genes which control the acceptance and 
rejection of transplants were discovered on antigen presenting cells in mouse 
models36. The product of these genes were found to fall into the MHC Class I and 
Class II glycoproteins which are involved in antigen presentation to T-cells. Figure 
1.3 shows a schematic representation of MHC Class I and Class II genes37. MHC 
Class I molecules are made up of a heavy 44kDa protein non-covalently linked to a 
smaller 12kDa polypeptide called a β2-microglobulin. As seen in Figure 1.3, the 
larger 44kDa polypeptide is organized into three globular domains namely α1, α2 
and α3. The whole MHC Class I molecule protrudes from the cell membrane. MHC 
Class II molecule, which is also a transmembrane glycoprotein, consists of an α and 
β polypeptide chain which is subdivided into 2 globular domains, α1 and α2; β1 and 
β2. Both MHC Class I and MHC Class II molecules present antigens but the peptides 
that are presented by them are different. MHC Class I molecules are only capable of 
presenting polypeptides of 8-9 amino acid residues. This is due to the fact that the 
binding groove of Class I molecule is closed at both ends and the binding takes place 
at peptide positions 2, 3, 5 and 7. Class II molecule on the other hand has an open 
groove and therefore able to present peptides ranging from 8 to 30 amino acids. The 
major anchorage pockets of the Class II are peptide positions 1, 4, 6, 7 and 9 with 
position 1 being the most important38.  
Antigens that are taken up by antigen presenting cells (APC) such as dendritic cells 
(DC), by phagocytosis or pinocytosis, are generally presented on MHC Class I 
molecules and presented to CD8+ T-cells for priming an immune response (This is 
called cross presentation). However, some antigens are digested by the immune 
proteasomes to form smaller peptide fragments and transported to the lumen of the 
endoplasmic reticulum via a peptide loading complex composed of calreticulin 
(CRT), Tapasin, Transporter associated with Antigen Processing (TAP) dimer and 
thiol oxidoreductase ERp57. ER aminopeptidase39 might be involved in trimming the 
peptide to an 8-10 amino acid sequence. The MHC Class I heavy chain associates 
with Calnexin chaperone to initiate folding and disulfide bond formation before 
binding to the peptide loading complex and beta-2-microglobulin (β2m). Once 
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peptide is loaded onto the MHC Class I, it will dissociate from the other complexes 
to form an MHC Class I molecule with β2m and the loaded peptide34. This is 










Figure 1.3 Schematic Representations of the Gene Organization of the Human 
HLA and Mouse H-2 Major Histocompatibility Complexes. Also presented is the 










Figure 1.4 Antigen processing and MHC Class I peptide presentation: 
Schematic presentation of antigen processing and MHC class I presentation (adapted 
from Cresswell et. al, 2005). Abbreviations ERAP, ER aminopeptidase; ER, 
endoplasmic reticulum; CNX, Calnexin; CRT, calreticulin; HC, Heavy chain; TAP, 
Transporter associated with Antigen Processing; Tpsn, Tapasin. 
 
Some infectious agents such mycobacteria replicate in the membrane bound vesicles 
in macrophages and are thus inaccessible to cytosolic proteasomes for degradation 
which will only occur after phagocytosis. However, during macrophage activation, 
proteases in these vesicles will degrade the protein into peptide fragments that bind 
to MHC Class II molecules and then presented to CD4+ T-cells. MHC Class II 
complexes are formed in the ER lumen together with an Invariant Chain (li) which 
blocks unspecific binding of peptides to the MHC class II molecules34. The complex 
is then transported to acidified vesicles where the li is cleaved by proteases leaving a 
short peptide fragment called CLIP on the MHC Class II complex. CLIP, which 
blocks peptide binding to MHC Class II, is released when HLA-DM binds to the 
MHC Class II in the presences of antigen peptide fragments. Once CLIP is released, 
peptides of 15-24 amino acid length bind to the MHC Class II molecule, which is 
then transported to the membrane for presentation34. This process is represented in 











Figure 1.5: MHC Class II presentation: (From Figure 1.5-10, Immunobiolgy, 6/e 
Garland Science 2005) 34 
 
Upon presentation of antigen on MHC molecules, T-cell priming can take place. The 
MHC Class I-antigen complex is recognized by the T-cell receptor (TCR) and the 
CD8 molecule. MHC Class II presented antigen on the other hand is recognised by 
TCR and CD4 molecule. This activates the T-cells via several signalling pathways 
and triggers clonal expansion as well as effector functions including the up-
regulation of cytokines such as IFN-γ, IL-2 and other inflammatory cytokines. T-cell 
activation will then take 4-5 days from its resting phase to a full blown activated 
state and trafficking of the activated T-cells to the site of infection34. The need for 
co-stimulatory factors is also noted and was explained in the previous section 
(Section 1.2). Generally, activation of CD8+ T-cells leads to effector functions while 
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1.4 Peptide vaccination and CD4+ T helper cells 
Work on cancer vaccination, as well as other peptide vaccinations has been centred 
on the activation of CD8+ T-cells, whereby MHC Class I restricted peptides are 
utilised either in combination with adjuvants and administered directly as a vaccine 
or by loading MHC class I restricted peptides onto dendritic cells ex-vivo before 
administration. However in a published review by Janssen et al., a consistent 
deficiency in memory CD8+ T-cells was shown when there was absence of CD4+ T-
cells or T-helper cells (TH)40. Depletion of CD4+ cells prior to vaccination was 
shown by Schoenberger et al., to block cytolytic capacity of peptide-specific T-cells 
in an in vitro stimulation assay after 14 days of vaccination41 showing the 
importance of CD4+ T-cell help. In the absence of help, secondary exposure to the 
antigen shows no secondary expansion of the CD8+ effector cells in vivo40. This 
clearly shows the importance of CD4+ TH cells in the generation of an effective 
immune response in terms of continued protective immunity provided by the antigen 
specific CD8+ effector T-cell40. A study by Sun et al. showed that mice that lack 
CD4+ T-cells were able to mount a primary response to Listeria monocytogenes with 
similar capacity to wild-type mice for eradication of infection. However, the 
protective capacity then decreases in the CD4 deficient mice, suggesting that CD8+ 
memory T-cells generated without CD4+ TH cells are unable to mount a response 
against a secondary infection42.  
Rocha et al. suggest that generation of CD8+ effector T-cells and CD8+ memory T-
cells are two separate entities and the generation of a strong effector response does 
not end with the generation of CD8+ memory T-cells. This implies that there is a 
separate process of CD8+ memory T-cell differentiation that might mimic B-cell 
memory generation, which depends on the help of antigen-specific CD4+ T cells. 
This process is irreversible and occurs progressively during the late expansion phase 
of the primary immune response with a similar mechanism; that is, the triggering of 
CD40 expression on B or CD8+ T-cells.43. CD4+ T-cell activation as an effect of 
MHC Class II peptide presentation produces cytokines that help the activation and 
expansion of CD8+ T-cells, eosinophils and macrophages, leading to more effective 
immune mediated protection including protective immunity against cancer and for 
therapeutic vaccinations against cancer44.  
                                                                                                  CHAPTER 1 
36 
 
Although it is clear that CD4+ T-cells are required to provide help for the 
proliferation of CD8+ T-cells and the differentiation of memory CD8+ T-cells, the 
method by which it is achieved is not entirely clear. An earlier model of help was 
introduced by Mitchison in 1987 whereby for the CD4+ T-cells to provide help in the 
form of cytokines, a cluster of 3 cells were required. This model requires CD4+ and 
CD8+ T-cells to be bind to the same APC, so that the local paracrine action of 
cytokines secreted by CD4+ T-cells binding the MHC class II molecules on the APC, 
would support the clonal expansion of the adjacent CD8+ T-cells which are bound to 
the MHC class I molecules of the same APC45. However, the probability of this 
happening is very low and a new model was introduced by Schoenberger et al. in 
1998, whereby the CD4+ cells activate DC via CD40L-CD40 interaction resulting in 
a “licensed” DC to become fully competent to activate naive CD8+ T-cells. This 
enables activated CD4+ T-cells to amplify their helper function as they could license 
the DC to support CD8+ T-cell responses41. Ridge et al. also showed clear evidence 
that when DC are pre-exposed to activated CD4+ T-cells, they become able to 
support CD8+ T-cell responses in vitro46.  
Toll-like receptors (TLR) were shown to trigger a variety of inflammatory responses 
and to mediate the activation of DC when bound to Pathogen Associated Molecular 
Patterns (PAMPs). The recognition of PAMPs by TLRs suggests the possibility of  
direct activation of DC and therefore bypassing the need for CD4+ T-cell help as 
TLR mediates the release of cytokines that lead to an inflammatory environment47, 48. 
However, the presence of an inflammatory environment does not render CD4+ TH 
help redundant as observed in the chronic infections of lymphocytic 
choriomeningitis virus (LCMV). In the absence of CD4+ T-cell, LCMV infection 
causes impaired cytotoxic lymphocyte (CTL) responses49. Specifically, the absence 
of CD4+ T-cells causes an inability to control viral replication and the functional 
inactivation of CTL responses in mice49. CD40L deficient mice which lack the 
ability to mount CD4+ T-cell responses were also shown to allow progression of 
LCMV50. Therefore, the vaccine mediated induction of effective immunological 
responses against cancer and even many infectious agents (e.g. HBV)51 appeared to 
require adequate activation of not only CD8+ T-cells but also the corresponding 
CD4+ T-cells. Wells et al. also showed that in a peptide vaccination study with 
combinations of TLR agonists and the presence of helper peptides or activating 
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antibody against CD40 are necessary to generate maximum antigen specific CD8 T-
cells responses52. 
Memory T-cells play an important role in increasing the survival against a previous 
exposure to a pathogen in a general population53. After pathogen clearance, excess 
number of pathogen specific T-cell clones occupy the lymphoid compartment and 
dominates the T-cell repertoire. In order to restore the immune homeostasis, 90% of 
effector T-cells undergo apoptosis or programmed cell death54. The 10% of the 
remaining population differentiates into small population of memory cells which will 
persist and protect a subsequent infection55.. The benefit of memory T-cells 
(especially central memory T-cells), lies in its capability of self renewal through 
stimulation with normal levels of IL-7 instead of requiring an antigen presenting cell 
to stimulate its proliferation leading to rapid response against a pathogen compared 
to naïve T-cells56. In a model suggested by Wherry et al., (2003), generation of 
effector memory or central memory T-cells are part of a continuum in a linear 
differentiation of naive T-cells to effector T-cells to effector memory T-cells to 
central memory T-cells. This was demonstrated in a LCMV infection C57BL/6 
mouse model whereby clearance of pathogen leads to decrease in effector memory 
T-cells characterized by antigen specific CD62LloCCR7-CD27lo/int CD8 T-cells and 
an increase in central memory T-cells characterized by antigen specific 
CD62LhiCCR7+CD27hi CD8 T-cells57. The central memory T-cells generated were 
also shown have significantly improved antigen driven proliferation rate both in vivo 
(adoptive transfer of T-cells)  and in vitro. Therefore, in order to generate an 
immunological response which would be able to protect against relapse in cancer or 
provide an improved secondary infection, generation of central memory T-cells will 
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1.5 Peptide vaccination and Tregs 
 
The use of peptides for stimulation of T-helper function is important for the 
induction of effective immunity but in cases where repeated vaccination is required 
to generate optimal CD8 T-cell responses, there will be a risk of generating antigen 
specific regulatory T-cells (Tregs: CD4+CD25+FoxP3+). In 1959, where clonal 
selection was first described, discrimination between self and non-self by the 
immune system was first established58. This led to the discovery of T and B cell 
clonal deletion in their respective immature stages of development where these 
clones are exposed to self antigens. The deletion of the potential self reactive clones 
were found to be incomplete, therefore leading to the notion that a regulatory system 
would be needed to avert immune mediated responses against self antigens58, 59. This 
was first shown in detail in 1969 where neonatal thymectomy of normal mice which 
were 2-4 days old were found to lead to developmental arrest of the ovaries in 
female mice. Thymectomy after 7 days of birth did not cause a similar problem with 
the development of the ovaries and thymus grafting enabled restoration of ovarian 
development showing that the developmental arrest was of an autoimmune nature59, 
60.  
Another concept leading to the notion of possible presence of these regulatory T-
cells surfaced following the observation of autoimmune responses in the 
thymetomised mice. An important observation was made by Penhale et al. in 1973, 
showing that thymectomy of adult rats, followed by sub-lethal irradiation, caused 
development of autoimmune thyroiditis in rats. Transfer of T-cells, and specifically 
CD4+ T-cells, was shown to prevent the disease. This pointed towards the presence 
of cells within the CD4+ population that confer inhibitory immune regulation, then 
averting the autoimmune thyroiditis61. It was only in 1985 that experimental proof 
showed direct correlation between CD4+ T-cells which are CD25+ and immune 
regulation. A critical experiment was as illustrated in Figure 1.6 A. Whole splenic 
CD4+ T-cells, or CD25- CD4+ T-cells, were transferred into immune deficient nude 
or severe combined immunodeficient (SCID) mice. Mice transfused with whole 
CD4+ T-cells developed normally as the transfusion involved both effector and 
regulatory T-cells. However, when the spleen cells were depleted of CD25+ T-cells, 
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(i.e. the regulatory cells), mice develops autoimmune disease, inflammatory bowel 




Figure 1.6 Tregs discovery: (A) Transfer of T cell suspensions depleted of 
CD25+CD4+ Tregs (TR) cells induces autoimmune disease and IBD, demonstrating 
heightened immune responses to nonself-antigens in athymic nude or SCID mice. (B) 
In male children afflicted with IPEX, their mothers with hemizygous defects of the 
FOXP3 gene bear defective and normal Tregs (TR) cells as a mosaic because of 
random inactivation of the X chromosome in each Treg cell. The mothers are 
completely normal because normal Tregs (TR) cells dominantly control the 
activation and expansion of effector T (TE) cells that mediate autoimmune disease, 
IBD, and allergy. However, in the affected children there are only defective Tregs, 
hence autoimmunity. Open circles represent intact TR or TE cells; closed circles 
indicate defective TR cells (Sakaguchi, 2004)59. 
 
 
IPEX is an X-linked immunodeficiency syndrome associated with autoimmune 
disease in multiple endocrine organs, IBD, atopic dermatitis and fatal infections in 
humans. Initial identification of Tregs and its correlation with the FoxP3 gene came 
with the identification of the Scrufy mice. These mice exhibit an X-linked recessive 
mutant with lethality in hemizygous males within a month of birth, exhibiting hyper-
activation of CD4+ T cells and overproduction of pro-inflammatory cytokines, a 
similar phenotype to IPEX in humans. The murine FoxP3 (forkhead box P3) gene 
that encodes for Scrufin, was identified and found to be mutated in the Scrufy mice 
in 2001. That enabled the identification of the human orthologue of the murine 
FoxP3 which was also found to be mutated in the IPEX patients in the same year63, 64. 
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From that point onwards, the phenotyping of Tregs and the role of FoxP3 as the 
master controller of regulatory T-cells took centre stage in the study of immune 
regulation59, 65. Tregs in mice are phenotyped as CD4+CD25+FoxP3+ T-cells, while 
Tregs in human are much more complex and phenotyped as CD4+CD25highCD127-
FoxP3+ T-cells59, 66.  
Tregs either in human or mice are divided into two main types, naturally occurring 
Tregs (nTregs) and induced Tregs (iTregs). Naturally occurring Tregs are produced 
in the thymus after exposure to self antigens. These Tregs are the core player in 
averting autoimmune diseases in humans as discussed earlier. Induced Tregs 
however are regulatory T-cells that obtain a regulatory function after exposure to 
antigen. The iTregs produce IL-10, TGF-β and are converted from non-FoxP3 CD4+ 
T-cells67. The iTregs are antigen specific Tregs and have been shown to be generated 
when there is continuous antigen stimulation in the absence of a co-stimulatory 
function. One of the earliest discoveries of this condition was shown by Apostolou et 
al. in 2004 when minute doses of antigen were delivered subcutaneously via an 
osmotic pump, leading to generation of antigen specific Tregs68. This discovery was 
important to denote the fact that continuous stimulation of CD4+ T-cells could lead 
to the generation of iTregs. These are antigen specific regulatory cells that are able to 
cause major limitations in attempts to induce better protective immunity against 
cancer or chronic infections by repeated vaccinations. However, the coralory has 
been repeated vaccinations with class II presented peptides to induce protective 
tolerance against autoimmune diseases such as autoimmune diabetes69.  
Therefore in this study (see Chapter 3), the focus was on manipulating the T-helper 
peptide stimulation in order to generate an improved immunological response, by 
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1.6 Peptide vaccination and adjuvants 
As previously discussed in section 1.4, vaccination with a single class I peptide 
would result in a suboptimal immunological response. However, with the inclusion 
of adjuvants such as TLR agonists, a strong CD8 T-cell response could be generated 
without T-helper peptides despite not generating recall responses47, 48. History of 
using an adjuvant (from the word adiuvare which means to aid in Latin) to improve 
vaccination outcome started in 1926 when the diphtheria toxin in addition with a 
potassium alum precipitate generated high antigenic responses for veterinary 
vaccinations against diptheria70, 71. This is because classical vaccination in the 
absence of adjuvants is insufficient for generation strong immunological responses 
for poorly immunogenic pathogens (Tuberculosis, malaria, HIV, etc). This is 
particularly relevant for patients that suffer from immune dysfunction, the elderly or 
in conditions of chronic infection. To further understand how adjuvants are able to 
enhance the immune response generated in response to vaccination, understanding of 










Figure 1.7 Exploiting the immune system for discoveries of new adjuvant: The 
activation of T-helper cells (Th1 and Th2) requires specific signals from an antigen 
presenting cell (APC). There are several targets for adjuvants to interact with this 
process and to modulate the adaptive immune response. Adjuvants can impact at 
different levels such as: (1) Recognition of a pathogen associated molecular pattern 
27 by a toll-like receptor (TLR). (2) Presentation of antigens by the major 
histocompatibility complex (MHC) to the T-cell receptor (TCR). (3) Recognition of 
co-stimulatory signals like CD28 or CD40L on T-cell by CD80/86 or CD40 ligands. 





As described in section 1.2, the immune responses can be divided into innate 
immunity and acquired immunity. Adjuvants A and D ( Figure 1.7), represent 
PAMPs which are recognised by TLRs on APC. These danger signals in the form of 
microbial cell wall, virus DNA, etc., provide the initial stimulation that primes the 
immune system to start producing pro-inflammatory cytokines such as tumour 
necrosis factor (TNF), type 1 interferon, IL-1, etc, by NF-κB mediated stimulation of 
gene expression. The use of TLR agonists will be further elaborated in the following 
section on novel adjuvants. Some adjuvant such as adjuvant B shown in Figure 1.7 
represent emulsions or alum precipitates that allow for improved antigen 
presentation by MHC molecules. The depot effect created by emulsion also enables 
the slow release of antigen as well as increased recruitment of APCs to the site of 
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vaccination. The proper presentation of the antigen then allows for an improved 
stimulation of T-cells, leading to improved immunological responses. An example of 
such an adjuvant is MF59, a squalene in water emulsion that improves the response 
against influenza vaccine in older individuals (Podda et al.)72. This again will be 
further reviewed in the discussion of classical adjuvants in the following section. 
Adjuvant C  (Figure 1.6) represents a co-stimulatory molecule needed for the 
efficient stimulation of T- and B-cells. This co-stimulatory signal is usually provided 
by "licensed" APC in the form of B7 family members (B7.1, B7.2, etc). One 
example of using such an adjuvant was presented in a study by Chan et al. in 2005 
where primary AML cells were genetically modified by infection with a lentivirus 
that encodes for B7.1, plus IL-2 as an additional stimulating factor allowing the 
expansion of CD8+ T-cells when co-cultured with autologous peripheral blood 
mononuclear cells (PBMC)9. This has also led to a clinical trial in AML patients 
(unpublished data). A  list of adjuvants that exploit the innate immune system can be 
seen in Table 1.2. The types of adjuvants used today can be divided into classical 
adjuvants, novel adjuvants and adjuvant systems71.  
 
1.6.1 Classical adjuvants 
Classical adjuvants are those that enable the enhancement of antigen presentation by 
APCs utilising the depot effects. A good example of a classical adjuvant is alum salts 
which have been used extensively for vaccination against hepatitis A (HavrixTM, 
VaqtaTM and AvaxinTM), hepatitis B (Engerix-BTM and RecombivaxTM HB), human 
papillomavirus (GardasilTM), etc71. In its early days of use, aluminium salts were 
shown to be working by providing a depot of the antigen at the vaccination site, thus 
improving the attraction of APC to the site, and enhances the uptake of antigen by 
APC for presentation73. However, in 2004, Morefield et al. used alpha casein (AC) 
which was labelled with a green fluorescent dye to determine its uptake by APCs 
when the AC was adsorbed onto alum salt. This showed that alum absorbed AC was 
better taken up by the APC compared to non-absorbed AC. The multivalent 
presentation of AC in combination with alum salt increased the efficacy of its uptake 
by APC71, 74.  
 




Table 1.2 Types of adjuvants currently in use: Table list the type of adjuvants in 
use that exploit the innate immunity to provide help for better induction of 
immunological responses to vaccines. The pathway that is activated for the adjuvant 
and the principal immune responses stimulated are indicated. (Coffman et al., 
2010(Coffman, 2010 #5820)) 
 
 
Emulsions are also widely used as classical adjuvants. Emulsions are normally made 
of oil and water combinations. One typical example of an emulsion is complete 
Freund's adjuvant (CFA), used in many animals studies, created by Jules Freund 
especially for the stimulation of B-cells to produce antibodies. CFA has been used 
extensively in generation of hybridomas for the production of monoclonal 
antibodies75. CFA contains heat-inactivated Mycobacterium tuberculosis, paraffin oil 
and surfactant, which was used in a priming stage together with an antigen followed 
by boosting with an incomplete Freund's adjuvant (IFA) which does not contain the 
inactivated mycobacteria. However, due to its reactogenic properties in the human 
body, CFA has been banned for human use71, 76. This has paved the way for other 
more refined emulsion adjuvants such as MF59 which has been described earlier in 
this section. Another key emulsion that is widely used at the present time is 
montanide. Montanide which is a squalene based adjuvant has been widely used for 
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several types of cancer vaccination studies. Montanide was used instead of IFA in 
cancer vaccination targeting the extra domain (ED-b) of fibronectin77. There has also 
been phase II studies on a commercial montanide vaccine for non-small-cell lung 
cancer called CimaVax EGF targeting epidermal growth factor showing that 73% of 
vaccinated patients generated antibodies against EGF78.  
Other classical adjuvants include liposomes and virosomes. They are synthetically 
made nanospheres that encapsulates antigen, serving as antigen delivery vehicles. 
Modulation of lipid composition, size and charge of the liposomes have been studied 
and the inclusion of the synthetic polymer poly-(ethylene glycol) (PEG) in liposome 
compositions has extended the liposome's  blood-circulation time while reducing 
mononuclear phagocyte system uptake79. However, liposomes do not generally have 
immune activation properties and only act as a delivery system71.  A variety of 
approved liposomes used in cancer treatment and other diseases has also been 
approved79. However, the use of liposomes is not restricted to vaccination, but also a 
variety of other applications including drug delivery (see Figure 1.8) 
 
 
Figure 1.8 Types of liposomes: The different types of liposomes - conventional, 
stealth and targeted, as well as virosomes and their uptake by target cells including 
APC (Adapted from Immordino et al., 2006)79. 
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1.6.2 Novel Adjuvants 
 Novel adjuvants are more refined products made by understanding the nature of the 
immune system, in order to generate an improved vaccination response. Amongst the 
key novel adjuvants are the Toll-like receptor (TLR) agonists. TLRs are a family of 
pathogen associated molecular pattern 27 immune-recognition receptors that are 
utilised by the innate immune cells (macrophages, dendritic cells and monocytes) to 
recognise certain molecular patterns presented by microbial pathogens80. 
Recognition of these danger signals induce the innate immunity directly and generate 
a pro-inflammatory environment which leads to enhancement of acquired immunity 
(activation of B- and T-cell responses). TLR agonists have also been shown to be 
able to skew the T helper responses to either the Th1, Th2 or Th17 types71, 76. TLR 
agonists will be discussed in more depth later. A list of TLR agonists are listed in 
Table 1.2 and Figure 1.9. 
One of the many TLR agonists in relatively common use is MPL, monophosphoryl 
lipid A (Corixa) which is a detoxified version of lipopolysaccharide81 from 
Salmonella minnesota. MPL, like LPS binds to TLR-4 on the surface of APCs 
(monocyte and dendritic cells)76, leading to activation of NF-κB and production of 
inflammatory cytokines such as TNF-α, promoting the generation of acquired 
immune responses. LPS activates NF-κB through the MyD88 and TRIF pathways 
but MPL activates NF-κB only through the TRIF signalling pathway as established 
by Mata-Haro, et al. (2007). This study also showed that MPL signalling activity 
leads to a Th1 type of response instead of the mixed Th1 and Th2 responses showed 
by LPS76, 82. LPS mediated stimulation was shown to be a more rapid inducer of NF-
κB activation via MyD88, while MPL activation is considered to be a slower inducer 
of NF-κB activation by the TRIF signalling pathway. MPL which is considered as a 
safe adjuvant for use in human applications has been approved for hepatitis B and 
human papillomavirus vaccination (Ceravix)83, 84. 
Double stranded RNA, generated in a subtype of viral infections was discovered by 
Alexopoulou et al. (2001) to activate TLR-3 in mammalian dendritic cells. Viral 
infection of mammalian cells resulted in activation of an innate immune response 
mediated by type I IFNs, IFN-α and IFN-β as well as interleukin (IL-6 and IL-12). 
Expression of TLR-3 is found intracellularly in APCs compared to TLR-4 which is 
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found on the extracellular matrix. Alexopoulou et al. used a 293T cell line which 
was genetically modified to produce TLR-3, TLR-6 and TLR-9 with a reporter gene 
that is dependent on NF-κB activation. This allowed the identification of NF-κB 
activation by TLR-3 stimulation, using Polyinosinic:polycytidylic acid (Poly I:C) 
which is a synthetic double stranded RNA80. Longhi et al. in 2009 showed that Poly 
I:C was an effective adjuvant in a dendritic cell based HIV-Gag protein vaccine in 
mice. Poly I:C was shown to be able to generate a predominantly Th1 response85. 
Poly I:C was shown to be able not only to stimulate predominantly Th1 responses, 
but also the activation of NK cells86. 
 
Figure 1.9 TLR agonists and the TLR receptors: The binding of TLR agonist to 
its receptor stimulates the indicated activation pathways (TRIF, TIRAP, TRAM or 
MyD88) in the activation of NF-κB in APCs, leading to the production of different 
types of cytokines. Depending on the type of cytokines involved Th1, Th2 or Th17 
(not shown here but referred to in Table 1.2) responses are activated (Pulendran B., 
2004)87.  
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Poly I:C has shown efficacy when co-administered with PR8 from H1N1 influenza 
virus administered by an intranasal route, resulting in antibody responses as 
indicated by increased levels of IgA and IgG in Balb/C mice88. This has made Poly 
I:C a key adjuvant in human influenza protective vaccinations89. Although TLR-3 
was shown to be expressed at a very low level in mice and upregulated only in 
response to LPS activation, TLR-3 is widely expressed in human dendritic cells 
without the need of LPS activation, thus making TLR-3 agonists potent adjuvants in 
the human setting90.  
Single stranded RNA (ssRNA) from influenza virus was first found to induce 
generation of IFN-α in dendritic cells by TLR-7 recognition of ssRNA and 
stimulation of MyD88 signalling pathway, by Diebold et.al. and Lund et al. in 
200491, 92. The use of Loxorobine, a TLR-7 agonist, led to the discovery of TLR-8 
activation with ssRNA93. ssRNA rich in guanosine and uracil are good activators of 
TLR-7 and TLR-8 found in the endosome of monocytes and dendritic cells. ssRNA 
can be easily degraded in the intracellular matrix by RNAase and therefore requires 
modification to enable optimal use in an adjuvant setting. These studies have led to 
the discovery of small synthetic compounds of the imidazoquinolines such as 
imiquimod (TLR-7 agonist) and resiquimod (TLR-7 and TLR-8 agonist) as potent 
TLR-7 and TLR-8 agonist that can be used as adjuvants. Other guanosine and uracil 
analogues were also used to avoid the breakdown by RNAase76. Imiquimod is 
currently use in clinic studies to treat melanoma and recent studies show that 
imiquimod used topically on the skin of mice post vaccination with genetically 
modified Listeria monocytogenes (modified to express Tyrosinase related protein-2, 
TRP2180-188 which is an antigen up-regulated in melanoma) increases survival rate in 
B16 melanoma challenged mice94.  
TLR-9 is the only intracellular TLR that binds to DNA sequences from bacteria and 
viruses. CpG nucleotide motifs are recognized by TLR-9, initiating the NF-κB 
signalling pathway through MyD88, leading to the production of pro-inflammatory 
cytokines such as TNF-α, IL-1, IL-6, IFN-γ and IFN-α71. In vaccinations, synthetic 
CpG optimized motifs of 18-25 bases, are widely used as adjuvants76.  
Another novel adjuvant is immune stimulating complexes (ISCOMs) which are 
solely used as delivery vehicles71. ISCOMs are cage-like nanoparticle saponins that 
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are purified from the bark of a South American tree called Quillaja saponaria. These 
saponins are made up of phospholipids and cholesterol. ISCOMs are used to 
encapsulate antigen for delivery in vaccination studies. Solubilisation of antigens and 
antigen-free ISCOM allowed the formation of ISCOMATRIX. These matrixes are 
not recognised by any of the pattern recognition receptors but enhance antigen 
uptake by APCs and prolong the retention of the vaccine in the draining lymph 
nodes. Maraskovsky et al. (2009) showed that the use of ISCOMATRIX adjuvant 
induces a broad range of specificity to the vaccine antigen which includes robust 
antibody, CD4+ and CD8+ T-cell responses95.  
 
1.6.3 Adjuvant systems - Combination of classical and novel adjuvants: The 
challenge of therapeutic vaccination especially in chronic diseases such as cancer, 
and chronic infections established by HBV or HIV, as well as vaccination in immune 
suppressed individuals, such as the elderly, has marked the need for improved 
vaccine adjuvants. This has led to the use of a combination of two or more type of 
adjuvants that will allow the generation of an enhanced immune response. The use of 
combinations of adjuvants could allow for synergistic enhancement of responses to 
vaccinations. Pharmaceutical companies such as GSK have developed a number of 






Table 1.3 GSK biological adjuvant systems, its components and current 
application in the clinic76. 




There is also a number of studies in which combinations of adjuvants are used (for 
example see Wells et al., 2008). The combination of adjuvants used by Wells et al., 
consist of an emulsion made of squalene and Tween 80, 2 TLR agonists 
(combination of a MyD88 and a non-MyD88 signalling pathway TLR agonist), 
recombinant IFN-γ plus an MHC Class I presented peptide with an MHC Class II 
presented peptide or anti-CD40 administered intradermally. They have called this 
combination of adjuvant Combined Adjuvant for Synergistic Activation of Cellular 
immunity (CASAC)52. In order to determine the best combination of adjuvants to 
generate CD8+ T-cell responses, Wells et al., utilised ovalbumin as the target antigen. 
52 
 
Figure 1.10 Generation of antigen specific CD8 T-cells by different 
combinations of adjuvant: Percentage of SIINFEKL specific CD8+ T-cells in 
different combination of adjuvants (Emulsion used is MPL plus TDM). In the 
emulsion only and emulsion plus IFN-γ vaccination with SIINFEKL, low levels of 
SIINFEKL specific CD8+ T-cells were generated. However with the inclusion of an 
anti-CD40, which acts to substitute for a helper peptide to license APC, the 
percentage of SIINFEKL specific CD8+ T-cells were seen to have increased.  By 
removing the anti-CD40 and introducing a second TLR agonist (CpG ODN 1826), 
the percentage of SIINFEKL specific CD8+ T-cells were found to have increased 
again compared to the single TLR plus anti-CD40 combination. The best 
combination however was described when an emulsion, two TLR agonist, IFN-γ and 
anti-CD40 was included in the SIINFEKL vaccination generating the highest 
percentage of SIINFEKL specific CD8 T-cells. (adapted from Wells. et al., 2008)52 
 
                                                                                                  CHAPTER 1 
51 
 
Initially a series of adjuvants were tested and the immune responses were quantified 
with a pentamer (ProImmune) which is made of five murine H-2Kb/SIINFEKL 
complex bound together in a coiled-coiled matrix tagged with a fluorescent dye. 
Pentamers are very specific and bind only to TCR that are antigen specific. 
Combining pentamers and fluorescently labelled anti-CD8  allows the quantification 
of the percentage of SIINFEKL specific CD8+ T-cells. The combination of adjuvants 
used and the generated immune responses could be seen in Figure 1.10. The best 
combination was determined after two rounds of vaccination, which were given 10 
days apart, followed by quantification of immunological responses 10 days later. The 
vaccination not only produced high levels of SIINFEKL specific CD8+ T-cells but 
also about 99% lysis of antigen positive target cell in an in vivo cyototoxic 
lymphocyte (CTL) assay, using SIINFEKL pulsed splenocytes as antigen positive 
target cells (Figure 1.11 a). These mice were injected with the peptide pulsed 
splenocytes that were labelled with a green fluorescent dye, Carboxyfluorescein 
diacetate, succinimidyl ester  (CFSE), intravenously. The mice were left overnight 
(16-18 hours) before they were culled to harvest the spleens. Splenocytes were 
obtained and analysed by Fluorescence activated cell sorting (FACS). Recall 
responses were also observed after the vaccinated mice were rested for about 3 
months before rechallenging with SIINFEKL peptides showing good memory CD8 
T-cell generation (Figure 1.11 b). The rested mice were also examined for in vivo 
CTL activity and were found to be still able to produce good clearance of target cells 
(Figure 1.11 c), showing that the generated memory T-cells within the population 
were long lived and able to mount a recall response. 
The potential showed by CASAC was immense and as discussed in the previous 
section, the use of combination of adjuvants was shown to generate the best response. 
Therefore, a series of combinations of different emulsion, TLR agonists and helper 
peptides were tested (Figure 1.12 a, b and c). This led the authors to conclude that 








Figure 1.11 Generation of functional CD8 T-cell responses by CASAC: a) In the 
vaccinated mice challenged with peptide pulse splenocytes, 99% of antigen positive 
target cells which were labelled with low levels of CFSE dye were cleared 10 days 
after second round of vaccination compared to no clearance in the naive mice. Non-
target (antigen negative) cells labelled with high levels of CFSE were not affected 
and were used as a reference to calculate the percentage of target cells lysis. b) Mice 
were then rested for about 3 months and a rechallenge with SIINFEKL showing the 
presence of  a recall response. c) The generated memory CD8 T-cells were also 
shown to have cytolytic function as when the rested mice were challenged with 
antigen positive cells, they were able to mount an effective in vivo CTL response as 
indicated by the clearance of 91% of target cells, but no cell lysis in the unvaccinated 














Figure 1.12 Comparison of different combinations of CASAC: a) CASAC in 
combination with complete emulsion (squalene and Tween80) or TDM emulsion 
generated the highest percentage of SIINFEKL specific CD8+ T-cells making the 
emulsion a crucial part of the vaccination as in absence of the non-emulsion vaccine 
did not generate as good a response. b) Combination of TLR agonist that provided 
the best percentages of SIINFEKL specific CD8+ T-cells were combinations of a 
MyD88 and non-MyD88 signalling pathway activation. c)  anti-CD40 antibody or an 
ovalbumin T-helper peptide was shown to be required for generation of highest 
percentages of SIINFEKL specific CD8+ T-cells. In these studies, the use of anti-
CD40, a class II presented (OVA or unrelated), or whole protein (OVA or unrelated) 
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In order to test the efficacy of the adjuvant combination, Wells et al. substituted 
OVA with TRP-2 to vaccinate against a self antigen which has been shown to be up-
regulated in melanoma cells. Vaccinating the mice with TRP-2180-188 peptide in 
combination with CASAC, increased levels of IFN-γ expressing cells. Higher 
percentages of IFN-γ expressing cells were seen in mice vaccinated with increasing 
quantities of peptide (Figure 1.13 a). The improvements in IFN-γ production were 
also translated into improved clearance of target cells (splenocytes) that were pulsed 
with the TRP-2180-188 peptide (Figure 1.13 b). Intravenous injection of B16 
melanoma cells in the vaccinated mice, resulted in the recovery of 2-3 log10 lower 
levels of B16, 3 days later, in the lungs of the TRP-2 peptide vaccinated mice 
(Figure 1.13 c) 
 
 
Figure 1.13 Vaccinating against a self antigen with CASAC: a) Mice were 
vaccinated with CASAC plus TRP-2180-188 peptide ranging from 100 - 400 µg. The 
increasing quantity of peptide resulted in increased detection of antigen specific IFN-
γ producing cells. b) Challenging the mice with an in vitro CTL assay using peptide 
pulsed splenocytes also showed the improved lysis of antigen positive target cells. c) 
In the vaccinated mice, there was substantially reduced recovery of B16 melanoma 
cells found in the lungs after 3 days of intravenous inoculation of B16. (adapted from 
Wells et al., 2008)52 
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In a therapeutic setting, CASAC was also shown to be effective in the B16 
melanoma tumour model. B16 cells were injected subcutaneously (105 cells per 
mouse) and vaccination with CASAC and TRP-2180-188 were conducted on days 3, 11 
and 19. Vaccination without CASAC showed only partial improvement in tumour 
diameter and survival compared to the unvaccinated mice. In the mice vaccinated 
with TRP-2 in combination with CASAC, there was little increase in the tumour size 
of the mice and 80% rejected the previously inoculated tumour and survived for the 
duration of the study (Figure 1.14 a and b). CASAC/TRP-2 vaccination followed by 
CD8 antibody mediated depletion of CD8 T-cells substantially abrogated the 
therapeutic effect of vaccination, demonstrating the involvement of CD8 T-cells in 
the CASAC mediated immune protection. 
 
Figure 1.14 Tumour rejection by CASAC vaccination: a) Mean tumour diameter 
recorded in the B16 innoculated mice and the effect of TRP-2180-188 vaccination with 
CASAC, CASAC plus a depleting anti-CD8 or CpG plus anti-CD40. The best 
tumour rejection was obtained when CASAC is use as an adjuvant for the TRP-2 
vaccination. b) Similar results were seen in the percentage of mice that survived the 
tumour inoculation. Vaccination resulted in death of all mice while 80% of mice 
vaccinated with CASAC survived till day 70 post the inoculation. (Adapted from 
Wells et al., 2008)52 
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In summary, CASAC vaccination improved the percentages of antigen specific T-
cells generated by peptide vaccination against a foreign antigen (OVA) as well as a 
self antigen (TRP-2). CASAC was also shown to be an excellent activator of 
dendritic cells and stimulated the production of IL-12 which promotes strong Th1 
responses and cross presentation of antigen52. CASAC vaccination has been 
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1.7 Peptide vaccination and IRX-2 
 IRX-2 is a combination of biological agents containing physiological quantities of 
IL-1β, IL-2, IL-6, IL-8, GM-CSF, interferon-gamma (IFN-γ) and tumour necrosis 
factor-alpha (TNF-α) generated by phytohemagglutinin (PHA) activation of human 
PBMC under Good Manufacturing Practice (GMP) conditions by IRX 
Therapeutics96. IRX-2 has immunomodulatory properties that restore immune 
responsiveness, induce tumour infiltration in head and neck squamous cell 
carcinoma (HNSCC), increasing the mean 5 year survival of patients in a phase II 
clinical trial97. IRX-2 was also found to have adjuvant properties when it was 
administered as 4 or 9 daily doses in a vaccination against a mouse immuno-
dominant peptide derived from human prostate-specific membrane antigen (NFT). 
Increased T-cell responses were observed when IRX-2 was used in combination with 
incomplete Freund's adjuvant or NFT peptide conjugated with keyhole limpet 
hemocyanin (KLH) or with irradiated cells expressing NFT. This was shown in a 
delayed type hypersensitivity (DTH) response where there was the most swelling 
found in the footpad of mice challenged with the target peptide after vaccinating the 
mice in combination with IRX-2 (Figure 1.15)98.  
 
 
Figure 1.15 DTH effects by IRX-2: Increased swelling was measured (0.01mm 
sensitivity caliper) at the area of the mouse footpad where the challenge with antigen 
(NFT) was conducted. A prime and boost vaccination was conducted with IRX-2 
was given 9 daily doses subcutaneously (from Naylor et al., 2010)98. 
 




Splenocytes or cells from lymph nodes of the vaccinated, as well as the unvaccinated 
mice were investigated for their ability to produce IFN-γ when challenged in vitro 
with the target antigen to determine T-cell responses. Naylor et al., reported the 
improved production of IFN-γ in both enzyme-linked immunosorbent assay 99 and 
enzyme-linked immunosorbent spot (ELIspot) assays in mice which were vaccinated 
with NFT plus IFA and IRX-2 showing data that show increased T-cell responses in 
IRX-2 vaccinated mice compared to IFA vaccination in the absence of IRX-2 
(Figure 1.16). This has prompted our interest in incorporating IRX-2 into our peptide 
vaccination studies to investigate its potential for synergy with CASAC. 
 
 
Figure 1.16 ELIspot and ELISA for IFN-γ in IRX-2 vaccinations: Data obtained 
from both ELIspot and ELISA assay show a significant increase in IFN-γ production 
when comparing IFA versus IFA plus IRX-2 vaccination with NFT peptides. The 
increase in the production of IFN-γ shows the potential of IRX-2 in generating T-cell 
responses in mice (Naylor et al., 2010)98 
 
Another key feature of IRX-2 that has prompted our interest in its investigation is its 
anti-apoptotic properties reported by Czystowska et al. (2009) and the protective 
action of IRX-2 on T-cells that were exposed to tumour cells100, 101. Many types of 
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cancer such as head and neck squamous-cell carcinoma (HNSCC) and melanoma 
expresses Fas ligand (FasL), while some cancers are capable of secreting micro 
vesicles 102 with membrane bound FasL. This leads to elimination of activated Fas+ 
effector T-cells by the FasL/Fas pathway, thus leading to a poor immunological 
response against the tumour100. MV isolated from sera of oral carcinoma patients 
were also shown to have the capacity to induce caspase-3 cleavage, DNA 
fragmentation, cytochrome c release, loss of mitochondrial membrane potential 
(MMP) and TCRζ-chain down-regulation in activated T lymphocytes, which leads to 
T-cell apoptosis, shown to be blocked by the presence IRX-2100, 103.  
Pre-incubation of Jurkat cells (which is a CD8+ human T-cell line) with IRX-2, 
protects from MV, CH-11 and staurosporine induced caspase activation and 
apoptosis100. Protection of Jurkat cells was seen to be directly correlated with the 
duration of IRX-2 incubation time. Similar effects were also seen in primary CD8+ 
and CD4+ T-cells making IRX-2 a potent agent for protecting against T-cell 
apoptosis (Figure 1.17)100. The mechanism of protection was later elucidated by 
Cysztowska et al., in 2011 when IRX-2 was shown to prevent over expression of Fas 
in the activated T-cells which were induced by MV, rather than by blocking the 
FasL/Fas pathway that leads to apoptosis. They were also able to discover the up-
regulation of cFLIP, a protease-deficient caspase homologue widely regarded as an 
apoptosis inhibitor, making the activated T-cells more resistant to MV induced 
apoptosis101, 104. This is important in terms of vaccination because in 2006, Wang et 
al., showed that vaccinating mice against an autologous inactivated auto-reactive T-
cells, in a model to eliminate auto-reactive T-cells, showed increased Fas+ T-cells in 
the vaccinated mice105. Therefore, IRX-2 could play a part in stimulating better 
responses to vaccination, especially in the context of chronic disease or vaccination 
in the elderly population. 
 




Figure 1.17 IRX-2 protects Jurkat cells and primary T-cells from MV induced 
apoptosis: Jurkat cells (human CD8+ T-cell line) were pre-incubated with or without 
IRX-2 24 hours prior to treatment with MV, CH-11 antibody (a Fas activating 
antibody) or staurosporine (SP - a drug that induces apoptosis) for 3 hours. FITC-
VAD-FMK staining indicates caspase activation while annexin V staining indicates 
cell apoptosis. a) and b) show that IRX-2 was capable of protecting Jurkat cells from 
caspase activation caused by MV, CH-11 antibody or SP treatment in the presence or 
absence of IRX-2. Increasing IRX-2 incubation time leads to better protection 
especially from MV. c) and d) shows protection of IRX-2 from cell apoptosis. In 
Table 1.e), primary T-cells were treated in the same manner as Jurkat cells, again 
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In 2011, Shiling et al., also showed that IRX-2 favours the expansion of effector T-
cells rather than Tregs in an in vitro human model106. CD3+CD4+CD25- naive human 
T-cells were co-cultured with immature dendritic cells and irradiated PCL-13 (a head 
and neck cancer cell line) in the presence or absence of IRX-2 for 10 days. The 
cultured cells were then identified for effector T-cells (Teff: CD25+CD122-CD132-
CD152-FoxP3-) and Tregs (Tr1: CD25+CD122+CD132+CD152+FoxP3+). Based on 
phenotypic marker analysis, IRX-2 was shown to have favoured the expansion of 
Teff instead of Tr1 (Figure 1.18 a)106. The expression of Tr1 associated markers as 
well as IL-10 and TGF-β, were seen to be increased in the co-culture of PCL-13 and 
T-cells in the absence of IRX-2, thus supporting the data showing Teff cell 
expansion. In the presences of IRX-2, Treg markers were significantly reduced 
compared to the non-IRX-2 treatment. IFN-γ, which supports Teff cell expansion, 
was also seen to have increased (Figure 1.18 b and c) 
The evidence provided by Schilling et al., suggests the importance of blocking the 
expansion of Tregs in response to vaccination as Tregs could impede immune 
responses generated by the vaccine, thus reduce efficacy. The expansion of effector 
T-cells on the other hand would lead to an improved generation of immunological 
responses that could increase the efficacy of vaccination. The evidence summarised 
suggests that IRX-2 could play an important role in enhancing protective immunity 
in response to vaccinations against tumour associated antigens. 




Figure 1.18 Generation of Teff with use of IRX-2: a) Numbers of effector T-cells 
(Teff) and regulatory T-cells (Tr1) were analysed post in vitro co-culture of T-cells 
with immature dendritic cells and PCL-13 tumour cell line with IRX-2, showing 
increased Teff and decrease Tr1 cells compared to the absence of a non-IRX-2 in the 
co-culture. b) IRX-2 incubation leads to reduced the expression of Treg phenotypic 
markers compared to non-IRX-2 co-culture. c) IRX-2 reduces the expression of 
Tregs related cytokines (IL-10 and TGF-β) while increasing IFN-γ expression 
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1.8 Vaccination in the exhausted, anergized and senescent immune states 
 The potential for vaccination as an immunotherapy in the clinic is usually 
investigated in young mice which have potent immunological responses. These 
vaccination studies have proven to indicate efficacy of a range of therapeutic 
vaccination strategies. However, the vast majority of these vaccinations have failed 
to produce a therapeutic response in clinical studies of human malignancy. Patients 
treated in the clinic had either chronic exposure to their malignant cells and are 
usually at a much older age. Therefore two major differences between murine 
models of cancer immune therapy and clinical human studies in immunotherapy of 
cancer are: 
1. Chronic exposure to cancer and the interaction between the tumour and the 
immune system. 
2. The aged, possibly exhausted, and  immune senescent status of the majority of 
cancer patients. 
Cancer patients would have lived with the disease for years before symptoms start to 
show. Therefore, the immune system would have seen the disease and been exposed 
to the tumour mediated immune suppression, including anergy and clonal exhaustion 
of specific effector T-cells. Long term exposure to tumours, and aging of the thymus 
can also cause patients to lose the ability to generate naive T-cell or maintain a 
repertoire with the required diversity to respond to vaccination107, 108. Similarly, a 
chronic infection like LCMV could lead to similar immune perturbations seen in 
cancer patients (Figure 1.19). 
Three main pathways have been identified that causes a negative regulatory effect in 
the immune system109. These are: 
 1) Tregs (refer to section 1.5) 
2) Cell surface inhibitory markers such as PD-1, KLRG-1, etc. 
3) Cytokines (IL-10, TGF-β, etc).  
 
 




Figure 1.19 Model of exhaustion: Exhausted antigen specific CD8+ T-cells were 
first identified in chronic LCMV infection. Exhaustion occurs in a hierarchical 
manner with CD8 T-cells losing their properties one by one, IL-2 production, 
proliferative capacity and ex-vivo killing are lost first followed by loss of TNF 
production. Severe exhaustion follows via the loss of IFN-γ production or beta-
chemokines production or the ability to degranulate. The altered expression of 
markers associated with exhaustion and immunesenescence markers are also 









                                                                                                  CHAPTER 1 
65 
 
One of the best known inhibitory receptors is programme death 1 (PD-1). The PD-
1/PD-L1 pathway regulate both the induction and the maintenance of peripheral 
tolerance. PD-L1 protein on tolerogenic DCs can induce T-cell tolerance. PD-L1 is 
constitutively expressed on APCs and T cells and is further up-regulated by pro-
inflammatory cytokines. PD-1 has a negative effect on the survival and proliferation 
of exhausted and senescent T-cells leading to cell death and apoptosis110. The 
mechanism of action of PD-1 can be seen in Figure 1.20. The activity of PD-1 in the 
thymus is required to ensure that T-cells specific for self antigens are eliminated in 
the course of their thymic maturation. However in diseased patients where the T-
cells have been exhausted and expresses high levels PD-1, the blockade of PD-1 may 
help to reinvigorate the T-cells. A model was suggested by Sharpe et al., in an 
extensive review in 2007 and Figure 1.21 shows a schematic diagram of the 
proposed use of a PD-1/PD-L1 blocker110.  
 
 
Figure 1.20 PD-1/PD-L1 natural pathway: Normal expression of PD-1 and PD-L1 
(PD-L) in the thymus where PD-1/PD-L1 pathway causes depletion of self-reactive 










Figure 1.21 Possibility of reinvigorating exhausted T-cells: In an activated T-cell 
state where exhausted cells are expressing high levels of PD-1, the interaction 
between PD-1 and PD-L1 causes the depletion of these T-cells and the elimination of 
the exhausted clone of antigen specific T-cells. Blocking antibodies have then been 
introduced to reinvigorate the exhausted T-cells (Adapted from Sharpe et al., 
2007)110.  
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Killer lectin like receptor G1 (KLRG-1) has also been shown to have been up-
regulated in highly activated T-cells and NK cells, especially in antigen experienced 
T-cells111. However, in senescent T-cells, KLRG-1 was shown to stop proliferation 
resulting in terminal differentiation. This has been reviewed extensively by Henson 
et al., in 2009 and its proposed mechanism of action is shown in  Figure 1.21112. 
KLRG-1 plays an important role in maintaining the ability of a T-cell population to 
proliferate thus affecting the generation of antigen specific T-cells especially when 
vaccinating the aged mice. In mice, KLRG-1 has been shown to be up-regulated in 
mice aged more than 18 months old. In humans however, CD57 is the primary 
marker of immunesenescence in individuals aged above 65 years113-116. 
 
 
Figure 1.22 Blockade of T-cell differentiation by KLRG-1: In 
naive/undifferentiated T-cells, no KLRG-1 was found on the cell surface of the T-
cells. This enables the T-cells to undergo proliferation by stimulation of CD28 
pathway,  leading to PI3K/Akt signalling thus proliferation can take place. However, 
in differentiated cells, the KLRG-1 marker replaces CD28 and causes inhibition of 
the PI3K/Akt pathway by blocking the conversion of PI3K to PIP3 required for Akt 
activation. This leads to terminal differentiation of the cells. However, the blockade 
of KLRG-1 would again restore the proliferative function of the T-cell, leading to 
continued proliferation. (Adapted from Henson et al., 2009)112 
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Other cell surface markers that play roles in immune dysfunctions are, LAG-3 which 
affects cell cycle progression, and the inhibitory receptor CTLA-4 which competes 
with CD28 for co-stimulatory ligands109. 
There are also important inhibitory immune regulatory cytokines, including IL-10 
and TGF-β. IL-10 is a key cytokine that leads to up-regulation of Tregs when 
combined with TGF-β. Evidence has shown that IL-10 is up-regulated in chronic 
infections and is linked to T cell dysfunction during persistent viral infection117. 
Blocking of IL-10 was shown to enhance viral control and to improve T-cell 
responses for clearance of virally infected cells in vivo as previously shown by 
Brooks et al., in 2006117. There was also correlation between IL-10 production by 
monocytes in HIV infected humans due to increased ligation of PD-1, thus causing 
impairment of CD4+ T-cells118. TGF-β has been linked to T cell exhaustion through 
the phosphorylation of Smad2, especially in chronic LCMV infection as shown by 
Tinoco et al., in 2009119. However, there are cytokines such as IL-7, IL-21 and IL-2 
which are positive immune regulatory factors in chronic infection. They are 
important in fostering more functional T-cell responses109. 
Aged mice which are >18 months old, are considered immunosenescent. An 
extensive review by Maue et al. (2009)107, has highlighted several important 
observations in immunosenescent mice (Table 1.4). The factors indicated in Table 
1.4 would hamper the generation of immunological responses against infections and 
diseases such as cancer. These markers of immune dysfunction in the aged mice are 
also indicative of immune senescence in human aging. Vu et al. (2002),  showed the 
presence of a correlation between increased influenza induced mortality and age of 
patients. Patients aged >65 years old have a higher risk of death compared to 
younger patients108 . Vaccination in the aged population was also found to be a 
challenge as age associated thymic involution leads to poorer thymic output of naive 
T-cell, thus diminishing the repertoire available for generation of new 
immunological responses in humans as stated by Aspinall et al.120.  
  










1.9 Objectives of this study: 
The focus of this project is the study of T-cell responses to peptide vaccination in 
combination with adjuvant combination referred to as CASAC and immune 
regulation by IRX-2. Specifically, the following chapters will focus on the primary 
objectives as below: 
1. The use of alternating class II presented T-helper peptides for vaccination induced 
stimulations of CD8 T-cell responses 
2. To study the effects of IRX-2 as a potential immunomodulatory agent to enhance 
potency of vaccination induced generation of antigen specific CD8 T-cells. 
3. Development of a peptide vaccination strategy for generation of functional antigen 
specific CD8+ T-cells in aged mice. 




























2.1.1 Reagents, chemicals and buffers 
AKFVAAWTLKAAA, 95% pure (PADRE); Peptide Protein Research Ltd. 
Ammonium chloride (NH4Cl); SIGMA 
Cell Trace™ Carboxyfluorescein diacetate, succinimidyl ester (CFSE); Invitrogen 
Cell Trace™ Far red DDAO-SE (DDAOSE); Invitrogen 
Chicken Ovalbumin, ≥98% Ovalbumin (OVA); SIGMA 
CpG ODN 1826 (5'-tccatgacgttcctgacgtt-3'), Phosphothiorate modified (S-Oligos); 
SIGMA-Genosys 
Detoxified Monophosphoryl Lipid A from S. minnesota (MPL); Invivogen 
Dimethyl sulfoxide - Hybri-Max™, sterile-filtered, BioReagent, suitable for 
hybridoma, ≥99.7% (DMSO); SIGMA 
 Dulbecco's phosphate buffered saline (DPBS); SIGMA 
Ethylenediaminetetraacetic acid (EDTA); SIGMA 
Fetal bovine serum (FBS); Gibco 
Flow-count™ Counting Beads; Beckman Coulter 
Foxp3 / Transcription Factor Staining Buffer Set; eBioscience 
Freund's Adjuvant, Complete (CFA); SIGMA 
Ionomycin calcium salt from Streptomyces conglobatus, ≥98% (Ionomycin); SIGMA 
IRX-2; IRX Therapeutics 
Isoflo® Isofluorane; Abbot's 
ISQAVHAAHAEINEAGR, >95% pure (ISQ, OVA323-339); Peptide Protein 
Research Ltd. 
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Monensin sodium salt, 90-95%; SIGMA 
Nuclease-free water; Promega. 
Penicillin/Streptomycin; SIGMA 
Phorbol 12-myristate 13-acetate, (PMA); SIGMA 
Polyinosinic–polycytidylic acid sodium salt (Poly I:C); SIGMA 
Potassium bicarbonate (KHCO3); SIGMA 
Recombinant mouse Interferon Gamma (mIFN-γ); Peprotech 
RMFPNAPYL, >95% pure (WT-1126–134); Peptide Protein Research Ltd. 
Roswell Park Memorial Institute media (RPMI-1640); SIGMA 
SIINFEKL peptide, >95% pure (SIINFEKL, OVA257-264); Peptide Protein Research 
Ltd. 
Sodium citrate pH 3; 0.05M – Polyethylene glycol 3350 12% (v/v) solution; SIGMA 
Sodium hydroxide 1.0N solution; SIGMA 
Squalene, ≥ 98%; SIGMA  
TEWTSSNVMEERKIKV, >95% pure (TEWT, OVA266-281); Peptide Protein 
Research Ltd. 
Tween® 80 - Cell culture tested; SIGMA 
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2.1.2 Monoclonal antibodies and pentamers  
All antibodies used were purchased from Ebioscience unless otherwise stated: 
R-Phycoerythrin (R-PE) pentamer (H-2Kb specific for SIINFEKL - ProImmune); 
Pacific Blue (PBlue) conjugated anti-mouse CD3 (17A2); Peridinin-chlorophyl-
Cy5.5 (PE-Cy5.5) or Allophycocyanin (APC) anti-mouse CD8a (53-6.7); APC anti-
mouse CD62L (MEL-14); Fluorescein isothiocyanate (FITC) anti-mouse CD44 
(IM7); FITC or PerCp-Cy5.5 anti-mouse CD4 (RM4-5); APC anti-mouse CD25 
(PC61.5); Phycoerythrin (PE) or PerCP-Cy5.5 anti-mouse FoxP3 (FJK-16s); PE Rat 
IgG2a kappa isotype control (eBR2a); PE or un-conjugated anti-mouse CD28 
(37.51); PE Anti-mouse IFN-γ (XMG 1.2 - BDBioscience); FITC Anti-mouse 
Interleukin-17 (eBio17B7); PE-Cy7 Anti-mouse Interleukin-4 (BVD6-24G2); Pblue 
Anti-mouse Tumour Necrosis Factor-α (MP6-XT22); PE anti-mouse GATA-3 
(TWAJ); eFluor® 660 Anti-Human/Mouse T-bet (eBio4B10);  PE Anti-
Human/Mouse RORγt (AFKJS-9); PE Anti-Mouse OVA257-264 (SIINFEKL) peptide 
bound to H-2Kb (25-D1.16); APC anti-mouse CD152 (CTLA-4) (UC10-4B9); PE 
anti-mouse CD274 (PD-L1) (MIH5); FITC anti-mouse CD279 (PD-1) (RMP1-30); 
PE anti-mouse CD223 (Lag-3) (eBioC9B7W (C9B7W)), Rat IgG1 K Isotype 
Control PE and PE-Cy7 anti-mouse KLRG1 (2F1) 
All volumes or concentrations of antibodies used were as suggested by the 
manufacturers. 
 
2.1.3 Preparation of RBC lysis solution 
8.26 g ammonium chloride (NH4Cl), 1 g potassium bicarbonate (KHCO3) and 0.037 
g EDTA were added to 1 litre of distilled water. The solution was filtered through a 
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2.2 Peptide Vaccination 
 
 
2.2.1 Animal Model 
C57BL/6 mice were selected as the animal model. The mice were bought from 
HARLAN and were housed according to Home Office regulations. Female C57BL/6 
(H2 Haplotype = b) mice aged 6-8 weeks were purchased and were left to adapt to 
the environment for at least 1 week at the Biological Services Unit before starting the 
experiments. Aged female C57BL/6 mice were also purchased from the same source 
aged 18 months for experiments involving immunesenescence. At the end of each 
study, mice were humanely killed by a Schedule 1 method.  
 
 
2.2.2 Preparation of vaccine components 
All vaccine components were prepared under sterile conditions using sterile 
solutions and plastics in a Class II microbiological safety cabinet (Howorth airtech 
Ltd.) 
 
2.2.2.1 Protein and peptides 
Chicken Albumin (OVA) and synthetic sequences of its peptides were used in all 
vaccination studies as a model antigen. SIINFEKL (MHC Class I), 
ISQAVHAAHAEINEAGR (MHC Class II) and TEWTSSNVMEERKIKV(MHC 
Class II) were in vials of 5 mg and diluted to 5 mg/ml by adding 100 µl of DMSO 
and 900 µl of DPBS and vortexed (Labinco L46 vortex) for 10 seconds. In cases 
where peptides did not dissolve well, 1 µl of 1N sodium hydroxide solution was 
added and vortexed. This was repeated until peptides had completely dissolved. The 
peptides were then divided into 4 aliquots of 250µl each in 1.5 ml tubes (Eppendorf) 
and stored in at -20oC (Leibherr -20oC Freezer). To avoid degradation of peptides, 
each tube of peptides would only undergo a maximum of 3 freeze thaw cycles. 
40 mg of Ovalbumin was weighed with a scale (Denver Instruments, APX-153, max 
= 150 g, sensitivity = 0.001 g) and diluted with 0.5 ml of DMSO and 4.5 ml of 
DPBS to obtain an 8 mg/ml concentration in a 15 ml Falcon tube (Beckton 
Dickinson). Ovalbumin was prepared fresh each time it was required.  
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2.2.2.2 TLR agonists and mIFN-γ 
 
MPL: MPL was prepared by diluting the stock vial (1 mg) with 200 µl of 100% 
ethanol to make a stock solution of 5 mg/ml. MPL was made fresh each time it was 
required. 
CpG: 10 mg of CpG was diluted in 2 ml of nuclease-free water to make a stock 
solution of 5 mg/ml. The stock solution was then divided into 200 µl aliquots in 0.5 
ml tubes (Eppendorf) and stored at -20oC. 
Poly I:C: 25 mg of Poly I:C was diluted in 5 ml of nuclease-free water to make a 
stock solution of 5 mg/ml. The stock solution was then divided into 200 µl aliquots 
in 0.5 ml tubes and stored -20oC. 
mIFN-γ: 100 µg of recombinant mouse IFN-γ was diluted in 1 ml of DPBS to make 
a 100 µg/ml stock solution. The stock solution was then divided into 50 µl aliquots 

























A standard 5 ml emulsion (0.4% Tween 80 and 8% Squalene) for CASAC 
vaccination was prepared by adding 20 µl of Tween 80 into a 15ml Falcon tube 
followed by 400 µl of Squalene and 4520 µl of DPBS. The mixture was sonicated 
(Sonics Vibra cell sonicator) on ice at 100% amplitude for 5 seconds and allowed 30 
seconds for cooling. A total of 4 rounds of sonication were conducted. The solution 
was clear prior to sonication (Figure 2.1 a) and after 4 rounds of sonication (Figure 
2.1 b), the emulsion mixture was formed as a milky white mixture (Figure 2.1 c). 
 
 
Figure 2.1 Preparation of emulsion: a) The emulsion mix prepared was clear after 
mixing squalene, Tween 80 and DPBS. b) 4 rounds of sonication at 100% amplitude 
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2.2.3 Vaccine preparation 
 
2.2.3.1 The alternating T-helper peptide vaccination regimen involving 
emulsion plus 2 TLR agonists as the adjuvant 
The vaccine mixture comprises of an emulsion (emulsion prepared as described in 
section 2.2.2.3), 2 TLR agonist (Poly I:C - 10 µl from 5 mg/ml stock to make 50 
µg/mouse and CpG - 5 µl from 5 mg/ml to make 25 µg/mouse), DPBS to make up 
the volume to 100 µl of the non-emulsion part and a combination of peptides as 
required by the vaccination regimen. For each mouse, 20 µl of each indicated peptide 
was added into the vaccine mixture from a stock solution of 5 mg/ml to make 100 
µg/mouse (Table 2.1).  
 
 




2.2.3.2 Alternating T-helper peptide vaccination regimen with a single TLR 
agonist and reduced peptide concentrations 
 In a separate vaccination regimen for the alternating T-helper peptide regimen 
involving reduced peptide concentration and a single TLR agonist (Poly I:C), the 
mixture was prepared without the presence of emulsion. 10 µl of Poly I:C (50 
µg/mouse, from a stock solution of 5mg/ml) was mixed with the combinations of 
peptides as indicated in the example in Table 2.1. Here the peptide concentration was 
reduced to 25 µg/mouse where only 5 µl of each peptide (from a stock solution of 5 
mg/ml) was added as indicated in the vaccination groups.   
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2.2.3.3 Priming with OVA protein in CFA for the alternating T-helper peptide 
vaccination 
5ml stock solution of Ovalbumin (8 mg/ml) was mixed with 5 ml of CFA to make a 
final concentration of 4 mg/ml Ovalbumin. The mixture was then emulsified by 
either sonication on ice at 100% amplitude for 4 x 5 seconds, allowing 30 seconds 
for cooling between pulses, or by continuously passing the mixture between two 5 
ml glass syringes (Scientific Laboratory Supplies) attached together with a three way 
valve (DJB Microtech ltd.) until a stable emulsion was formed. To check for stable 
formation of emulsion, the emulsion was dropped into a beaker of water. The 
emulsion was regarded as stable if the drop formed on the surface of the water does 
not disperse (Figure 2.2 a and b). After the priming dose, the boosting dose was 




Figure 2.2 Emulsion formation: Emulsion prepared with pushing the mixture of 
CFA and OVA through 2 glass syringes. a) Emulsion formed after 10 rounds of 
pushing between syringes was not stable and starts to disperse in water. b) Stable 
emulsion is formed after approximately 100 rounds pushing the mixture through the 
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2.2.3.4 Preparation of the combined adjuvant for synergistic activation of 
cellular immunity (CASAC) 
There were 2 versions of CASAC used in our studies. Preparations were as described 
below: 
 
Poly I:C version - The vaccine comprises of 2 separate parts. The first part 
comprises of an emulsion which was made as described in section 2.2.2.3 and left in 
a 37oC water bath (Clifton unstirred waterbath) to be kept warm for administration. 
The second part was made by combining 20 µl of an MHC class I presented peptide 
(100 µg/mouse, 5mg/ml stock solution), 20 µl of an MHC class II presented peptide 
(100 µg/mouse, 5mg/ml stock solution), 10 µl Poly I:C (50 µg/mouse, 5 mg/ml stock 
solution), 5µl CpG (25 µg/mouse, 5 mg/ml stock solution),  1µl recombinant mIFN-γ 
(100 ng/mouse, 100 µg/ml stock solution) and 44 µl DPBS to make a final volume of 
100 µl. 100 µl of emulsion and 100 µl of the adjuvant were then mixed and vortexed 
for 1 minute. The vaccine prepared was administered within a 2 hours period. 
 
MPL version - The preparation of the MPL version of CASAC was similar to that 
of the Poly I:C version. In this version, 10 µl of MPL (25 µg/mouse, 5 mg/ml stock 
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2.2.3.5 Preparation of CASAC with IRX-2 in the vaccine mixture 
IRX-2 is a combination of biologic agents containing physiological quantities of IL-
1β, IL-2, IL-6, IL-8, GM-CSF, interferon-gamma (IFN-γ) and tumornecrosis factor-
alpha (TNF-α) generated by phytohemagglutinin (PHA) activation of human PBMC 
under GMP conditions by IRX Therapeutics.  
 
IRX-2 was obtained in aliquots of 10ml. In our studies, the lot number of IRX-2 used 
was #042908 which comprised of: 
IL-2 (6.3 ng/ml); IL-1β (0.71 ng/ml); IFN-γ (2.48 ng/ml); TNF-α (2.1 ng/ml);  IL-8 
(34.4 ng/ml); IL-6 (1.01 ng/ml) and GM-CSF (0.52 ng/ml) as quantified by IRX 
Therapeutics.  
 
The preparation of CASAC was as stated in section 2.2.3.4 but instead of inclusion 
of 44 µl of DPBS, 100 µl of IRX-2 was added into the vaccine mixture to make the 
final volume 156 µl of the first part of CASAC. 156 µl (equal volume) of emulsion 
was then added to the vaccine mixture and was vortexed for 1 minute. The prepared 
vaccine was then administered within a 2 hours period.  
 
In situations where IRX-2 is required to be given as a daily dose, IRX-2 is then 
thawed to room temperature and injection of 100 µl of IRX-2 was conducted near 




2.2.3.6 Preparation of rechallenge dose 
In vaccinations where a rechallenge with class I peptides were required, 20µl of the 
SIINFEKL peptides (100 µg/mouse, from a stock solution of 5 mg/ml) was mixed 
with 80 µl of DPBS to make a final volume of 100 µl. Rechallenge was conducted 
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2.2.4 Vaccine administration 
 
2.2.4.1 Intradermal injection (i.d.) 
For i.d. injections, mice were anesthetized with isofluorane using an anaesthetic 
system (VetTech Solutions Ltd - Figure 2.3). 5 mice were placed in the anaesthetic 
chamber and the system was turned on (2 litre/minute of oxygen and a flow rate of 4 
for isofluorane) for the initiation of anaesthesia. Once the mice were anaesthetized, 
one mouse was removed from the chamber and placed on the anaesthetic nozzle to 
ensure the mouse continued to receive isofluorane. At this stage, the flow rate for 
isofluorane was brought down to flow rate of 2. The anaesthetized mouse was then 
shaved (Wella contour clipper) on both the right and left flank. Area of injection was 
sterilized with an antiseptic, normally Chlorohexidine (Vetasept). Vaccine was then 
injected with a 0.3 ml insulin syringe with a 30 gauge needle (Beckton Dickinson) 
intradermally by pinching the skin layer and administering the vaccine into the 
pinched skin Half of the vaccine dose was administered with into each flank of the 
mouse. A bulge would appear if the intradermal vaccination was successful (Figure 
2.4). The mice were monitored until they were fully awake before returning them to 
their holding rooms.  
 
Figure 2.3 VetTech Solutions Ltd. anaesthetic system: Components of the system 
were as labelled.  
 




Figure 2.4 Intradermal injection: a) Initiation of anaesthesia in the anaesthetic 
chamber. b) Mouse transferred to anaesthesia nozzle for continued administration of 
anaesthetics. c) Mouse was shaved on both flanks. d) Vaccine was administered 
intradermally with an insulin syringe. e) After the i.d. vaccination on both flanks, 
bulging of the skin at the vaccination site could be observed indicating the 




2.2.4.2. Intraperitoneal injections (i.p.) 
Intraperitoneal injections were conducted for the priming dose of vaccine. Mouse 
was scruffed by the back of the neck and turned over to expose the abdomen after it 
had been restrained. A 0.3 ml insulin syringe with 30 gauge needle was used for the 
i.p. injection. The needle was inserted to the middle of the abdomen and then the 
priming dose was delivered.  
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2.3 Harvesting of blood and tissue 
  
2.3.1 Bleeding by tail vein 
Mice were bled through their tails. A sterile sharp scissors (Scientific Laboratory 
Supplies) or a No. 10 disposable blade (Swann Morton) was used to clip 1mm of the 
tip of the tail. 1.5 ml tube (pre-filled with 20 µl of sodium citrate as anticoagulant) 
was used to collect 100-150 µl of blood from a mouse. In cases where absolute cell 
counting was conducted, a 1.5 ml tube containing dried sodium citrate was used. 
These tubes were prepared by adding 20 µl of sodium citrate and left open to dry in a 
biological safety hood for 1-2 days.  
 
2.3.2 Harvesting the spleen 
In analyses where splenocytes was required, mice were first humanely killed with a 
schedule 1 procedure. Here we used a carbon dioxide (CO2) chamber (VetTech 
Solutions Ltd.) with rising levels of CO2 at a rate of 4 litre/minute. A maximum of 
10 mice could be humanely killed at once. Mice were left in the chamber till rigor 
mortis had set in. A mouse was then removed from the chamber and placed into a 
biological safety cabinet. It was sprayed with chlorohexidine for sterilization 
purposes. An incision was made on the right abdominal flank, as the mouse was 
placed on its back, with a sterile pair of scissors. A pair of tweezers was then used to 
slowly remove the spleen. Spleen was then placed into a 50 ml Falcon tube (Beckton 
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2.4 Fluorescent Assisted Cell Sorting (FACS) analysis of immunological 
responses 
 
2.4.1 FACS machine and setup 
In all of the FACS analyses, a 3-laser FACS Canto II (Beckton Dickinson) was used. 
In a multi-colour FACS analysis, compensation for the fluorochrome involved was 
conducted using single colour stained samples and an unstained sample for control. 
Compensation was calculated by the BD FACS Diva software (Beckton Dickinson) 
and manually readjusted with FlowJo software (Tree Star) where required. In the 
FACS analysis, 2 staining protocols were used. Surface staining was conducted for 
markers on the cell surface (i.e. CD3, CD8 and CD4) while intracellular staining was 
conducted for intracellular markers (i.e. FoxP3 and IFN-γ). 
 
2.4.2 Analysis of Antigen specific T-cells 
2 µl of R-PE H-2Kb SIINFEKL pentamer was added to 40 µl of whole blood in wells 
of a 96 well plate (Greiner Bio One). Pentamers were titrated with antigen specific 
OT-1 splenocytes to saturation point and were tested from batch to batch for 
variability. Incubation was conducted in the dark for 15 minutes followed by 
addition of 2 µl of PBlue anti-mouse CD3, 1 µl PE-Cy5.5 anti-mouse CD8a, 1 µl 
APC anti-mouse CD62L and 1 µl FITC anti-mouse CD44. After 15 minutes of 
incubation, red blood cells were lysed with 200 µl of RBC lysis solution for 7 
minutes or until the mixture turned clear. Plates were centrifuged (Rotanta 460R 
centrifuge) for 5 minutes at 400 xg. Supernatant was discarded and cells were 
resuspended with 200 µl of DPBS. This was repeated twice and finally resuspended 
with 200 µl of DPBS. Cells were analysed on the FACS machine and the data 
obtained was analysed with FlowJo (TreeStar).  
To gate for the SIINFEKL specific CD8 T-cells, the gating strategy was as outlined  
in Figure 2.5. The population of lymphocytes was gated by size (forward scatter - 
FSC) and granularity (side scatter - SSC) of the cells (Figure 2.5 a). The lymphocyte 
population was then gated for CD3 and CD8 positive cells (Figure 2.5 b). 
CD3+CD8+ T-cells were then gated for CD8+SIINFEKL+ T-cells. The data is 
presented as a dot plot of CD8 vs. SIINFEKL in which the percentage of 
CD3+CD8+SIINFEKL+ T-cells are determined (Figure 2.5 c). In order to set the 
gates on the SIINFEKL positive cells, negative gating was confirmed with 
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unvaccinated mouse PBMC stained with SIINFEKL pentamer (Figure 2.5 c-I) or a 
vaccinated mouse PBMC stained with an irrelevant LCMV pentamer (Figure 2.5 c-
II). SIINFEKL pentamer staining of OT-1 splenocytes which are almost 100% 
transgenic with a T cell receptor recognizing SIINFEKL, served as a positive control 
(Figure 2.5 c-III). This gating strategy was then applied for the stained vaccinated 






Figure 2.5 Gating strategy for SIINFEKL specific CD8+ T-cells: a) FSC vs. SSC 
gating of cells to determine the lymphocyte population according to size and 
granularity based on light scattering. b) Identification of the CD3+CD8+ T-cells. c) A 
negative control can be obtained by I) staining PBMC from unvaccinated mice with 
SIINFEKL pentamer or II) staining the PBMC from vaccinated mice with LCMV 
pentamer. III) Positive control for SIINFEKL pentamer by staining of OT-1 
splenocytes with the SIINFEKL pentamer. IV) An example of SIINFEKL pentamer 
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2.4.3 Analysis of FoxP3+ cells 
Cell surface marker staining was conducted with 1µl FITC anti-mouse CD4 and 1µl 
APC anti-mouse CD25 on 40 µl of whole blood aliquots in a 96 wells plate. 
Incubation was for 30 minutes in the dark at room temperature. RBC lysis conducted 
as stated in 2.4.2 and 2 washing steps with DPBS was carried out before 
reconstituting with 200 µl of Fix/Permeabilization buffer (Ebioscience). Cells were 
fixed and permeabilized for 30 minutes in the fridge (dark and cold). Cells can be 
left in this condition up to 18 hours with no significant difference in data obtained 
from cells incubated for 30 minutes. Cells were then washed with 200 µl of ice-cold 
Permeabilization Buffer for 3 times. The cells were finally resuspended in 100 µl of 
ice-cold Permeabilization buffer. 2 µl PE anti-mouse FoxP3 was used to stain the 
cells. 2 µl of PE Rat IgG2a kappa (isotype control) was used as an isotype control for 
FoxP3 staining. Staining was conducted in the fridge for 30 minutes. Cells were then 
washed twice with Permeabilization buffer and once with DPBS before being 
resuspended in 200 µl of DPBS for FACS analysis. Data were analysed with FlowJo 
and the gating strategy for PBMC stained for Tregs is shown in Figure 2.6. A 
population of lymphocytes was gated based on the FSC and SSC (Figure 2.6 a). 
CD4+ population was then gated on the lymphocytes (Figure 2.6 b) followed by 
CD4+CD25+ T-cells (Figure 2.6 c). The CD4+CD25+ were then determined for 
FoxP3+ staining by using an isotype control (Figure 2.6 d). The gating was then 
applied to a stained sample to determine the percentage of FoxP3 stained cells 
(Figure 2.6 e).  
 




Figure 2.6 Gating for Tregs: a) Lymphocytes were gated based on their FSC and 
SSC. b) Lymphocytes were then gated for CD4+ and c) for CD4+CD25+ cells. d) The 
CD4+CD25+ were stained with an isotype control to determine the gating for FoxP3+ 
cells and e) the gating applied to a stained sample, identifying the 






2.4.4 Intracellular Cytokine analysis 
Spleen from mice were made into single cell suspensions by mashing the cut up 
tissue with a syringe before filtering it through a 40 µm cell strainer (Beckton 
Dickinson) in sterile DPBS. After one round of washing, 1 ml of RBC lysis buffer 
was added to the pellet and resuspended gently. After 7 minutes the cells were 
washed twice with DPBS and counted in a haemocytometer to make a final 
concentration of 1 X 106 cells/200 µl in complete RPMI medium (10% Foetal calf 
serum (Dulbecco), 1% Penicillin/Streptomycin (Sigma) and Roswell Park Memorial 
Institute (RPMI) media (Sigma). 2 µl of 10mM Monensin (final concentration of 3 
µM - SIGMA), 0.2µl of 1mg/ml anti-mouse CD28 (final concentration of 1 µg/ml) 
and 1 µl of 5mg/ml peptide (for each peptide and final concentration of 25 µg/ml) 
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were added to the cell suspension and incubated for 5 hours in 37oC, 5% CO2 
incubator (Thermo Scientific) to produce cytokines. PMA (50 ng/ml)/Ionomycin (1 
µg/ml) stimulation was used to provide positive controls for staining. After the 
incubation period, cells were washed twice with 200 µl of DPBS before 
resuspending in a final volume of 100 µl of DPBS. Depending on subset of T-cells 
and type of cytokines to be analysed, the list of antibodies used is as below: 
CD4 subsets:  1.0 µl Percp-Cy5.5 Anti-mouse CD4 
  1.0 µl PE Anti-mouse IFN-γ  
  0.5 µl FITC Anti-mouse IL-17 
  2.5 µl PE-Cy7 Anti-mouse IL-4 
  1.0 µl Pblue Anti-mouse TNF-α  
CD8 subsets:  1.0 µl PercpCy5.5 Anti-mouse CD8 
  1.0 µl PE Anti-mouse IFN-γ 
Surface markers such as CD4 and CD8 were first stained for 30 minutes in the dark. 
2 washing steps followed by resuspensing the cells in 100 µl of DPBS. Cells were 
transferred to BD Falcon™ 5 ml round-bottom tubes (Beckton Dickinson). Cells in 
tubes were vortexed and 100 µl of IC fixation buffer (Ebioscience) was added drop-
wise. Cells were then left to be fixed for 20 minutes in the dark. 1ml of ice-cold 1 X 
Permeabilization buffer was added and centrifuged at 400 x g for 5 minutes. This 
step was repeated twice and cells were resuspended with 100 µl of 1 X 
Permeabilization buffer and transferred to a 96 well plate for subsequent staining 
with cytokine specific antibodies as shown above. Staining was conducted for 30 
minutes in the fridge, followed by 2 rounds of washing with 1 X permeabilization 




2.4.5 Absolute cell count 
20 µl of Flow-Count™ counting beads (1000 beads/µl) was added to 20 µl of whole 
blood from samples collected in tubes with dried anticoagulant. Cells were mixed 
gently by pipetting and lysed with 200 µl of RBC lysis buffer for 7 minutes. Cells 
were then centrifuged for 5 minutes at 400 x g and the supernatant was discarded. 
Finally, these cells were resuspended in 200µl of DPBS ready for FACS analysis.  
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2.4.6. Surface staining of senescence, exhaustion and activatory markers 
Surface staining for these markers was conducted in a similar fashion to that 
described in section 2.4.2. The antibodies and their concentrations were as follow: 2 
µl APC anti-mouse CD152 (CTLA-4); 2 µl PE anti-mouse CD274 (PD-L1); 2 µl 
FITC anti-mouse CD279 (PD-1); 1 µl PE anti-mouse CD223 (Lag-3); 1 µl PE-Cy7 
anti-mouse KLRG1 and 2 µl PE anti-mouse CD28. Cells were also stained with CD3, 
CD8 and CD4 antibodies as previously described. Gating strategy for CD28/CTLA-4 
is shown in Figure 2.7. Monocytes and lymphocytes were selected based on size 
(FSC) and granularity (SSC). Monocytes do not express CD28 or CTLA-4 and were 
used to determine the negative gating.  
 
 
Figure 2.7 Gating strategy for CD28 and CTLA-4: a) Lymphocytes and 
monocytes were gated according to FSC and SSC. b) The monocytes were then 
gated for CD3-CD8- cells and used as a negative control for stained T-cells shown in 
e and f. CD4 and CD8 T-cells gating is as shown in c and d. Percentage of CD28 and 
CTLA-4 in these cells were determined with the negative gating of monocytes (e and 
f). 
                                                                                                      CHAPTER 2 
90 
 
CpG has been shown to upregulate expression of PD-L1 in mouse monocytes121. 
Therefore, CASAC vaccinated mice and unvaccinated mice could be utilised to 




Figure 2.8 Gating strategy for PD-L1: Gating strategy for PD-L1 utilising 
monocytes from unvaccinated and vaccinated mouse. In the CASAC vaccinated 
mice, the monocytes express PD-L1, which is absent in unvaccinated mouse. 
Therefore the gate set here for CD8 vs. PD-L1 was utilised to determine PD-L1 
expression in T-cells. 
 
Gating strategy for PD-1 and KLRG-1 was based on the expression of PD-1 and 
KLRG-1 positive cells in activated T-cells (antigen specific CD8 T-cells). In young 
mice which are not antigen experienced, CD3+CD8+ T-cells showed almost no PD-1 
and KLRG-1 expression111. This enables the gating strategy for PD-1 (Figure 2.9 a 
and b) and KLRG-1 (Figure 2.9 c and d) to be conducted based on stained CD8 T-
cells from unvaccinated young mice as a negative control while stained SIINFEKL 
specific CD8+ T-cells were used as positive controls. An isotype control was used in 
determining the gate for LAG-3 (Figure 2.9 d and e)  




Figure 2.9 Gating strategy for PD-1, KLRG-1 and LAG-3: Gating for PD-1 
conducted with unvaccinated mouse PBMC for CD3+CD8+ T-cells as negative 
control (a) and SIINFEKL specific CD8 T-cells for positive control (b). Gating for 
KLRG-1 conducted with unvaccinated mouse PBMC for CD3+CD8+ T-cells as 
negative control (c) and SIINFEKL specific CD8 T-cells for positive control (d). 
Gating for LAG-3 was by staining PBMC from vaccinated mice with an isotype 
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2.5 Functional analysis of T-cells responses 
 
2.5.1 In-vivo Cytolytic T-Lymphocyte (CTL) assay 
Spleens were collected from healthy C57Bl/6 female mice. One healthy spleen was 
required to provide sufficient cells for 5 sets of in vivo CTL assays. Spleens from 
mice were made into single cell suspensions by cutting with a scalpel and then 
mashing with a syringe before filtering it through a 40 µm Cell strainer in sterile 
DPBS. After one round of washing, 1 ml of RBC lysis buffer (1 ml per spleen) was 
added to the pellet and resuspended gently. After 7 minutes of lysis, the cells were 
washed twice with DPBS, resuspended in DPBS and were counted with a 
haemocytometer. Splenocytes were then made to a final density of 1 X 107 cells/ml 
in serum free X-vivo 15 media (Lonza).  
 
Cells were separated into two 50 ml Falcon tubes (Beckton Dickinson) of equal 
volume. Antigen positive target cells for the in vivo CTL assay were made using 1 X 
107 splenocytes/ml pulsed with 10µg/ml SIINFEKL peptide. After 1 hour incubation, 
the peptide pulsed splenocytes were washed twice with DPBS. Cells were 
resuspended in DPBS at 2-5 X 107 cells/ml. These cells were then tested for 
presences of SIINFEKL in MHC-I H2Kb by staining a small aliquot of the cells with 
2 µl of PE Anti-Mouse OVA257-264 SIINFEKL peptide bound to H-2Kb. Almost 100% 
of splenocytes were shown to be loaded with SIINFEKL peptides (Figure 2.10 a). 
The target cells were then labelled with 0.3 µM of DDAOSE or CFSE 
(DDAOSE/CFSE low). DDAOSE is a succinimidyl ester similar to CFSE but has 
excitation at 640nm and emission of 663-687. Antigen negative cells were not pulsed 
with peptide and were labelled with 3 µM of DDAOSE (DDAOSE high). After 7 
minutes of incubation in the dark, cells were washed with RPMI complete medium 
at 10 fold of the staining volume, repeated twice. Cells were finally resuspended in 
DPBS at a concentration of 1 X 108 cells/ml. A ratio of 1:1 (antigen positive target 
cells : antigen negative cells) was obtained (Figure 2.10 b). The cell mixture was 
then injected intravenously (i.v.) through the tail vein in a volume of 100 µl 
containing 107 of the antigen positive and antigen negative cells. An aliquot of the 
cell mixture was incubated in a 37oC, 5% CO2 incubator. 
Sixteen to eighteen hours after i.v. injections of cells, mice were humanely killed by 
schedule 1 procedure and spleens were harvested. Spleens were made into single cell 
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suspension as mentioned above in DPBS and analysed with FACS (Figure 2.10 c). 
Cell mixture incubated with the same period of time was also used as a negative 
control to ensure no changes occur to the percentage of antigen positive and antigen 
negative cells (Figure 2.10 d). Percentage of antigen specific cell lysis was calculated 




Figure 2.10 In-vivo CTL assay gatings: a) Histogram shows the peptide pulsed 
(red line) and unpulsed (blue line) splenocyte populations after staining with anti-
mouse OVA bound to H-2Kb PE antibody. b) CFSE low and CFSE high splenocytes 
were at an approximately 1:1 ratio (antigen positive : antigen negative). c) In vitro 
mixed population of target and non-target cells which were left for the same period 
as the in vivo CTL assay confirmed the presence of the two cell populations at a ratio 
of approximately 1:1. d) A representation of the recovered splenocytes from an 
emulsion only vaccinated mouse, where the percentages of cells obtained confirmed 
the presence of the two cell populations at a ratio of approximately 1:1. 
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2.5.2 In-vitro proliferation of antigen specific Tregs 
Splenocytes from vaccinated mice were made into single cell suspension and stained 
with 3 µM CFSE as described in 2.5.1. Cells were then resuspended at a density of 1 
X 106 cells/ml in complete RPMI medium and aliquoted into 48 well plates (Greiner 
Bio One). 25 µg of each peptide (ISQ and TEWT or PADRE) was added to the 
culture. On day 4, cells were analysed for proliferation as indicated by lower 
intensity of CFSE. 250 µl of cells were collected from each well into a 96 well plate. 
Cells were washed twice with DPBS and resuspended in 100 µl DPBS. Cells were 
stained with LIVE⁄DEAD® Fixable Far Red Dead Cell Stain (0.2 µl/well from stock 
solution (Invitrogen) for 15 minutes in the dark at room temperature. Cells were 
washed twice with RPMI medium and 1 X DPBS before resuspension in 100µl 
DPBS. Cells are then stained with anti-mouse CD4 and FoxP3. Staining was 
conducted as described in section 2.4.3 and after completion of staining and washing, 







2.6 Statistical analysis 
Two-tailed Student's t test was conducted on data with a normal distribution to 
determine significance. However, in instances where a normal distribution of data 
was not seen, Mann Whitney test was conducted to determine statistical significance. 
All statistically analysis were conducted using GraphPad Prism (GraphPad Software, 
Inc) 
Standard error of mean (SEM) were used in all the analysis conducted. SEM is a 
hypothetical quantity of error from the mean value of samples from a population. In 
all my analysis, I assumed that the vaccinated or unvaccinated mice were samples 
from a population (by definition the entire mice population). However, this is 
inaccurate as the vaccinated and unvaccinated mice are the population that I have 
been studying. Therefore the use of standard deviation (SD) which is defined as the 
average deviation of the samples values from the mean in a population would be a 
more accurate statistical analysis.  
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Multiple comparisons should also be considered when comparing three or more 
groups. In this case an analysis of variance (ANOVA) could be conducted. Further 
analysis can be conducted with the Bonferroni method to determine the differences 
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3.1 Introduction and Study objectives 
 
3.1.1 Introduction 
Peptide vaccination, particularly when used in combination with appropriate 
adjuvants can generate the stimulation and expansion of antigen specific T-cells. If 
the antigenic peptide used is an MHC I (Class I) restricted peptide, the stimulated T-
cells will be of the CD8+ subset. In the absence of a T-helper peptide which is 
usually an MHC II (Class II) restricted peptide, antigen specific CD8 T-cells can still 
be generated but with less expansion of the memory CD8 T-cells40. A strong CD8 
response without help does not necessarily generate memory T-cells43. However, 
repeated stimulation of the same population of CD4+ T-cells with a CD4 restricted 
peptide (T-helper peptide) could generate antigen specific Tregs as shown by 
Apostolou et al., (2004) when minute doses of the antigen were delivered by an 
osmotic pump68. Belkaid et al. (2009) stated that Tregs are important in controlling 
collateral damage in inflammatory situations123 and therefore in vaccination, the 
repeated stimulation of the same population of CD4+ T-cells could suppress the 
generation and expansion of CD8+ T-cell responses.  
In the light of this background information, T-helper peptides are on the one hand 
necessary for induction of effective and long term immunological responses. On the 
other hand, repeated stimulation of CD4+ T-cells by multiple rounds of vaccination 
could prove counterproductive, resulting in greater stimulation of Tregs and reduced 
or shorter lived duration of CD8+ mediated responses (e.g. by exhaustion and/or 
eventual depletion of a specific clone of CD4+ T-helper cells). We hypothesised that 
by alternating the T-helper peptides in consecutive rounds of  vaccinations, it would 
be possible to obtain robust and long term CD8+ T-cell responses required for 
disease clearance (e.g. as in cancer therapy), whilst avoiding the generation of Tregs. 
Chicken ovalbumin (OVA) was utilised as a model antigen as it is well studied. In a 
standard peptide vaccination protocol, an MHC class I presented OVA peptide, i.e., 
SIINFEKL, and an MHC class II presented OVA peptide (as T-helper peptide, 
ISQAVHAAHAEINEAGR - ISQ) were used repeatedly to vaccinate mice (Figure 
3.1 a). In an alternating T-helper peptide vaccination protocol, SIINFEKL was used 
together with two alternating T-helper peptides ISQ and another OVA derived 
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peptide restricted by class II, TEWTSSNVMEERKIKVY (TEWT) in consecutive 
rounds of vaccination (Figure 3.1 b)  
 
 
Figure 3.1 Concept of alternating T-helper peptides: a) A standard vaccination 
protocol where the same set of class I and class II peptides were administered at 
every vaccination time point. b) An alternating T-helper peptide vaccination protocol 
where the same class I peptide was used together with alternating T-helper peptides 
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3.1.2 Study Objectives 
a) Investigate the optimum vaccination regimen and adjuvants required to 
generate enhanced antigen specific CD8 T-cell responses through alternating 
T-helper peptide vaccinations. 
b) Assess if the magnitude of Treg expansion differs in the two vaccination 
protocols. 
c) Functional analysis of antigen specific CD8+ T-cell responses generated by 
the two vaccination protocols. 
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3.2 Alternating T-helper peptide vaccination to promote SIINFEKL specific 
CD8+ T-cells.  
 
3.2.1 Vaccination design 
Effective vaccination requires one or more adjuvant to provide sufficient innate 
stimulation. Adjuvants from CASAC52, which is a combination of a class I peptide, a 
class II peptide, two TLR agonist (which activates independent NF-κB pathway), 
mIFN-γ and emulsion (Tween-80 and squalene) were adapted to investigate the use 
of alternating T-helper peptides. The adjuvant chosen for this study was a 
combination of TLR-3 agonist, Poly I:C (50µg); TLR-9 agonist, CpG ODN 1826 
(25µg) and emulsion (4% Squalene and 0.2% Tween 80). 100µg of each peptide 
were used to vaccinate each mouse. The groups of mice vaccinated are shown in 










Figure 3.2 Vaccination and analysis time points: a) Vaccination group and 
components of vaccine. Adjuvant used in this design consists of Poly I:C 
(50µg/mouse), CpG (25µg/mouse), 0.2% Tween 80, 4% Squalene and PBS. Each 
peptide included in the vaccine is 100µg/mouse. b) Vaccination schedule with 
vaccination and analysis time points. Intra dermal vaccination was conducted while 
collection of PBMC for analyses were conducted by tail vein clipping. Analyses as 
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3.2.2 Vaccination with Poly I:C and CpG produces high percentages of 
SIINFEKL specific CD8+ T-cell 
In this vaccination protocol, high percentages of SIINFEKL specific CD8+ T-cells 
were obtained with no significant differences between groups vaccinated with a 
single class I peptide alone or in combination with a T-helper peptide. SIINFEKL 
specific CD8+ T-cells were analysed 10 days post each vaccination on PBMC 
collected by tail vein using an H-2Kb/SIINFEKL pentamer. FACS gating was as 
presented in Figure 3.3. CD3+CD8+ T-cells in the unvaccinated mice stained with 
SIINFEKL pentamer were used as a negative control to set the background gate 
according to Figure 3.3 and the same gating strategy was then applied to other 
samples which were pentamer stained. A representative example of a stained sample 
is shown in Figure 3.3. Positive control staining was also conducted with the use of 
OT-1 splenocytes which produced almost 85% SIINFEKL specific CD8+ T-cells 
(Figure 3.4). 
The use of Poly I:C and CpG in the vaccine generated 40-75% SIINFEKL specific 
CD8+ T-cells after 7 rounds of vaccination. From the second vaccine onwards, the 
percentages of SIINFEKL specific CD8+ T-cells increased consistently across all 
groups. No statistically significant differences were seen by comparison of the 
alternating T-helper peptides with the repeated use of the same one or two helper 
peptides. Even in the absence of a class II T-helper peptide, the group vaccinated 
with SIINFEKL alone generated similar responses to groups vaccinated with T-
helper peptides. The data was not significantly different using a Student's t test 
analysis (Figure 3.5). 
 




Figure 3.3 Gating strategy for SIINFEKL specific CD8+ T-cells: a) The 
lymphocyte population was identified and then b) gated for CD3+CD8+ cells. The 
CD3+CD8+ population was gated for CD8+ and SIINFEKL+ pentamer staining. c) 
Scatter plot shows staining with SIINFEKL pentamer on a PBMC sample from an 
unvaccinated mouse while d) shows staining on a PBMC sample from a vaccinated 
mouse 10 days after the first vaccination. 
 
 
Figure 3.4  Pentamer staining of OT-1 splenocytes: Splenocytes obtained from an 
OT-1 transgenic mouse in which all T-cells express has SIINFEKL specific T-cell 
receptor. The left panel shows LCMV specific pentamer staining and the right panel 
shows SIINFEKL specific pentamer staining in the OT-1 splenocytes. 
 




Figure 3.5 Percentage of SIINFEKL specific CD8+ T-cells detected 10 days post 
each vaccination: The data shown was not significantly different when comparing 
between the groups at each time point with a Student's t test analysis. Mean ± SEM 
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3.2.3 SIINFEKL specific CD8+ T-cells generated have a predominantly effector 
memory phenotype 
Having found that the presence of T-helper peptides did not enhance the generation 
of SIINFEKL specific CD8+ T-cells (see section 3.2.2); memory subsets were 
investigated in the SIINFEKL specific CD8+ T-cells to determine if the use of T-
helper peptides had enhanced the generation of the memory CD8+ T-cells. In this 
study we found that SIINFEKL specific CD8+ T-cells generated were found to be 
predominantly of the effector memory phenotype. Memory subsets were identified 
with CD44 and CD62L markers124 (see Figure 3.6 a). Unvaccinated mice were 
analysed for memory subsets within the CD3+CD8+ T-cells as no SIINFEKL specific 
CD8+ T-cells were detectable prior to vaccination (Figure 3.5). Percentages of 
memory subsets on CD3+CD8+ T-cells of unvaccinated mice are shown in Figure 3.6 
b.   
In the population of SIINFEKL specific CD8+ T-cells about 95% of all SIINFEKL 
specific CD8+ T-cells were found to have the effector memory phenotype in all of 
the vaccinated groups (Figure 3.6 c). Therefore, presence of T-helper peptides did 
not impact on memory CD8 T-cell type. There were few central memory cells within 
the SIINFEKL specific CD8+ T-cells. This is probably due to the repeated 
stimulation with the vaccine which emulates a persisting need of effector memory 
SIINFEKL specific CD8+ T-cells as in an infection where the antigen has not been 
eliminated57. The high percentage of effector memory T-cells within this population 
was also previously seen in CASAC vaccinations, producing high percentages of 
antigen specific T-cells52.  
The percentage of naïve T-cells in the unvaccinated mice is significantly higher 
compared to the vaccinated mice (Figure 3.6 d and 6 e). Almost no naive T-cells 
were found within the SIINFEKL specific CD8+ T-cells. This is consistent with 
other studies and to be expected from the continuum linear differentiation of cells 
from naive → effector → effector memory → central memory cells57. 




Figure 3.6 Memory phenotype analysis: a) Gating strategy for memory T-cells 
subsets. b) In unvaccinated mice, memory subsets were determined from total 
CD3+CD8+ T-cells in order to understand the percentages in normal resting mice.  
Percentage of c) effector memory, d) central memory and e) naïve T-cells within the 








In all the vaccinated mice, either in the presence or absence of T-helper peptides, no 
significant differences were evident in the generation of SIINFEKL specific CD8+ T-
cells. The percentage of SIINFEKL specific CD8+ T-cells increased consistently 
throughout the 7 cycles of vaccination with an effector memory phenotype for the 
majority of T-cells. Low percentages of central memory T-cells were also found 
within the SIINFEKL specific CD8+ T-cells but no significant differences were seen 
between the different vaccinated groups. The continuous expansion and proliferation 
of SIINFEKL specific CD8+ T-cells was probably due to the effect of the strong 
adjuvant used. Poly I:C and CpG ODN1826 are capable of causing a synergistic 
effect on NF-κB activation by two different signalling pathways52, 125.  High quantity 
of peptides (100µg) might also be a cause for the continuous expansion of 
SIINFEKL specific CD8+ T-cells. Therefore any effects by T-helper peptides 
appeared to be masked by this vaccination strategy. 
The original plan for these studies was to proceed to ten rounds of vaccination. 
However, following the eighth vaccination some of the mice were unwell and 
humanely killed. Therefore, the study was terminated at this point. Spleen, lymph 
nodes, liver, lungs and heart tissue were sent for pathological examinations to 
establish possible illness due to the vaccination regimen resulting to lymphocytes 
infiltrating organs. However, pathology results showed very little invasion of 
lymphocytes into these organs. Therefore, we were unable to conclude the primary 
cause of the illness suffered by the vaccinated mice. 
To study the effects of T-helper peptides, an experiment which induces less CD8 T-
cells responses was designed. The vaccine adjuvant consisted of Poly I:C only. Poly 
I:C is a weaker TLR agonist compared to CpG in mice because APC in mice express 
lower level of TLR-3 which requires stimulation by the TLR-4 agonist by LPS126, 127. 
The high numbers of vaccinations conducted also eliminates the need for an 
emulsion which provides the depository effect. Peptide quantity was also reduced 
from 100µg to 25µg to reduce the percentage of SIINFEKL specific CD8+ T-cell 
generated. Resting mice for a period of approximately 50 days also allowed 
investigation of a recall response52. 
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3.3 The use of a single TLR agonist to analyse the effect of T-helper peptides on 
the generation of SIINFEKL specific CD8+ T-cells. 
  
3.3.1 Vaccination design 
The groups remained the same as shown in Figure 3.2 a. The vaccine components 
and the vaccination schedule are shown in Figure 3.7 a and b, respectively.  
 
Figure 3.7 Vaccination schedule and analysis time points: a) Vaccination groups 
and components of vaccine. Adjuvant used in this design was Poly I:C (50µg/mouse) 
in PBS. Each peptide included in the vaccine is 25µg/mouse. b) Vaccination 
schedule and analysis time points. Intra dermal vaccination was conducted while 
collection of PBMC for analysis was conducted by a tail vein clipping. Analysis 
parameters were as described in section 2.4.2.  
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3.3.2 Peptide vaccination with a single TLR agonist produces low percentage of 
SIINFEKL specific CD8+ T-cells 
Vaccination with Poly I:C and use of a reduced quantity of peptides (25µg/mouse) 
produced lower percentages of SIINFEKL specific CD8+ T-cells compared to the 
previous vaccination regimen. However, vaccination with SIINFEKL alone and 
vaccination with SIINFEKL together with alternating T-helper peptides produced 
lower percentages of SIINFEKL specific CD8+ T-cells compared to vaccinations 
with the same one or two T-helper peptides. This was consistent following each of 
the 8 rounds of vaccination with SIINFEKL and SIINFEKL plus alternating T-helper 
peptides. Resting the mice for 50 days followed by a challenge with SIINFEKL 
peptides in PBS did not produce a significant increase in the percentage of 
SIINFEKL specific CD8+ T-cells, therefore no evidence of a recall response, except 
in the SIINFEKL + ISQ group. Even then the data was not significantly different 
with a Student's t test analysis when compared to SIINFEKL plus TEWT and 
SIINFEKL plus ISQ and TEWT.  
Groups vaccinated with one or two peptides produced higher percentages of 
SIINFEKL specific CD8+ T-cells after the 8th round of vaccination. The three 
groups vaccinated with ISQ, TEWT and ISQ plus TEWT as T-helper peptides 
generated higher percentages of SIINFEKL specific CD8+ T-cells from vaccine 4 
onwards. (Figure 3.8) 
 
 




Figure 3.8 Percentage of antigen specific T-cells generated 10 days after each 
round of vaccination: Group vaccinated with SIINFEKL + alternating ISQ or 
TEWT T-helper peptide did not produce comparable percentage of SIINFEKL 
specific CD8+ T-cells when compared to groups vaccinated with SIINFEKL + ISQ, 
SIINFEKL + TEWT and SIINFEKL + ISQ + TEWT.  A challenge with SIINFEKL 
plus PBS took place 50 days after resting the mice post the 8th vaccine. Mean ± 
SEM percentage. (n=5) 
 
 
3.3.3 SIINFEKL specific CD8+ T-cells have a predominant effector memory T-
cells phenotype 
Referring to Figure 3.8, levels of SIINFEKL specific CD8+ T-cells in groups 
vaccinated with alternating T-helper peptide vaccination or SIINFEKL only 
vaccination were at background (similar to unvaccinated group). Therefore, the data 
for memory subsets of these groups was not meaningful. After rechallenge with 
SIINFEKL, vaccination with one or two T-helper peptides generated a predominant 
effector memory T-cell phenotype within the SIINFEKL specific CD8+ T-cells and 
were not significantly different when compared between these groups (Figure 3.9 a).  
The percentage of central memory cells and naive cells detected were low and was 
                                                                                                      CHAPTER 3 
111 
 
not significantly different between those groups (Figure 3.9 b and c) after the 
challenge with SIINFEKL. 
 
Figure 3.9 Memory subsets of SIINFEKL specific CD8+ T-cells: a) Percentage of 
effector memory, b) central memory and c) naive memory cells in total SIINFEKL 
specific CD8+ T-cells present 10 days after each round of vaccination and 
rechallenge. No significant differences were found when comparing the groups 
vaccinated with one or two T-helper peptides after the rechallenge. Mean ± SEM 
percentage is shown. (Student's t test analysis, n=5) 
 
                                                                                                      CHAPTER 3 
112 
 
3.3.4 Vaccinations with a single TLR agonist and T-helper peptides do not 
expand Tregs 
The stimulation of CD4+ T-cells with a T-helper peptide might increase the 
percentage of Tregs and therefore the Treg population was analysed after eight 
rounds of vaccination. The percentage of Tregs from total CD4+ T-cells did not show 
differences between the different vaccination groups (Figure 3.10). The mean 
percentage of Tregs in each group was between 2.5% to 4% of the total CD4+ T-cells. 
 
 
Percentage of Tregs (CD4+CD25+Foxp3+)

































































Figure 3.10 Percentages of Tregs from total CD4+ T-cells after the 8th 
vaccination: No significant differences were seen using Student's t test analysis 










Vaccination with a single TLR agonist (Poly I:C - 50µg per mouse) and a lower level 
of peptide (25µg instead of 100µg) generated lower percentages of SIINFEKL 
specific CD8+ T-cells compared to when two TLR agonist (Poly I:C 50µg and CpG 
25µg per mouse) were used in combination. This lowered the level of responses and 
allowed the benefits of adding T-helper peptides to be seen. However, the use of 
alternating T-helper peptides, failed to generate significantly improved SIINFEKL 
specific CD8+ T-cell responses. In fact the lowest levels of SIINFEKL specific CD8+ 
T-cells were obtained when the helper peptides were completely excluded or when 
the two helper peptides (ISQ and TEWT) were used in cycles of alternating 
vaccination. In groups which produced SIINFEKL specific CD8+ T-cells (with 
inclusion of one or two helper peptide), the predominant cells had an effector 
memory phenotype. In order to further investigate the effect of using alternating T-
helper peptides, a priming step with OVA protein prior to the start of the vaccination 
regimen was introduced. In this approach, mice were inoculated with the OVA 
protein in complete Freund's adjuvant (CFA) 14 days prior to the vaccination with 
50µg of poly I:C and 25µg of each of one or more peptides as described in the next 
section. (3.4). Priming with complete Freund's adjuvant (CFA) provides an initial 
exposure of OVA antigens to the mice and therefore potentially generates a more 
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3.4. Peptide vaccination following initial priming step with whole OVA protein. 
 
3.4.1. Vaccination design 
Mice were primed with an intraperitoneal (i.p.) administration of 400µg of OVA 
protein in CFA and then vaccinated according to the groups (n=5) shown in Figure 
3.11 a. The adjuvant used in this study was similar to that described in section 3.3.1 
where 50µg of Poly I:C and 25µg of each peptide were mixed in PBS and 
administered intradermally.  The vaccination schedule and the analysis time points 
were as indicated (Figure 3.11 b). In this study, PBMCs were analysed for the 
presence of SIINFEKL specific CD8+ T-cells 3 and 10 days after each round of 
vaccination, in order to determine whether day 10 analysis may miss responses that 
could be detectable on day 3.  
 
Figure 3.11 Vaccination design: a) Vaccination groups and vaccine components. 
Mice were primed intraperitoneally with 400µg of OVA protein in CFA. Adjuvant 
used in this design was Poly I:C (50µg/mouse) in PBS. Each peptide included in the 
vaccine was 25µg/mouse. b) Vaccination schedule and analysis time points. 
Intradermal vaccination was conducted while collection of PBMC for analysis was 
by a tail vein clipping. Analysis parameters were as described in section 2.4.2.  
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3.4.2 Analysis of PBMC 10 days after each round of vaccination shows a higher 
percentage of SIINFEKL specific CD8+ T-cells percentage compared to 3 days 
after vaccination 
PBMC were harvested and analysed at three days and ten days after each round of 
vaccination (Figure 3.12). An initial priming vaccination with whole OVA protein in 
CFA enhanced the generation of a subsequent response to SIINFEKL vaccination 
with alternating T-helper peptides. Mice in groups 1 to 6 (either without a helper 
peptide or with the same helper peptide/s without alternating between the helper 
peptides) showed hints of lower percentages of SIINFEKL specific CD8+ T-cells 
than mice in group 7 where alternating T-helper peptides was used although it is not 
statistically significant. The responses over the first 5 doses of the vaccine were 
highly variable and the reasons for this were not clear.  This study also showed a 
trend that PBMC analyzed 3 days after vaccination had lower percentage of 
SIINFEKL specific CD8+ T-cells compared to samples analyzed 10 days after 
vaccination, although the data was not significantly different. In subsequent studies, 
responses to vaccination were examined only ten days after each round of 
vaccination. 
 




Figure 3.12 Percentage of SIINFEKL specific CD8+ T-cells 3 and 10 days after 
each round of vaccination: Student's t test conducted comparing 3 and 10 days 
showed no statistically significant variation. Mean ± SEM percentage was shown. 
(n=5) 




Figure 3.13 Alternative presentation of data: a) Percentage of SIINFEKL specific 
CD8+ T-cells obtained 3 days after each vaccination. b) Percentage of SIINFEKL 
specific CD8+ T-cells obtained 10 days after each vaccination. Means ± SEM (n=5) 
 
An alternative presentation of the data presented in Figure 3.12 is shown in Figure 
3.13 with data for analysis at 3 and 10 days after vaccination shown separately. All 
data points at 3 or 10 days after vaccination showed vaccine numbers 1 to 4 to have 
highly variable percentages of SIINFEKL specific CD8+ T-cells. For the 
presentation of data 10 days after each vaccination (Figure 3.13 b), data for vaccine 
rounds 1 to 4 were omitted as the data were inconsistent and not significantly 
different. The highest percentage of SIINFEKL specific CD8+ T-cells were detected 
in mice vaccinated with SIINFEKL in combination with alternating T-helper peptide 
(ISQ or TEWT) but the detected increase was not significantly different when 
compared to each of the other vaccinated groups. 
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3.4.3 Reduced percentage of Tregs in mice vaccinated with alternating T-helper 
peptides 
To investigate if the basis for the increased percentage of SIINFEKL specific CD8+ 
T-cells in mice vaccinated with the alternating T-helper peptides might be due to 
reduced suppression, the frequency of Treg was examined after the tenth round of 
vaccination (Figure 3.14). Cells with a Treg phenotype (CD4+CD25+FoxP3+) 
comprised between 2 and 7.5%. The lowest mean percentage of Tregs was found in 
mice that were vaccinated with SIINFEKL in combination with the alternating T-
helper peptides, suggestive that there may be reduced Tregs mediated suppression in 
this vaccination regimen. Vaccination with the adjuvant in the absence of peptides 
did not significantly alter the percentage of CD4 T-cells with a Treg phenotype. The 
reduced level of Tregs in mice vaccinated with the alternating T-helper peptides and 
SIINFEKL was statistically significant when compared with SIINFEKL alone 
(p=0.015) and SIINFEKL plus ISQ (p=0.034). The use of increased number and 
quantity of T-helper peptides was expected to increase the percentage of Tregs but in 
the SIINFEKL plus ISQ plus TEWT group, this increase was not observed. The 
basis for this observation is not clear and we are yet to be able to explain this data. 
 
Figure 3.14 Percentage of Tregs in the total CD4+ T-cells after 10 rounds of 
vaccination: Mean percentage shown. (n=1-5, *p<0.05 when compared to 
SIINFEKL or SIINFEKL plus ISQ, Student's t test analysis) 




The inclusion of a priming step with CFA and the whole OVA protein in this 
experiment has enabled the enhancing effect of alternating T-helper peptides 
vaccination on generation of SIINFEKL specific CD8+ T-cells to be revealed. 
Compared to previous experiments where only 0.4% SIINFEKL specific CD8+ T-
cells were generated with this peptide vaccination regimen (refer to Figure 3.8), the 
data now showed the generation of an average of 4.5% SIINFEKL specific CD8+ T-
cells. This higher level of response maybe due to the lower levels of Tregs in mice 
vaccinated with the alternating T-helper peptides and priming with OVA protein. 
With the combination of adjuvant, peptide quantity and priming step for the 
vaccination established, further investigation was undertaken to study the underlying 
mechanism of improved CD8 T-cell response generated by vaccination with the 
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3.5 Vaccination with the aid of alternating T-helper peptides generates 
enhanced SIINFEKL specific CD8+ T-cell responses 
 
3.5.1 Vaccination design: Two similar experiments were designed. In the first, mice 
were vaccinated every 7 days (weekly). In the second, the standard 14 days 
vaccination cycle was used (biweekly). The aim was to assess whether shortening 
the interval between vaccinations would enhance SIINFEKL specific CD8+ T-cell 
responses. Analysis were conducted 10 days after the indicated cycles of vaccination 
(Post vaccination 2, 4, 6, 8 and 10). The vaccination protocol for both the weekly 
and bi-weekly cycles are shown in Figures 3.15 and 3.16, respectively. 
  
Figure 3.15 Weekly vaccination protocol: a) Vaccination groups and vaccine 
components. Mice were primed intraperitoneally with 400µg of OVA protein in 
CFA. Adjuvant used in this was Poly I:C (50µg/mouse) in PBS. Each peptide 
included in the vaccine was 25µg/mouse. b) Vaccination schedule and analysis time 
points. Intradermal vaccination was conducted while collection of PBMC for 
analysis was by tail vein clipping. Analysis parameters were as described in section 
2.4.2. 




Figure 3.16 Biweekly vaccination protocol: a) Vaccination groups and vaccine 
components. Mice were primed intraperitoneally with 400µg of OVA protein in 
CFA. Adjuvant used in this was Poly I:C (50µg/mouse) in PBS. Each peptide 
included in the vaccine was 25µg/mouse. b) Vaccination schedule and analysis time 
points. Intradermal vaccination was conducted while collection of PBMC for 
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3.5.2 Vaccination on a weekly basis generates SIINFEKL specific CD8+ T-cell 
but was not significantly enhanced by alternating the T-helper peptides 
Vaccination 7 days apart resulted in generation of SIINFEKL specific CD8+ T-cells 
for all vaccinated groups. However there was no evidence of significant 
enhancement by the presence of one or two helper peptides, or the use of the 
alternating helper peptides. A recall response was also observed in all the vaccinated 
groups (Figure 3.17 a). There was a detectable trend to improved SIINFEKL specific 
CD8+ T-cell cell numbers (Figure 3.17 b). However, there was no statistically 
significant differences amongst the different vaccination groups. 




Figure 3.17 SIINFEKL specific CD8 T-cells in weekly vaccination: a) Percentage 
of SIINFEKL specific CD8+ T-cells generated in the weekly vaccination regimen. 
After 10 rounds of vaccination, mice were left to rest for 50 days before a 
rechallenge with SIINFEKL peptide (100µg/mouse) in PBS. Mean ± SEM 
percentage shown. (n=5). b) Absolute numbers of SIINFEKL specific CD8+ T-cells 
generated after 10 rounds of vaccination were obtained using counting beads 
(SIINFEKL specific CD8+ T-cells/µl of blood). Mean percentage shown. (Student's t 
test was carried out between the groups but no significant differences were observed 
when comparing between the vaccinated groups.) 
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3.5.3 Vaccination generates long lasting central memory phenotype within the 
SIINFEKL specific CD8+ T-cells 
In section 3.5.2, a recall response was observed in Figure 3.17 a. To investigate the 
effect of the different vaccination regimens on the effector and central memory T-
cells, the memory phenotype of the SIINFEKL specific CD8+ T-cells were examined.  
After resting the mice for 50 days, the SIINFEKL specific CD8+ T-cells were found 
to be "quiescent" presenting with a central memory phenotype (designated as Pre 
challenge in Figure 3.18) with less effector memory phenotype compared to previous 
analysis time points. This phenomenon of increased central memory phenotype is 
desirable in vaccinations as they provide long term protection. Central memory T-
cells generated, which have self renewing properties, remained within the SIINFEKL 
specific CD8+ T-cells but effector memory T-cells were depleted as these cells 
lacked CD127 expression which is an IL-7 receptor crucial for self renewal. The 
change in the percentages of central and effector memory cells has been shown by 
other studies57, 129 to be caused by the conversion of effector memory cells to central 
memory cells. 
By challenging the mice with 100µg of SIINFEKL peptide in PBS (i.d.), a recall 
response was observed as an increase in the percentage of SIINFEKL specific CD8+ 
T-cells (Figure 3.18 a). Reduced levels of central memory T-cells (Figure 3.18 b) 
and the increased levels of effector memory T-cells were observed within the 
SIINFEKL specific CD8+ T-cells cells, providing the basis for the robust recall 
responses presented. This was likely to be driven by the conversion of central 
memory T-cells to effector memory T-cells. However, there were no significant 
differences when comparing the different regimens. Therefore the use of alternating 
T-helper peptides was not shown to be superior or inferior in generating effector or 
central memory T-cells in the weekly vaccination regimen. 
 




Figure 3.18 Subsets of memory T-cells: Percentage of a) effector memory 
(CD44+CD62L-) and b) central memory (CD44+CD62L+) in the SIINFEKL specific 
CD8+ T-cells obtained 10 days after the indicated vaccine rounds for the weekly 
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3.5.4 Weekly vaccination with alternating T-helper peptides does not 
significantly affect the numbers or percentage of Tregs 
No significant changes were seen in the percentage of Tregs generated in each of the 
various vaccination groups (Figure 3.19 a). Vaccination with alternating T-helper 
peptides did not change the percentage of Tregs. However, SIINFEKL plus ISQ, 
SIINFEKL plus TEWT, and SIINFEKL plus ISQ and TEWT resulted in 
significantly increased numbers of Tregs when compared to unvaccinated mice or 
mice vaccinated with SIINFEKL plus alternating T-helper peptides (Figure 3.19 b). 
In section 3.4.3 (Figure 3.14), SIINFEKL alone and SIINFEKL plus ISQ vaccination 
resulted in higher percentage of Tregs compared to vaccination with alternating T-
helper peptides. Here the absolute cell numbers of Tregs showed a statistically 
significant increase in groups vaccinated with SIINFEKL plus ISQ (111 ± 8.7 
Tregs/µl blood), SIINFEKL plus TEWT (107 ± 11 Tregs/µl blood) and SIINFEKL 
plus ISQ and TEWT (113 ± 6 Tregs/µl blood) when compared to unvaccinated mice 
(62 ± 11 Tregs/µl blood) as well as SIINFEKL plus alternating T-helper peptide 
vaccinated mice (72 ± 8 Tregs/µl blood).   
  
Figure 3.19 Tregs analysis on weekly vaccination: a) Percentage of Tregs in the 
total CD4 T-cells after the 10th vaccination round. b) Absolute cell count of Tregs 
post the tenth vaccine using counting beads. Data obtain 10 days post the tenth 
vaccination. Mean ± SEM percentage shown. (*p>0.05 compared to group which 
was unvaccinated or group vaccinated with SIINFEKL plus alternating T-helper 
peptide, Student's t test analysis)  
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3.5.5 Priming step and biweekly vaccination is required for generation of robust 
SIINFEKL specific CD8+ T-cell in alternating T-helper peptide vaccination 
Investigation into vaccination conducted every 14 days showed the improved 
generation of SIINFEKL specific CD8+ T-cells with the alternating T-helper 
peptides vaccination as shown in Figure 3.19 a. After the 8th round of vaccination, 
the percentage of SIINFEKL specific CD8+ T-cells generated were higher than the 
rest of the vaccinated groups at 11.6 ± 4.6% compared with the highest percentage of 
3.6 ± 0.9% either with one or two helper peptides without alternating these peptides 
(Figure 3.20 a). The data obtained for the groups vaccinated with the alternating T-
helper peptides was shown to be significantly higher than each of the unimmunized, 
SIINFEKL only and SIINFEKL plus TEWT vaccinated groups (p<0.05, Student's t 
test). After the tenth, vaccination the mean percentage of SIINFEKL specific CD8+ 
T-cells was 29.9 ± 15.8% compared to maximum of 8.3 ± 2.7% in the other groups. 
The data was significant when compared to the unimmunized and SIINFEKL plus 
TEWT vaccination (p<0.05, Student's t test).  
SIINFEKL specific CD8+ T-cells number were determined after the tenth 
vaccination (Figure 3.20 b). Vaccination with alternating T-helper peptides 
generated the highest number of SIINFEKL specific CD8+ T-cells compared to all 
the other groups at 477 cells/µl of blood. This data is statistically significant when 
compared to unimmunized (3 cells/µl of whole blood), SIINFEKL plus TEWT (29 
cells/µl of whole blood) and SIINFEKL plus ISQ and TEWT (37 cells/µl of whole 
blood), (p=0.05. Comparison with other groups was not statistically significant. This 
data did not show normal distribution and thus Mann Whitney Test was employed) 
After the tenth round of vaccination, the mice were rested for 50 days and a 
prechallenge analysis of the percentage of SIINFEKL specific CD8+ T-cells was 
conducted. This showed a decrease in the percentages of SIINFEKL specific CD8+ 
T-cells in all groups. The challenge with 100µg of SIINFEKL (in PBS) then showed 
a recall response where the percentage of SIINFEKL specific CD8+ T-cells were 
seen to have increased in each of the vaccinated groups. Cell numbers were also 
quantified (Figure 3.20 d). Despite the higher absolute number of SIINFEKL 
specific CD8+ T-cells in the group with alternating T-helper peptides after challenge 
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with SIINFEKL peptides (837 cells/µl of whole blood), the data was not statistically 
significant when compared to other vaccinated groups. 
 
Figure 3.20 Percentage and absolute numbers of SIINFEKL specific CD8 T-
cells: a) Percentage of SIINFEKL specific CD8+ T-cells generated 10 days post 
vaccination number 2, 4, 6, 8 and 10; including the pre- and post-challenge 
percentages. The resting period is shown in the dotted lines for 50 days prior to a 
rechallenge. b) Representative plots of SIINFEKL specific CD8 T-cells gating in 
vaccinated mice. c) Absolute cell numbers of SIINFEKL specific CD8+ T-cells post 
the tenth vaccination. Peptide alternating vaccination was only found to be 
significantly different when compared to SIINFEKL + TEWT and SIINFEKL + ISQ 
+ TEWT. d) Absolute cell numbers of antigen specific T-cells generated after the 
rechallenge with SIINFEKL only. No significant differences were observed. 
(Student's t test employed in Figure 3.20a, Mann Whitney Test employed in Figure 
3.20 b and c) 




Figure 3.21 Memory subsets: Percentage of a) effector memory (CD44+CD62L-) 
and b) central memory (CD44+CD62L+) in the SIINFEKL specific CD8+ T-cells 
obtained 10 days after the indicated vaccine rounds for the biweekly vaccination 
regimen. Mean ± SEM percentage is shown (n=5). 
 
The percentages of central and effector memory T-cells in the biweekly vaccination 
were similar to the previous experiment in section 3.5.3 (Figure 3.17), where the 
dominant population was effector memory cells (Figure 3.21 a). During the rest 
period, there was loss of effector memory cells but increased percentage of the 
central memory population (Figure 3.21 b). The percentage of effector memory cells 
then increased again after the challenge with SIINFEKL as described previously in 
section 3.5.3. 
The increase in the percentage and the absolute cell number of SIINFEKL specific 
CD8+ T-cells in the group vaccinated with the alternating T-helper peptides showed 
the need for a priming step. Timing of the vaccination was also crucial as the weekly 
cycles of vaccination did not produce an improved response by the alternating helper 
peptides. 
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3.5.6 Vaccination with the alternating T-helper peptides does not result in 
expansion of Tregs 
With weekly cycles of vaccination, the alternating T-helper peptides regimen did not 
result in an expanded Tregs population. Similar results were obtained with the 
biweekly cycles of vaccination. There was no significant differences in percentages 
and absolute cell numbers in the group vaccinated with alternating T-helper peptides 
compared to the unvaccinated group. This might be one of the main reasons for the 
increased numbers of SIINFEKL specific CD8+ T-cells obtained by this vaccination 
regimen (Figure 3.22 a). Groups vaccinated with SIINFEKL and SIINFEKL plus 
ISQ showed significantly higher percentage of Tregs when compared to alternating 
T-helper peptide vaccination (Figure 3.22 a). This shows that in cases where T-
helper peptide was administered repeatedly over a long period of time, there is bound 
to be upregulation of Tregs and alternating T-helper peptides restricts the expansion 
of Tregs.  
A very important observation when comparing the numbers of Tregs generated in the 
weekly to the biweekly vaccination was the increased numbers of Tregs in the 
weekly vaccination (Comparing Figure 3.19 b to Figure 3.22 b). The unvaccinated 
mice showed about 50 Tregs/µl of blood for both sets of experiments showing that 
the data obtained in the two vaccinations are comparable. However, the weekly 
vaccination showed a significantly higher number of Tregs especially in the group 
vaccinated with SIINFEKL plus ISQ, SIINFEKL plus TEWT and SIINFEKL plus 
ISQ and TEWT compared to the biweekly vaccination. There was no significant 
differences when comparing the SIINFEKL and SIINFEKL plus alternating T-helper 
peptide vaccinations in the weekly and biweekly schedule. This shows that Treg 
expansion was seen after the repeated rounds of vaccination at short time intervals 
but this was avoided when using alternating T-helper peptides. 
 Analysis of antigen specific Tregs was also conducted in this batch of mice. After 
the in vivo CTL assay was conducted, splenocytes were harvested from the mice and 
made into a single cells suspension. 1 x 106 splenocytes from each mouse were 
labelled with 3µM of CFSE and subjected to T-helper peptides (25µg of ISQ and 25 
µg of TEWT) stimulation for 4 days. The cells were CFSE-labelled in order to 
observe antigen specific Treg proliferation. Proliferation of cells was measured by 
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CFSE dilution and detection by FACS analysis. Four days after the in vitro 
stimulation, cells were stained for FoxP3 and evaluated for intensity of CFSE 
staining. The FoxP3+ cells that proliferated represent the antigen specific Tregs 
(Figure 3.22 c). The data obtained showed a significant reduction of Tregs in groups 
vaccinated with SIINFEKL plus TEWT, SIINFEKL plus ISQ and TEWT and 
SIINFEKL plus alternating T-helper peptides compared to SIINFEKL vaccinated 
mice. However, results of Treg proliferation were puzzling because the unvaccinated 
and SIINFEKL vaccinated splenocytes showed significantly increased percentage of 
proliferated antigen specific Tregs when compared to groups which were vaccinated 
with 1 or 2 T-helper peptides where generation of induced-Tregs was anticipated. 
Based on Figure 3.22 d, a possible explanation might be that the number of cells 
recovered post the stimulation was insufficient in the groups vaccinated with T-
helper peptides despite inclusion of a cell death exclusion dye and the selection of 
only singlet cells by FACS analysis.  
This experiment should be repeated in future studies to investigate the generation of 
antigen specific Tregs in repeated vaccination with one or two T-helper peptides 










Figure 3.22 Tregs analysis: a) Percentage of Tregs from total CD4+ T-cells 
quantified after 10 rounds of vaccination. b) Absolute numbers of Tregs quantified. c) 
Percentage of proliferated antigen specific Tregs (CD4+FoxP3+) after four days of in 
vitro stimulation with ISQ and TEWT. Mean ± SEM was shown. (Student's t test for 
analysis of statistical significance) d) Representative example of gating strategy of 





                                                                                                      CHAPTER 3 
133 
 
3.5.7 Vaccination with alternating T-helper peptides generates SIINFEKL 
specific CD8+ T-cells with improved in-vivo cytolytic activity 
The SIINFEKL specific CD8+ T-cells were found to be increased in the mice 
vaccinated with SIINFEKL plus alternating T-helper peptides. In order to investigate 
the functionality of the SIINFEKL specific CD8+ T-cells, in vivo CTL killing of 
antigen positive target cells was examined.  Target cells for the in vivo CTL assay 
were made using 107 cells/ml splenocytes which were peptide pulsed with 10µg/ml 
SIINFEKL. The target cells were then labelled with 0.3µM of DDAOSE (DDAOSE 
low). Non-target cells were not pulsed with peptide and labelled with 3µM of 
DDAOSE (DDAOSE high). The 1:1 mixture of antigen positive (DDAOSE Low): 
antigen negative cells (DDAOSE high) was then injected intravenously (100µl 
containing 1 X 108 cells) into the vaccinated mice. The following day splenocytes 
were harvested and analysed by flow cytometry. Figure 3.23 a, shows representative 
histogram of the recovered antigen positive and antigen negative cells in each group 
of mice. 
The in vivo CTL killing assay showed a significant increase in target cell lysis only 
in the mice vaccinated with the alternating T-helper peptides compared to the 
unvaccinated mice. There was clear evidence of in vivo antigen specific lysis within 
the other groups, but the increased cytolytic activity was not significant because of 
the low numbers of mice and the variation in the magnitude of responses in 
individual mice. Similarly the higher level of in vivo CTL activity in mice vaccinated 
with the alternating helper peptides was not statistically significant when compared 
to other vaccination groups (Figure 3.23 b).  




Figure 3.23 In-vivo CTL assay: a) Representative histogram showing the levels of 
target and non-target cells for each group in the in vivo CTL killing assay of 
DDAOSE labelled splenocytes. DDAOSE low cells are target cells whereas 
DDAOSE high cells are non-target cells. b) Percentage of target cell lysis generated 
in each group post flow cytometry analysis. The percentage of cell lysis was 
calculated based on the calculation in section 2.3.1. Mean ± SEM percentage shown. 
(p>0.05, Student's t test analysis was conducted, n = 3-5) 
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Percentage of IFN-γ producing CD8+ T-cells were examined with an intracellular 
cytokine analysis assay. Splenocytes obtained from the mice were stimulated with 
SIINFEKL peptide, WT-1 peptide or subjected to PMA/Ionomycin stimulation 
(Refer to section 2.4.4 for intracellular cytokine analysis). Figure 3.22 a, shows 
representative plots of IFN-γ producing CD8+ T-cells post stimulation. All 
vaccinated groups were found to have IFN-γ producing CD8+ T-cells after 5 hours of 
in vitro stimulation with SIINFEKL peptide (25 µg/ml final concentration) (Figure 
3.22 b).  
Vaccination with alternating T-helper peptides produced significantly higher levels 
of CD8+IFN-γ+ cells when compared to splenocytes stimulated with an irrelevant 
peptide (WT-1). There were however no significant differences in the percentage of 
CD8+IFN-γ+ responses to SIINFEKL peptide between the vaccinated groups. 
Furthermore, no significant differences were detected in the amount of IFN-γ 
produced (as measured by geometric MFI) by the different groups (Figure 3.22 c) 




Figure 3.24 IFN-γ analysis: a) Representative plot for gating of IFN-γ+ CD8 T-cells. 
Splenocytes from SIINFEKL plus ISQ vaccinated mice were stimulated with an 
irrelevant peptide (here WT-1 was used) to provide the negative gating for IFN-γ 
producing cells. Splenocytes from unvaccinated mice were stimulated with 
SIINFEKL peptide to provide a negative gating as well. In order to obtain a positive 
gating for IFN-γ, splenocytes from SIINFEKL plus ISQ vaccinated mice were 
stimulated with PMA/Ionomycin. b) Percentage and b) Geometric MFI of IFN-γ 
producing CD8 T-cells after a 5 hours in vitro stimulation and in vitro cytokine 











Peptide vaccination is a cheap and simple method of augmenting cellular immunity. 
Improved antigen specific T-cell responses can be obtained if the right vaccination 
regimen is implemented. The experiments reported in this chapter addressed a 
number of specific questions:  
a) Optimum vaccination regimen and adjuvants required to generate enhanced 
antigen specific CD8 T-cell responses through alternating T-helper peptide 
vaccinations. 
Selection of an adjuvant is important as not all antigens used are strongly 
immunogenic28. Combinations of vaccine components such as different TLR agonist 
which activate the NF-κB130 by different signalling cascades is important for 
production of inflammatory cytokines that support the proliferation, differentiation, 
and survival of lymphocytes131. The CASAC52 vaccine adjuvant was modified to 
include a single TLR agonist (Poly I:C) in order to be able to address the 
requirement for helper functions. In addition, peptide quantities in the vaccine were 
reduced to a level where the benefits of T-helper peptide addition could be evaluated. 
Repeated vaccination with single or two T-helper peptides generated high percentage 
of SIINFEKL specific CD8+ T-cells as determined by pentamer staining. However 
the group vaccinated with alternating T-helper peptides failed to produce any 
responses. The introduction of a priming step which involved the use of CFA, an 
adjuvant derived from heat inactivated mycobacterium in an paraffin oil and 
surfactant mixture132, enhanced the percentage and number of SIINFEKL specific 
CD8+ T-cells. The priming step was found to be essential for improved CD8 T-cell 
responses to vaccination with alternating T-helper peptides128. The frequency of 
vaccination was also established to be best when conducted every 14 days compared 
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b) Differences in the magnitude of Treg expansion caused by the two 
vaccination protocols. 
In all the different vaccination protocols, continuous stimulation of a single CD4+ T-
cell epitope with a T-helper peptide lead to the generation of Tregs. This was most 
clearly evident when the vaccination was conducted every 7 days (Figure 3.19). By 
alternating T-helper peptide in the vaccination, there was no significant increase in 
either the percentages or numbers of Tregs, even after 10 rounds of vaccination. 
Banerjee et al. (2006)133 have reported that vaccination with cytokine matured 
dendritic cells expanded FoxP3 Tregs in melanoma patients133. The importance of 
generating antigen specific CD8 T-cell responses while avoiding expansion of Tregs 
was also stressed by Zou et al., (2006)134 
 
c) Functional analysis of antigen specific CD8+ T-cell responses generated by 
the two vaccination protocols. 
All vaccinations regimens showed increases in the percentage of IFN-γ producing 
CD8 T-cells following in vitro peptide stimulation with SIINFEKL. Comparison 
between regimens did not show any significant differences, possibly due to the 
variation in the magnitude of responses. The in vivo CTL killing assay however, did 
show that the use of alternating T-helper peptide induced significantly better killing 
of target cells compared to the other vaccination regimens 
 
d) Analysis of the type of memory CD8 T-cells generated by the two 
vaccination protocols. 
All vaccination regimens stimulated SIINFEKL specific CD8+ T-cells, 
predominantly comprising of the effector memory phenotype (CD44+CD62L-) when 
analysed 10 days after vaccination. After 50 days of rest, SIINFEKL specific CD8+ 
T-cells were predominantly of the central memory phenotype (CD44+CD62L+), 
which is indicative of conversion from effector to central memory cells. Central 
memory provides better long-term protective immunity and this was shown to be the 
case when the recall response was examined after 50 days of rest and rechallenged 
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with SIINFEKL peptide in the absence of adjuvant. This pattern of conversion from 
effector memory T-cells to central memory T-cells and recalled again from central 
memory T-cells to effector memory T-cells has been reported by Wherry et al.57 and 
Seder et al.129.  
 
3.7 Conclusion and future studies 
 
The data obtained from the experiments described in this chapter suggest that 
vaccination with alternating T-helper peptides generates enhanced cytotoxic antigen 
specific CD8 T-cells with reduced expansion of Tregs. However, more studies are 
required to further establish the benefits of the alternating T-helper peptides in 
vaccinations. Investigation into the generation of antigen specific CD4+ T helper 
cells as well as characterization of their function could provide a more detailed 
understanding. Different models of diseases should also be selected to study the 
effects of alternating T-helper peptide vaccination to break tolerance, especially 
when vaccinating against self antigens that are over expressed in cancer. For instance, 
WT-1 in leukaemia would be an excellent choice as it has been shown to be 
upregulated in leukemic cells and already used extensively in vaccination against 
cancer associated antigens135.   
Further analysis of the phenotype of the T-cells generated will also be crucial to 
determine the nature of the immunological responses generated. Markers such as 
PD-1, KLRG-1 and LAG-3 can be used to determine whether alternating T-helper 
peptide vaccination could reduce the risk of vaccination induced exhaustion of 
effector CD8 T-cells109.  
The ultimate test of a vaccination regimen will always be its protective or therapeutic 
efficacy. By pitting the vaccine against a well established tumour or a chronic 
infectious disease, it will be possible to assess whether vaccination with alternating 
T-helper peptides vaccination has the ability to enhance the immune mediated 
rejection of a chronic infectious disease or cancer. 






IRX-2 as a potential immunomodulatory agent 
to enhance the efficiency of vaccinating against 
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4.1 Introduction and Study objectives 
 
4.1.1 Introduction: IRX-2 is a combination of biologic agents containing 
physiological quantities of IL-1β, IL-2, IL-6, IL-8, GM-CSF, interferon-gamma 
(IFN-γ) and tumornecrosis factor-alpha (TNF-α) generated by phytohemagglutinin 
(PHA) activation of human PBMC under GMP conditions by IRX Therapeutics96. It 
has immunomodulatory properties that restore immune responsiveness, induces 
tumour infiltration in head and neck squamous cell carcinoma, increasing patient's 
survival outcome at 5 years97. IRX-2 was also found to  have adjuvant properties 
when administered to mice as 4 or 9 daily subcutaneous injections of 100µl with an 
immuno-dominant peptide derived from human prostate-specific membrane antigen 
(designated as NFT) which is found to be antigenic in Balb/c mice. Increased T cell 
responses were observed when IRX-2 was used in combination with incomplete 
Freund's adjuvant, NFT peptide conjugated with KLH or with irradiated cells 
expressing NFT98. These observations prompted the question of whether IRX-2 
could enhance the efficacy of generating of cyototoxic T-cells by CASAC 
vaccination52.  
We hypothesized that by including IRX-2 into CASAC vaccination, we would be 
able to generate more potent CD8 T-cell responses than is possible with the use of 
CASAC or IRX-2 individually.  
 
4.1.2 Study Objectives 
a) Investigation of different combinations of TLR agonists for assessment of 
synergy with IRX-2 
b) Investigation of the effects of IRX-2 on the memory and regulatory 
populations of T-cells 
c) Investigation of the potency of antigen specific CD8 T-cell responses 
generated by the combined adjuvant vaccination. 
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4.2. Optimizing the use of IRX-2 with CASAC vaccination.  
 
4.2.1 Vaccination design 
As shown in Chapter 3 and by Wells et al. (2008), different combination of vaccine 
components affect the level of antigen specific T-cells as well as their functional 
competence (e.g. cytotoxic activity). Thus comparison of the two best combinations 
of CASAC with IRX-2 was conducted as shown in G3 and G5 (Table 4.1 a). G3 
includes the use of MPL (a TLR-4 agonist) while G5 includes Poly I:C (a TLR-3 
agonist). Despite stimulating different NF-κB activation pathways, Poly I:C and 
MPL induced signalling are independent of the MyD88 pathway which is stimulated 
by CpG in order to enhance vaccination efficacy52, 125, 130.  ISQ peptide, an MHC 
class II presented T-helper peptide was used to provide help as part of the CASAC 
vaccination. 
 
Table 4.1 Vaccination design: a) Outline description of vaccination groups using 
CASAC and IRX-2. b) Outline of vaccination schedule. Refer to section 2.2.3.4 and 
2.2.3.5 for the concentration of CASAC and IRX-2 used.  
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IRX-2 has been recommended by Naylor et al. and IRX Therapeutics to be 
administered in 9 consecutive injections of 100µl/mouse (equivalent to 0.6ng of IL-2) 
at or near the site of vaccination98. The use of IRX-2 is as indicated in Table 4.1. 
Two rounds of vaccination with CASAC waswere conducted according to the 
schedule suggested by Wells et al. (2008)52. The percentages of SIINFEKL specific 
CD8+ T-cells were quantified on days 10 and 17 after the first vaccination. An in 
vivo CTL assay was conducted on day 18 to investigate the cytolytic activity 
generated by the different vaccination regimens. 
 
4.2.2 IRX-2 does not significantly enhance the generation of SIINFEKL specific 
CD8+ T-cells responses in combination with CASAC 
In this study, two versions of CASAC adjuvant were employed. Group 2 and 3 
utilised the MPL version while MPL were substituted with Poly I:C in Group 5. An 
adjuvant comprising emulsion and just one TLR agonist (MPL) was also tested 
(Group 4). Results presented in Figure 4.1 a show that all vaccination groups with 
CASAC generated SIINFEKL specific CD8+ T-cells at levels significantly above 
background (Group 1 - emulsion only) 17 days after the first round of vaccination. 
Some enhancement was seen in the percentage of SIINFEKL specific CD8+ T-cells 
present at day 17 in mice vaccinated with CASAC + IRX-2 compared to CASAC 
alone. However, differences were not statistically significant. Group 3 and Group 5 
generated 11.2 ± 3.8% and 8.3 ± 1.8% SIINFEKL specific CD8+ T-cells respectively 
compared to 4.7 ± 1.5%  in Group 2 (p=0.15) (Figure 4.1 b). A single TLR agonist 
(MPL) + IRX-2 vaccination (Group 4) did not stimulate SIINFEKL specific CD8+ T-
cells above the level in Group 1 -emulsion only control group. 
Although the data was not significantly different, IRX-2 did appear to be providing 
some help towards generation of increased levels of SIINFEKL specific CD8+ T-
cells. The data also shows that in the presence of IRX-2 either in the Poly I:C or 
MPL version of CASAC, the generation of SIINFEKL specific CD8+ T-cells were 
not impaired. 




Figure 4.1 Analysis of SIINFEKL specific CD8 T-cells in CASAC plus IRX-2 
vaccinations: Vaccine components were as describe in Table 4.1. Concentration of 
vaccine components were as described in section 2.2.3.4 and 2.2.3.5. a) The changes 
in percentage of SIINFEKL specific CD8+ T-cells and geometric MFI generated on 
day 10 and day 17 after the first vaccination. b) Comparison of percentages of 
SIINFEKL specific CD8+ T-cells in each groups on day 17 based on SIINFEKL 
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4.2.3 CASAC vaccination, either in the presence or absence of IRX-2, generates 
maximal target cell killing 
To determine if there was any improvement or impairment to the functionality of the 
SIINFEKL specific CD8+ T-cells generated by vaccination in the combined presence 
of IRX-2 with CASAC, an in vivo CTL killing assay was conducted. The method 
was as described in section 2.5.1. Target cells were splenocytes pulsed with 
SIINFEKL peptide (10µg/ml). The SIINFEKL loaded, target cells were stained with 
CFSE dye at a concentration of 0.3µM (CFSE low cells) while the non-target cells 
which were not loaded with SIINFEKL, were stained with a log higher concentration 
of CFSE at 3.0µM (CFSE high cells). Equal numbers of target (CFSE low cells) and 
non-target cells (CFSE high cells) were mixed together making the cell concentration 
1 X 108 cells/ml (in PBS). 100µl of the cell mixture were injected intravenously by 
tail vein injection of the vaccinated C57BL/6 mice and left overnight (16-18 hours).  
The splenocytes recovered from the vaccinated mice showed lower levels of the 
CFSE low (target) compared to the CFSE high (non-target) cells (Figure 4.2 a). In 
vivo CTL killing showed all groups vaccinated with CASAC in the presence or 
absence of IRX-2 to produced similar percentages of target cell lysislysis. CASAC 
vaccinated mice in Group 2 lysed 89 ± 3% of target cells (Figure 4.2 b). The 
inclusion of IRX-2 in CASAC vaccination showed similar levels of in vivo target 
cell lysislysis compared to CASAC only vaccination with 94 ± 0.6% and 92 ± 1.4% 
in G3 and G5 with no significant differences in the levels of lysislysis (Figure 4.2 b). 
The data presented showed that the use of either Poly I:C or MPL version of CASAC 
in combination with IRX-2 produced no significant differences compared to CASAC 
by itself. 
Despite no convincing expansion of SIINFEKL specific CD8+ T-cells detected by 
pentamer staining of mice vaccinated with emulsion + MPL + IRX-2 (Group 4), 
antigen specific cytolytic activity was detected, although at reduced levels (mean of 
40 ± 9%) compared to the other vaccination groups. (Figure 4.2 b). 
Further studies were needed to assess the possible benefits of IRX-2 to the outcome 
of vaccination. 




Figure 4.2 In-vivo CTL assay: a) Representative FACS plot of in vivo CTL activity 
in each vaccination group 18 hours after the tail vein injection of the cell mixture. 
Target cells which were loaded with SIINFEKL were CFSE low while non-target 
cells were CFSE high. b) Analysis of target cell lysis by the SIINFEKL specific 
CD8+ T-cells in each group. All vaccination groups showed statistically significant 
higher levels of lysis of antigen pulsed splenocytes (CFSE low, target cells) than the 















IRX-2 was shown by Naylor et al. (2010) to have the ability of increasing T-cell 
specific immune responses (DTH) against human prostate-specific membrane 
antigen (NFT) in mice, when combined with IFA or other adjuvants as described in 
section 4.1.198. The inclusion of IRX-2 in CASAC (either MPL or Poly I:C version) 
vaccination, however, did not generate significant differences in the generation of 
SIINFEKL specific CD8+ T-cells or target cell lysis when compared to CASAC only 
vaccination (MPL version). Vaccination using emulsion + MPL + IRX-2 was 
conducted to investigate the effect of inclusion of just a single TLR agonist, but no 
significant increase in SIINFEKL specific CD8+ T-cells was observed when 
compared to an emulsion only vaccination (without peptides). However, there was a 
significant increase in target cell lysis within the group vaccinated with  emulsion + 
MPL + IRX-2 when compared to the emulsion only vaccination. Unfortunately, this 
data could not be used to assess the possible benefits of addition of IRX-2 because a 
comparator group containing emulsion + MPL (without IRX-2) was not examined. 
In this experiment, IRX-2 was administered separately to the vaccine as an 
immunomodulator. In the next set of studies (section 4.2.1), IRX-2 was incorporated 
into the vaccine to act as a component of the adjuvant. 
In one arm of the vaccination regimen, IRX-2 was included directly into the vaccine 
(mixed with emulsion, adjuvant and peptides) and in the other arm IRX-2 was 
administered as in its standard protocol (administered in 5 daily doses or 9 daily 
doses after the first vaccination near the site of vaccination). IRX-2 has previously 
been shown to provide protection against apoptosis by downregulating FasL on 
primary T-cells which were co-cultured with tumour micro vesicles (TMV)100. 
Therefore, the inclusion of the IRX-2 into the adjuvant mix and its administration 
with each round of vaccination as an adjuvant might protect the activated T-cells 
from FasL/Fas induced apoptosis because activated T-cells in mice up-regulate 
FasL105. IRX-2 also promotes translocation of NF-κB to the nucleus thus stimulating 
the production of pro-inflammatory cytokines which sustain T-cell responses101. On 
this basis, it was speculated that CD8+ T-cell responses could be improved if IRX-2 
was mixed into the vaccine and administered as an adjuvant rather than a separately 
administered immunomodulator.  
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Investigation into generation of Tregs and subsets of memory T-cells was also 
performed to provide additional information on the efficacy and mechanism of IRX-
2 synergy with CASAC as IRX-2 has been shown to favour generation of effector T-
cells over regulatory T-cells in an in vitro setting106.  
The two different versions of CASAC (MPL and Poly I:C version) in the presence of 
IRX-2 showed no differences in the percentage of SIINFEKL specific CD8+ T-cells  
or the level of target cell lysis. Therefore only the Poly I:C version was used for 
subsequent studies because it is more readily available and less expensive. Poly I:C 
is a TLR-3 agonist that activates the TRIF pathway for the stimulation of NF-κB 
mediated responses while CpG is a TLR-9 agonist that activates the MyD88 pathway. 
This synergy between a MyD88-dependant and a MyD88-independent136 activation 
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4.3 Potential efficacy of IRX-2 as an immune adjuvant for peptide vaccination.  
 
4.3.1 Vaccination design 
The ability of IRX-2 to act as an immune adjuvant for inclusion in peptide 
vaccination or as a separately administered immunomodulator for the enhancement 
of efficacy of peptide vaccination was further examined. In these studies, IRX-2 was 
included in the vaccine preparation (with or without TLR agonists as indicated in 
Table 2). Alternatively, IRX-2 was given as a potential immunomodulator by 
intradermal injections for 5 consecutive days starting on day 2 after the first 
vaccination. In the study conducted by Naylor et al., 4 doses and 9 doses of IRX-2 
administered 1 day after the first vaccination, was shown to produce similar 
responses98. The vaccine combinations and groups were as indicated in Table 2. For 
the outline of the vaccination schedule, see Figure 4.3.  
Analysis of the immunological responses in the vaccinated mice included pentamer 
staining for SIINFEKL specific T-cells, and the quantification of Tregs and memory 
T-cells subsets. In vivo CTL killing assay was also carried out to determine the 
cytolytic activity of the SIINFEKL specific CD8+ T-cells generated. 
 
 
Table 4.2 Vaccination groups: Eight groups of mice were vaccinated as described 
above. The combination of "E + OVA + P + C + I" represents  CASAC vaccination 
(See G6). IRX-2 as an immunomodulator is given in 5 consecutive doses after the 
first vaccination. The final concentration of emulsion was 0.2% Tween80 and 4% 












4.3.2 Different IRX-2 vaccination regimens generate similar levels of 
SIINFEKL specific CD8+ T-cells 
The inclusion of 100µl of IRX-2 in the CASAC vaccine preparation, instead of 
administering it as 5 daily doses of 100µl after the first vaccination, generates the 
same percentages of SIINFEKL specific CD8+ T-cells (approximately 20%). The 
percentage of SIINFEKL specific CD8+ T-cells generated by CASAC alone was 
about 5% lower than the groups vaccinated with CASAC plus IRX-2 (Figure 4.4 a). 
The data is also corroborated by the geometric MFI generated (Figure 4.4 b). Despite 
the increase in the percentages of SIINFEKL specific CD8+ T-cells in the groups 
vaccinated with both CASAC and IRX-2, compared to the CASAC only group, the 
detected increase was not statistically significant.  
IRX-2 in combination with emulsion (0.2% Tween80 and 4% squalene) did not 
stimulate the generation of SIINFEKL specific CD8+ T-cells (Figure 4.4 a). It was 
shown by others that IRX-2 requires the presence of other adjuvants such as IFA or 
conjugation of peptide to KLH to induce the expansion/activation of antigen specific 
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CD8+ T-cells responses98. Therefore, IRX-2 by itself is not a effective immune 
adjuvant for peptide vaccination, but it may be able to act synergistically with other 
adjuvants such as Poly I:C or CpG, to enhance the response to vaccination.  
 
 
Figure 4.4 Analysis of SIINFEKL pentamer staining: a) Percentage of SIINFEKL 
specific CD8+ T-cells generated on day 20 in the emulsion and emulsion with IRX-2 
(in the vaccine or as 5 daily doses) and the CASAC vaccinated mice (with or without 
IRX-2). b) Geometric MFI of SIINFEKL pentamer positive CD8 T-cells 
corroborated with the percentage of SIINFEKL specific CD8+ T-cells. Mean ± SEM 
percentage and geometric MFI shown (Student's t test analysis, n=5). 
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4.3.3 CASAC plus IRX-2 vaccination generates effector memory SIINFEKL 
specific CD8 T-cells without increasing Tregs 
CASAC has been shown to generate predominantly effector memory SIINFEKL 
specific CD8 T-cells52. In this experiment, over 90% of the SIINFEKL specific 
CD8+ T-cells were found to have an effector memory phenotype (CD44+CD62L-) in 
all the CASAC vaccinated mice (Figure 4.5 a). This was observed either with or 
without IRX-2. The inclusion of IRX-2 in CASAC showed a statistically significant 
increase of 4% in the effector memory cells compared to CASAC only vaccination 
(Figure 4.5 a). There was no significant differences in the percentage of cells with a 
central memory phenotype (CD44+CD62L+) when comparing the two groups (Figure 
4.5 b). No naive cell phenotype was seen in groups vaccinated with CASAC (with or 
without IRX-2). In the unvaccinated mice, analysis of memory T-cell subsets were 
conducted on the CD3+CD8+ cells (data not shown but similar to that in section 
3.2.3). 
Repeated stimulation of CD4+ T-cells may lead to generation of Tregs which could 
suppress the activation and proliferation of antigen specific CD8+ T-cells. However, 
none of the vaccinated groups showed significant differences in the percentages of 
Tregs (CD4+CD25+FoxP3+) after two rounds of vaccination which included a T-
helper peptide 138 (Figure 4.5 d).  




Figure 4.5 Analysis of Memory subsets and Tregs: a) The percentages of effector 
memory SIINFEKL specific CD8 T-cells generated by CASAC vaccination at 10 
days after the second vaccination. b) The percentages of central memory SIINFEKL 
specific CD8 T-cells 10 days post the second vaccination. c) The percentages of 
naive CD8 T-cells 10 days post the second vaccination. d) The percentage of Tregs 
from total CD4+ T-cells 10 days post the second vaccination. (Student's t test 
analysis) 
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4.3.4 CASAC vaccination generates maximal cell killing in an in-vivo CTL 
killing assay 
 In section 4.2.3, the in vivo CTL killing assay showed no significant differences in 
the potency of CASAC compared to CASAC plus IRX-2 vaccination. Similar results 
were obtained in this experiment where over  95% of target cell (peptide loaded, 
CFSE low) lysis was detected (Figure 4.6). The inclusion of IRX-2, either in the 
vaccine or given as 5 daily intradermal injections after the first vaccination with 
emulsion and OVA peptides showed small, consistent, but not statistically 
significant increases (about 5%) in the in vivo CTL activity (Figure 4.6). Given that 
CASAC by itself could induce the in vivo lysis of over 95% of the target cells, the 
experimental design used here appears to be not suitable for assessment of any 
additional effects of IRX-2 in the stimulation of in vivo CTL activities.  
 
Figure 4.6 In-vivo CTL assays for the different vaccination regimens conducted 
on day 22 post the second vaccination. (*p<0.001 compared to all groups 
vaccinated with emulsion and OVA peptide without the TLR agonists (Poly I:C and 
CpG) or the unvaccinated group; Student's t test analysis, n=5) 
 




OVA peptides (SIINFEKL + ISQ) vaccination with emulsion and IRX-2 did not 
promote generation of SIINFEKL specific CD8+ T-cells beyond the background 
levels. This was the case whether IRX-2 was included in the vaccine or administered 
as daily intradermal injections after the first round of vaccination. In contrast, OVA 
peptides (SIINFEKL + ISQ) vaccination with CASAC generates high percentages of 
SIINFEKL specific CD8+ T-cells. The combination of CASAC with IRX-2 
administered either on a standard 5 daily doses or included in the vaccine preparation, 
did not enhance levels above the very high percentages of SIINFEKL specific CD8+ 
T-cells obtained with CASAC alone. These studies were therefore unable to assess 
the potential immune modulatory or immune adjuvant activity of IRX-2, as 
evaluated by either percentage of SIINFEKL specific CD8+ T-cells or by in vivo 
CTL activity. 
The memory subset of T-cells generated by CASAC vaccination corroborated with 
the data generated by Wells et al. (2008), where the SIINFEKL specific CD8+ T-
cells were found to be predominantly of the effector memory phenotype. Schilling 
et.al., (2011) also showed the ability of IRX-2 to expand effector memory subset 
instead of Tregs. In the present studies, IRX-2 combined with CASAC showed a 
significant 4% increase in the effector memory T-cell subset. CD4 T-cells in the 
vaccinated mice (CASAC ± IRX-2) showed no alteration in the percentage with 
regulatory phenotype (CD4+CD25+FoxP3+) 
Based on this data and also results from others98, 106, it would appear that IRX-2 by 
itself does not generate antigen specific CD8 T-cell responses. However, when IRX-
2 was combined with other adjuvants, it was shown to have immunomodulatory 
activities. Our data shows that CASAC alone is a very potent adjuvant and that 
inclusion of IRX-2 does not promote any further stimulation of the very high levels 
of T-cell activation induced by CASAC. Dilution of CASAC in order to stimulate 
suboptimal CD8 responses was therefore undertaken in order to be able to study the 
effects of IRX-2 in combination with CASAC. 
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4.4. Analysis of IRX-2 in combination with reduced concentration of CASAC. 
  
4.4.1 Vaccination design: CASAC was diluted from its standard concentration in 
order to weaken the CD8 T-cell responses, thus facilitating the investigation of the 
effects of IRX-2. Here, CASAC was diluted to a level where it would induce no 
significant SIINFEKL specific CD8 T-cells response by itself. The quantity of 
peptide for the vaccination remained as used previously (100µg of peptide per 
mouse). Dilution of the other components of the vaccine is shown in Figure 4.7. 
 
Figure 4.7 Vaccination design for CASAC dilution: a) Groups and dilution of 
CASAC, ranging from undiluted to 5000X dilution in 5 different groups and the 
vaccination schedule. b) Peptides and emulsion concentrations were unchanged 
while recombinant mIFN-γ, CpG and Poly I:C were diluted as indicated by the 
dilution factor. As an example in the 5X dilution, 100 µg of SIINFEKL, 100 µg of 
ISQ, 0.2% of Tween80, 4% of Squalene, 20 ng of recombinant mIFN-γ, 5 µg of CpG 
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4.4.2 5000X diluted CASAC vaccination generates background levels of 
SIINFEKL specific CD8+ T-cells 
The percentage of SIINFEKL specific CD8+ T-cells generated declined with 
increasing dilutions of CASAC (Figure 4.8 a). In the group vaccinated with emulsion 
and OVA peptides (SIINFEKL and ISQ), background levels of 0.4% SIINFEKL 
specific CD8+ T-cells were detected. The undiluted CASAC vaccination generated 
an average of 27 ± 4.6% SIINFEKL specific CD8+ T-cells. The percentages of 
SIINFEKL specific CD8+ T-cells declined with increasing CASAC dilutions. At 5X 
dilution of CASAC, an average of 19 ± 2.5% SIINFEKL specific CD8+ T-cells were 
generated. At 25X, 100X, 500X and 5000X dilution, the percentage of SIINFEKL 
specific CD8+ T-cells generated were 8 ± 1.8%, 3.5 ± 1%, 0.8 ± 0.2% and 0.4 ± 0.04% 
respectively. The data generated for undiluted CASAC and all dilutions till 500X 
were significantly higher than obtained by vaccination with the OVA peptides plus 
emulsion. At 5000X dilution of CASAC, the percentage of SIINFEKL specific CD8+ 
T-cells generated showed no significant difference compared to emulsion plus OVA 
peptide vaccination. 
The percentage of effector memory in SIINFEKL specific CD8+ T-cells declined 
with the reducing concentrations of CASAC (Figure 4.8 b), but was still significantly 
higher for the group vaccinated with CASAC diluted up to 25-fold. The percentages 
were similar for the higher dilutions when compared to the emulsion and OVA 
peptide vaccination.  
Treg phenotyping showed significantly lower levels in the standard CASAC and up 
to 100-fold dilution of CASAC groups compared to the emulsion and OVA peptides 
vaccination. However the, emulsion and OVA peptides, 500- or 5000-fold diluted 
CASAC showed a significant increase in Treg levels when compared to the 









Figure 4.8 Analysis of immunological effects of dilution of CASAC: a) 
Percentage of SIINFEKL specific CD8+ T-cells generated following vaccination 
with diluted CASAC preparations. b) Percentage of effector memory phenotype 
(CD44+CD62L-) in the total antigen specific T-cells. c) Percentage of Tregs 
(CD4+CD25+FoxP3+) in the total CD4+ T-cells generated after the second round of 
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4.4.3 Selection of CASAC dilution for IRX-2 study 
To study the potency of IRX-2, 100-fold dilution of CASAC was chosen. This 
dilution of CASAC generates a significantly higher percentage of SIINFEKL 
specific CD8+ T-cells compared to the emulsion only vaccination against OVA 
peptides. Percentage of Tregs generated in the 100X diluted CASAC was between 
the levels of Tregs generated in the unimmunized group and emulsion only 
vaccination against OVA peptides. 
 
4.4.4 Vaccination design for 100X diluted CASAC and IRX-2 
100X diluted CASAC, chosen as previously described, was combined with standard 
IRX-2 administration of 5 and 9 daily doses starting after the first vaccine. IRX-2 
was also included in the CASAC vaccine mix (Figure 4.9) 




Figure 4.9 Vaccination design with 100-fold diluted CASAC in the presence or 
absence of IRX-2: a) Vaccination schedule for the inclusion of IRX-2 into 100X 
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4.4.5 Inclusion of IRX-2 in the vaccine significantly increased percentage of 
SIINFEKL specific CD8+ T-cells generated by vaccination with a 100-fold 
diluted CASAC 
 In OVA plus IRX-2 vaccination, only background levels of SIINFEKL specific 
CD8+ T-cells were detected with no significant difference compared to the 
unvaccinated mice. All CASAC vaccinated mice showed significantly higher levels 
of SIINFEKL specific CD8+ T-cells compared to the non-CASAC vaccinated mice. 
Inclusion of IRX-2 in the 100-fold diluted CASAC vaccination showed a significant 
increase in percentage of SIINFEKL specific CD8+ T-cells compared to the 100-fold 
diluted CASAC vaccination (1.3 ± 0.3% compared to 0.6 ± 0.1%, p=0.047). The 5 
and 9  daily doses of IRX-2 did not enhance the generation of SIINFEKL specific 
CD8+ T-cells with 100-fold diluted CASAC (0.5 ± 0.06% and 0.9 ± 0.2% compared 
0.6 ± 0.1%) (Figure 4.10) 
 
Figure 4.10: Percentage of SIINFEKL specific CD8+ T-cells generated 10 days 
after the second vaccination with 100-fold diluted CASAC (Student's t test 
analysis, n=5) 
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4.4.6 100-fold diluted CASAC ± IRX-2 vaccination generates predominantly 
effector memory SIINFEKL specific CD8+ T-cells without expanding the Treg 
population 
SIINFEKL specific CD8+ T-cells were phenotyped for memory subset to investigate 
the effects of IRX-2 on the CASAC vaccination (100-fold dilution). In all the 
CASAC vaccinated groups (CASAC, CASAC + 5 doses IRX-2, CASAC plus 9 
doses IRX-2 and CASAC + IRX-2 in the vaccine), the SIINFEKL specific CD8+ T-
cells had a predominantly effector memory phenotype (CD44+CD62L-, see Figure 
4.11 a). Within the CASAC vaccinated groups, CASAC + IRX-2 in the vaccine 
generated the highest percentage of effector memory SIINFEKL specific CD8 T-
cells (84 ± 2.5%). This increase was significant when compared to CASAC only 
vaccination in which 69 ± 3% of the cells were of the effector memory phenotype 
(p=0.042). The other combination of 100-fold diluted CASAC and IRX-2 did not 
produce any significant changes in the effector memory cells.   
All CASAC vaccination regimens produced similar percentages of central memory 
SIINFEKL specific CD8 T-cells (CD44+CD62L+) (Figure 4.11 b). All vaccinated 
groups showed less than 5% naive T-cells (CD44-CD62L+). This shows that the 
SIINFEKL specific CD8 T-cells were all antigen experienced (Figure 4.11 c). 
In all non-CASAC vaccinated groups, there was no change in the percentage of 
Tregs compared to the unvaccinated mice (Figure 4.11 d). CASAC only vaccination 
produced no significant difference when compared to the unvaccinated mice. There 
was a significant increase in the CASAC + IRX-2 (IV) vaccination, 6.6 ± 0.4% 
Tregs of total CD4+ T-cells compared to 4.2 ± 0.2% unvaccinated mice (p=0.0078). 
However, there was no significant differences when comparing CASAC + IRX-2 
with the CASAC only vaccinated group. 




Figure 4.11 Analysis of memory subsets and Tregs: Percentage of effector 
memory (a), central memory (b) and naive T-cells (c)  in the SIINFEKL specific 
CD8+ T-cells after 2 rounds of vaccination with the indicated combinations of 
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 4.4.7 IRX-2 enhances the in-vivo CTL activity when used in combination with 
100-fold diluted CASAC vaccination 
Effects of IRX-2 on the in vivo CTL mediated lysis of antigen positive target cells 
were masked in the earlier studies reported in this chapter (see section 4.2.3 and 
4.3.4). This was interpreted to be due to induction of maximal SIINFEKL specific 
CD8+ T-cells responses by vaccination with the full strength CASAC. The dilution 
of CASAC to 100-fold of its original concentration of TLR agonists and mIFN-γ 
reduced the killing of target cells to 4.2 ± 1.2% (Figure 4.12 a). This reduction in the 
in vivo lysis of antigen positive target cells enabled the investigation of the effects of 
IRX-2 in CASAC vaccination. Vaccination with the OVA peptides plus IRX-2 did 
not produce any significant increases in the in vivo CTL activity. 
The combination of 100-fold diluted CASAC and IRX-2 given as 9 daily doses 
increased the in vivo lysis of target cells to 11.5 ± 3.8%, although the increase was 
just below the significance level (p=0.071). In the 5 daily dose administration of 
IRX-2 + 100-fold diluted CASAC vaccination, 12.2 + 2.1% of target cells were 
lysed and this was  significantly higher compared to the 100-fold diluted CASAC 
alone (p=0.012). The combination of IRX-2 in 100X diluted CASAC given as two 
doses mixed in the vaccine generated significantly higher percentage of in vivo CTL 
activity (11.7 ± 2.7%) when compared to 4.2 ± 1.2% lysis in the group vaccinated 
with 100-fold CASAC alone (p=0.036). There was a similar increase in the in vivo 
CTL activity of about 2 fold when 100-fold diluted CASAC was used in 
combination with IRX-2, given as 5 daily doses or mixed in the vaccine.  
 
 




Figure 4.12 In vivo CTL assay: a) Percentage of target cell lysis based on in vivo 
CTL killing assay by SIINFEKL specific CD8 T-cells 11 days after the second round 
of vaccination. b) Representative plot for the in vivo CTL assay (*p<0.05 when 













The mixture of adjuvants referred to as CASAC can be diluted to produce lower 
levels of SIINFEKL specific CD8+ T-cells. This involved reducing the concentration 
of the two TLR agonists and mIFN-γ, but maintaining the concentration and 
composition of the emulsion and OVA peptides. The decrease in the efficacy of 
vaccination with the diluted CASAC enabled the investigation of the effects of IRX-
2, as an immune adjuvant or immune modulator, for enhancing cellular immunity in 
response to peptide vaccination.  
IRX-2 alone was a poor adjuvant for peptide vaccination. Even in the presence of 
tween/squalene emulsion, IRX-2 did not provide sufficient stimulation to generate 
potent antigen specific CD8 T-cell responses. However, the combination of IRX-2 
with a 100-fold diluted CASAC showed that IRX-2 can increase the potency of CD8 
responses generated in vaccination with a combination of two TLR agonists. In this 
setting, IRX-2 was also able to increase the percentage of effector memory 
SIINFEKL specific CD8+ T-cells, without causing a significant increases in Tregs. 
This may provide the basis for the detected increase in the potency of the SIINFEKL 
specific CD8+ T-cells in the in vivo lysis of antigen positive target cells. Therefore, 
IRX-2 may be a suitable immunomodulator to enhance the potency of a weak 
vaccine as modelled here with the use of a diluted CASAC adjuvant. In addition, 
IRX-2 may provide a means to achieving better immunological responses when 
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4.5. Discussion  
The study reported in this chapter aimed to combine a potent adjuvant, CASAC, with 
IRX-2 which has been shown to have immunomodulatory activities. The objective 
was to increase the efficacy of generating potent CD8 T-cells responses, particularly 
against poorly immunogenic targets such as tumour associated antigens or antigens 
associated with chronic infections 
a) Investigation of different combinations of TLR agonists for assessment of 
synergy with IRX-2 
As stated in section 1.6.2, multiple potential combinations of TLR agonists in 
CASAC are able to produce similarly high levels of T-cell activation. Here it was 
shown that the Poly I:C and MPL version of CASAC in combination with IRX-2 
does not a significant increase in the very high level of response that can be achieved 
even without IRX-2. The addition of IRX-2 did show increase of a few percentage  
in the level of SIINFEKL specific CD8+ T-cells, but this was not statistically 
significant. The absence of detectable improvements could be because CASAC is a 
very potent combination of adjuvants. Therefore, to investigate the potential synergy 
between IRX-2 and other adjuvants, lower concentrations of CASAC were used. A 
CASAC formulation with a 100-fold lower concentration of Poly I:C and CpG was 
tested in combination with 3 different regimens of administering IRX-2. Vaccination 
with this 100-fold diluted CASAC yielded much lower percentages of SIINFEKL 
specific CD8+ T-cells, but still significantly above background. Although the 
addition of IRX-2 did not significantly increase the fraction of SIINFEKL specific 
CD8+ T-cells, the combination did significantly increase the lysis of the antigen 
positive target cells in the in vivo CTL assay. This is consistent with previously 
published data showing improved T-cell responses when IRX-2 was used for 
vaccination in combination with other weak adjuvants such as IFA98. The increase in 
potency may also be attributed to the demonstrated ability of IRX-2 in translocating 
NF-κB to the nucleus, leading to improved production of pro-inflammatory 
cytokines that enhance Th1 responses. Protection from apoptosis may also play a key 
role as most activated CD8 T-cells would go into apoptosis after the clearance of 
antigen100, 101.  
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b) Effects of IRX-2 on the memory population and Tregs 
Tregs were shown to be slightly increased in IRX-2 plus CASAC vaccination 
compared to unvaccinated mice, although previous studies have reported no 
expansion of Tregs when IRX-2 was co-culture with primary T-cells in the presence 
of immature DCs and irradiated tumour cells. The expansion of effector memory T-
cells seen in our vaccinated mice (100X diluted CASAC + IRX-2) was consistent 
with the previous findings that IRX-2 favours expansion of effector T-cells106. 
However, the increase seen in percentage of Tregs did not block the generation of 
higher levels of SIINFEKL specific CD8+ T-cells, or the in vivo cytolytic activity 
induced by the combined use of 100-fold diluted CASAC and IRX-2. Instead, the 
increase seen in the in vivo cytolytic activity potentially rendered the increase in 
Tregs insignificant to the vaccination. The most effective means of delivery of IRX-
2 appeared to be as a component of the vaccine mixture rather than the intradermal 
injections for 5 or 9 consecutive days after the first round of vaccination. 
 
c) The potency of antigen specific CD8 T-cell responses generated 
IRX-2 was shown to be a potential modulator/enhancer of cellular immunity, 
improving the potency of in vivo CTL activity. There is a possibility that the increase 
in the cytolytic activity is caused by improved survival of the T-cells generated. As 
mentioned in section 1.7, IRX-2 is able to block T-cell apoptosis, thus improving the 
survival of the activated T-cells. Such improved survival would lead to improved 
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4.6  Conclusion and future Studies 
 
In summary, IRX-2 by itself is not an effective adjuvant for vaccine mediated 
induction of peptide specific CD8 T-cell responses. However, when combined with 
other adjuvants, IRX-2 can enhance the efficiency of vaccination mediated induction 
of antigen specific CD8+ T-cell responses. Therefore, IRX-2 maybe a useful 
component in vaccination against diseases where immunological responses are 
difficult to achieve. Examples include vaccination against self antigens (e.g. WT-1 
for myeloid leukaemias and solid malignancies) or therapeutic vaccination against 
chronic infections (ege.g. chronic HBV infection) 
 Another possible use of IRX-2 could be to reverse age associated immunological 
deficiencies referred to as immune senescence or exhaustion. The aged population is 
more difficult to efficiently vaccinate as there is a much more restricted repertoire of 
T-cells available107. This is at least in part a product of age associated thymic atrophy 
hence a restricted ability to produce new naive T-cells139. In addition, the presence of 
a higher percentage of regulatory T-cells, hampers the ability to generate antigen 
specific CD8 T-cells in the aged population140. Therefore, IRX-2 is a potential 
candidate for improving immunological responses to vaccination in the aged 
population109. 






Peptide vaccination for generating functional 
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5.1 Introduction and study objective 
 
5.1.1 Introduction 
Vaccination for cancer and infectious disease can alter potentially effective means of 
immune therapy. However, such vaccination studies are usually carried out in young 
animals which have potent immunological responses, in part due to a proficient 
thymic output of naive T-cells, thus providing a sufficiently diverse population of 
immune competent T-cell. However, this is not necessarily true for the older 
individuals with a substantially atrophied thymus, and an immune system that is 
much less functional in multiple other ways120. In particular, patients requiring 
therapeutic vaccinations are generally older, especially true of cancer sufferers. Long 
term exposure to tumours, environmental factors and aging of the thymus causes 
patients to lose the ability to generate a complex enough repertoire of T-cells with 
the required diversity and functional competence for generating therapeutically 
effective immunological responses to vaccination107, 108, 139.  
To better emulate the situation in humans, mice that have aged more than 18 months 
could be used114-116. Aging in mice is associated with weak CD4+ and CD8+ T-cells 
responses due to deficiency in CD4+ naïve T-cells and a reduced repertoire of CD8+ 
T-cells, leading to less efficient generation of CD8+ T-cell responses, including 
memory T-cells107. Here we hypothesize that the use of CASAC in combination with 
IRX-2 could lead to the generation of enhanced CD8 T-cell cytolytic activity in the 
aged mice. Responses in both the aged and the young C57BL/6 mice were compared 
to the effects of vaccination with CFA as a standard adjuvant. 
Aged mice show increased expression of Killer cell lectin-like receptor G1 (KLRG-1) 
an inhibitory receptor expressed by NK and T-cells is the primary marker used to 
identify senescence in mice. In humans however, CD57 is an equally useful marker 
of senescence113. Increased expression of exhaustion markers such as PD-1 and 
LAG-3 has also been correlated with age and are known to be up-regulated with 
continuous exposure to antigen109. The increased expression of PD-1 and LAG-3 
have been associated with tolerance to both self and tumour associated antigens141. 
Increased presence of Tregs and expression of CTLA-4 on the surface of T-cells has 
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also been seen as part of the exhaustion mechanism. Therefore, the mechanisms 
involved in generating CD8+ T-cell responses could be investigated in terms of these 




5.1.2 Study Objectives: 
a) To investigate differences in senescence and exhaustion markers in T-cell 
population subsets between aged and young mice pre-vaccination 
b) To investigate the ability of aged and young mice to generate functional 
antigen specific CD8+ T-cells responses following vaccination with CASAC 
in combination with IRX-2 compared to a standard vaccination with CFA. 
c) To investigate changes in expression of exhaustion, senescence, activation 
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5.2 Pre-vaccination differences between the young and aged mice.  
 
5.2.1 Lower numbers of lymphocytes in aged mice 
Blood was collected from aged (>18 months old) and young mice (6-8 weeks old) 
from two different batches of C57BL/6 mice pre-vaccination. Cell count was 
conducted using counting beads of equal volume to anti-coagulated blood obtained 
by tail vein clipping. The initial lymphocyte cell numbers recorded for young mice 
were 6495 ± 673 cells/µl blood (batch one) and 4630 ± 512 cells/µl blood (batch 
two), values which were consistent with previous reports (Doeing et al., 2003), 8500 
cells/µl142. Lymphocyte count for aged mice however were lower at 3385 ± 358 
cells/µl blood (batch one) and 2254 ± 259 cells/µl blood (batch two) (p<0.001). This 
could be explained by thymic involution in the aged mice causing less T-cells to be 
produced and also the limited lifespan of naïve T-cells in the aged mice leading to 
loss of cell numbers120. The cell numbers and percentages of CD8+ and CD4+ T-cells 
were also found to be decreased significantly in the aged compared to the young 
mice as shown in Figure 5.1.  
 
 




Figure 5.1 Quantification of CD8 and CD4 in aged and young mice: 
Quantification of CD3+CD8+ and CD3+CD4+ T-cells of total lymphocytes. a) & b) 
represents the cell numbers and percentages in the first batch of mice while c) & d) 
represents the cell numbers and percentages in the second batch of mice prior to 
vaccination. Mean ± SEM percentages is shown. (* p<0.001 comparing aged and 
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5.2.2 Increased expression of senescence and exhaustion markers by T-cells in 
aged compared to young mice 
Percentages of PD-1 and KLRG-1 positive cells were analysed on the CD3+CD8+ T-
cell population. The percentage of cells expressing KLRG-1, a marker for 
senescence was significantly increased from 2.3% to 22.6% of the CD3+CD8+ T-
cells in the aged population compared to the young (p=0.0051). PD-1, an important 
marker for exhaustion is also expressed on more CD3+CD8+ T-cells in the aged 
C57BL/6 compared to the young. In the young, 1.2% of CD3+CD8+ T-cells was PD-
1 positive and increased to 5.7% in the aged (p=0.0184). Up-regulation of KLRG-1 
is consistent with previously published studies of aged mice (>18 months old)109, 111, 
113.  Representative plots were shown in Figure 5.2 a  and results were shown in 
Figure 5.2 b.  
Differences in expression of KLRG-1 and PD-1 in young and aged CD8 T-cells were 
confirmed in another cohort of young and aged C57BL/6 mice (Figure 5.3). In this 
cohort, the expression of LAG-3, a terminal differentiation marker associated with 
exhaustion and PD-L1, which is the ligand for PD-1, were also investigated. Aged 
mice showed significant up-regulation in the percentage of LAG-3 in CD8+ T-cells 
compared to young mice. LAG-3 was expressed by 16.9% of aged CD8+ T-cells 
compared to 9.8% of young CD8+ T-cells (p=0.0272). No expression of PD-L1 was 
found in both aged and young mice. Analysis of PD-1, KLRG-1, LAG-3 and PD-L1 
by CD4 T-cells was performed. Unfortunately, data was of poor quality, but 
suggestive of increased expression of these markers by CD4 T-cells from aged mice 
(data not shown) 
 




Figure 5.2 Expression of PD-1 and KLRG-1 in young and aged mice: a) A 
representative plot of PD-1 and KLRG-1 in young and aged mouse (Gating strategy 
for PD-1 and KLRG-1 was shown in Section 2.5.6) b) Percentages of PD-1 and 
KLRG-1 positive cells of total CD3+CD8+ T-cells in the aged (>18 months old) and 
young (6-8 weeks old) C57BL/6 mice. Mean ± SEM percentages shown. (n=5-20, 
Student T-test analysis) 
 
 




Figure 5.3 Expression of senescence and exhaustion markers in young and aged 
mice: A representative plot for a) PD-L1 and b) LAG-3 in aged C57Bl/6 mice 
(Gating strategy for both PD-L1 and LAG-3 was shown in materials and method 
section 2.5.6). c) Percentage of KLRG-1, PD-1, PD-L1 and LAG-3 in CD8+ T-cells 
of aged and young mice prior to vaccination. Mean ± SEM percentages is shown. 
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5.2.3 No differences in expression of co-stimulatory molecules by T-cells in 
young or aged mice 
T-cell receptor (TCR) activation together with co-stimulation via CD80 or CD86 
generates antigen specific CD8+ T-cell responses32. CD28 and CTLA-4 competes for 
CD80 and CD86 co-stimulation. CD28 is constitutively expressed by T-cells and 
activated by engagement with CD80 or CD86. CTLA-4 is an inhibitory receptor that 
is only expressed at the surface when a T-cell is activated. CTLA-4 upregulation 
typically last for about 48 hours although it has been reported that CTLA-4 is 
constitutively upregulated in mice with chronic viral infection suggesting association 
with an exhausted phenotype109. 
In this study, CD28 was found to be expressed by the majority of CD4 and CD8 T-
cells with no significant differences in young or aged mice (Figure 5.4). CTLA-4 
was expressed by a very small percentage of CD4 and CD8 T-cells with no 
indication of increased expansion in aged mice (Figure 5.4). 
 
 
Figure 5.4 Expression of CD28 and CTLA-4 in young and aged mice: 
Percentages of CD28, CTLA-4 and double positive T-cells in young and aged mice 
prior to vaccination. Gating strategy for CD28 and CTLA-4 was shown in materials 
and methods section 2.5.6. Mean ± SEM percentages shown. (n=10) 
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5.3 Vaccination design 
Young (6-8 weeks old) and aged (>18 months old) C57BL/6 mice were vaccinated 
on Days 1 and 11 followed by analysis and quantification of SIINFEKL specific 
CD8+ T-cells and the study of various T-cell subsets, on day 21.  
On day 22, an in vivo cytotoxic T-cell killing assay was initiated, with the analysis of 
SIINFEKL specific cytolytic activity on day 23 (Refer section 2.6.1 for in vivo CTL 
assay). Splenocytes obtained from the vaccinated mice were used to determine levels 
of cytokines produced by CD4+ T-cells by an in vitro peptide stimulation assay. 
Vaccination protocol is displayed in Figure 5.5. 
 
Figure 5.5 Vaccination design for young and aged mice: a) Vaccination protocol 
and experimental flow to analyse the effects of CASAC with/without IRX-2 in aged 
C57BL/6 mice compared to the young. b) Vaccination groups. c) Vaccination 
components. The concentration of the components are: 50µg/mouse of Poly I:C, 
25µg/mouse of CpG, 100µg/mouse of SIINFEKL and ISQ, 0.2% Tween 80, 4% 
Squalene, 100, 100µl/mouse of IRX-2, 100ng of mIFN-γ and 1:1 ratio of CFA to 
vaccine. IRX-2 was included into the mixture of the vaccine in the indicated groups. 
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5.4 Vaccination with CASAC generates functional SIINFEKL specific CD8 T-
cells in aged mice 
 
5.4.1 CASAC vaccination generates improved target cell killing in aged mice 
compared to CFA 
Previous published studies have shown that vaccination of older humans induces 
poorer responses120, 143-146. A good example of this phenomenon in a mouse model 
was vaccination of aged (>12 months old) and young (6-8 weeks old) Balb/C mice 
against attenuated Venezuelan equine encephalitis virus (VEE) replicon particle 
which showed protection in the young mice but not in the aged147. Comparison of in 
vivo CTL activity induced by vaccination of aged or young mice using standard CFA 
showed that although responses were significantly above background (unvaccinated 
mice) for all mice, responses were significantly weaker in aged mice (16% compared 
to 54% respectively, p=0.0051) (Figure 5.6 b). 
The use of CASAC in the presence or absence of IRX-2 resulted in substantially 
higher levels of in vivo CTL activity as indicated by 95-98% lysis of antigen positive 
target cells both in the young and aged. This was a significant increase compared to 
unvaccinated, CFA or IRX-2 alone vaccinations (p<0.005).  
IRX-2 alone did not induce in vivo CTL activity (Figure 5.6). In the young mice, 
IRX-2 alone generated 7% target cell lysis but was not significantly different 
compared to unvaccinated young mice (p=0.27). In the aged mice, IRX-2 
vaccination generated 33% target cell lysis but again was not statistically significant 
when compared to the unvaccinated aged mice (p=0.15). This was in agreement with 
the data shown in section 4.2.4 (Figure 4.7). 




Figure 5.6 In-vivo CTL activity was quantified on day 23 after 2 rounds of 
vaccination: Antigen positive target cells, loaded with SIINFEKL peptide were 
labelled with low concentration of CFSE (0.3µM) and antigen negative non-target 
cells were labelled with high concentration of CFSE (3.0µM). The mixture of target 
and non-target cells (1:1 ratio) were injected intravenously into the groups of mice 
and recovered after 18 hours. a) Representative plots for target cell lysed in each 
group. b) Percentage of target cells lysed in each group. Mean ± SEM percentage 








                                                                                                     CHAPTER 5 
182 
 
5.4.2 IRX-2 can enhance response to vaccination with CASAC in the aged mice 
In chapter 4.1.3, where young mice were used, it was shown that CASAC promotes 
maximal cytolytic activity of SIINFEKL specific CD8+ T-cells. The enhancing effect 
of adding IRX-2 was only revealed when CASAC was diluted to 100 fold.  
In experiments to compare immune responses in young and aged mice, one 
experiment using undiluted CASAC induced maximal cytolytic activity in all mice 
and therefore the impact of IRX-2 could not be seen (Figure 5.6). However in a 
second experiment (Figure 5.7), antigen specific cytolytic activity after vaccination 
of aged mice with CASAC was lower (75 ± 7%), and in this setting the significant 
enhancing effect of IRX-2 was observed (92 ± 3%) (p=0.0258). This was only seen 
in the aged mice. In the young mice, CASAC vaccination resulted in the in vivo lysis 
of 98 ± 0.7% of the antigen positive target cells both in the presence and absence of 
IRX-2 treatment. 
 
Figure 5.7 In-vivo CTL activity in vaccinated young and aged mice: The 
percentage of antigen positive target cell lysis in young and aged mice. In vivo CTL 
activity was quantified on day 23 after 2 rounds of vaccination. Antigen positive 
target cells, loaded with SIINFEKL peptide were labelled with low concentration of 
CFSE (0.3µM) and antigen negative non-target cells were labelled with high 
concentration of CFSE (3.0µM). The mixture of target and non-target cells (1:1 ratio) 
were injected intravenously into the groups of mice and recovered after 18 hours. 
Mean percentage ± SEM were shown. (n=3-10) (Student T-test analysis) 
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5.5 Quantification of SIINFEKL specific CD8+ T-cells. 
 
5.5.1 Numbers of SIINFEKL specific CD8 T-cells generated are higher in the 
young compared to the aged mice despite similar percentages 
The in vivo CTL data shown in section 5.4.1, indicate the improved cytolytic activity 
of SIINFEKL specific CD8+ T-cells in the aged mice vaccinated with CASAC 
compared to CFA. Therefore, we analysed the quantitative generation of SIINFEKL 
specific CD8+ T-cell responses. When comparing CASAC in the presence or absence 
of IRX-2 to CFA, there was much lower percentage of SIINFEKL specific CD8+ T-
cells in the CFA vaccinated mice, consistent with the induction of a lower level of in 
vivo CTL activity (Figure 5.8 a). Despite the similar percentage of SIINFEKL 
specific CD8+ T-cells generated in the young and the aged mice that were CFA 
vaccinated, the absolute numbers of these cells were lower in the aged (12 ± 5 
cells/µl blood) compared to in the young (27 ± 7 cells/µl blood), although this 
differences was not statistically significant (p=0.16) (Figure 5.8 b). 
No differences were found in the percentage of SIINFEKL specific CD8+ T-cells 
when comparing CASAC vaccination in the presence or absence of IRX-2 between 
the young and the aged (Figure 5.8 a). However, SIINFEKL specific CD8+ T-cells 
numbers were lower in the aged compared to the young (Figure 5.8 b). In the aged 
mice, CASAC in the presence or absence of IRX-2 generated between 140-200 
SIINFEKL specific CD8+ T-cells/µl blood. This was significantly lower when 
compared to in the young mice (between 620-790 SIINFEKL specific CD8+ T-
cells/µl blood, p<0.05) 
The generation of lower absolute numbers of SIINFEKL specific CD8+ T-cells in the 
aged mice could be attributed to the lower numbers of T-cells (or total lymphocytes) 
compared to the young mice. 




Figure 5.8 SIINFEKL specific CD8+ T-cell in young and aged mice: After 2 
rounds of vaccination, whole blood was collected on day 21 and percentage (a) and 
absolute numbers (b) of SIINFEKL specific CD8+ T-cells were quantified. Mean ± 
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5.5.2 IRX-2 enhanced the cytolytic activity of SIINFEKL specific CD8+ T-cells 
in CASAC vaccination, but without detectable changes in the percentages or 
absolute numbers of antigen specific T-cells 
In one experiment, vaccination of aged mice using CASAC combined with IRX-2 
was shown to significantly increase the in vivo lysis of antigen positive target cells 
(Figure 5.7). SIINFEKL specific CD8+ T-cells in these mice were quantified to 
assess any differences in the population generated in response to vaccination with 
CASAC or CASAC + IRX-2.  
No significant differences in the percentage or absolute numbers of SIINFEKL 
specific CD8+ T-cells generated by vaccination with CASAC and CASAC + IRX-2 
were found between the young and aged mice (Figure 5.9). The significant increase 
was in vivo lysis of antigen positive target cells that was seen by addition of IRX-2 
was therefore not due to quantitative differences in SIINFEKL specific CD8 T-cell 
populations. This is reflective of the results obtained in section 4.3.5 and 4.3.7  
where IRX-2 in combination with 100 fold diluted CASAC did not enhance the 
generation of SIINFEKL specific CD8+ T-cells but did increased the in vivo cytolytic 
activity of CD8+ T-cells generated by a suboptimal formulation of CASAC (100 fold 
dilution). 
 
Figure 5.9 Quantification of SIINFEKL specific CD8 T-cells in mice where 
IRX-2 enhances cytolytic activity: After 2 rounds of vaccination, whole blood was 
collected on day 21. Percentage (a) and absolute numbers (b) of SIINFEKL specific 
CD8+ T-cells were quantified. Mean ± SEM percentage and cell numbers shown. 
(n=3-10, Student T-test analysis)  




CFA vaccination generated SIINFEKL specific CD8+ T-cells in aged mice. These 
CD8 T-were less cytolytic in the aged compared to the young CFA vaccinated mice. 
This data suggests that aging of mice causes decline in the ability of the vaccination 
induced cytolytic activity of SIINFEKL specific CD8+ T-cells. The cytolytic activity 
of CASAC stimulated SIINFEKL specific CD8+ T-cells in the aged mice was higher 
than after CFA vaccination and similar to that generated in young mice. Therefore 
CASAC is a superior adjuvant for the induction of cellular immune responses in 
aged mice compared to CFA. When CASAC alone did not produce maximal 
cytolytic activity, addition of IRX-2 to the vaccination regimen generated SIINFEKL 
specific CD8+ T-cells with greater cytolytic activity. However this enhancement was 
not due to an increase in the absolute number or percentage of the SIINFEKL 
specific CD8+ T-cells. This led us to investigate the differences caused by CASAC 
and CASAC plus IRX-2 vaccination in the aged mice. We speculated that there 
might be differences in senescence and exhaustion markers by the SIINFEKL 
specific CD8+ T-cells generated by the different vaccination strategies in the two age 
groups. Young and aged mice after vaccination were also assessed for differences in 
T-cell activation levels, Tregs percentage and type of CD4 T-helper cell activity 
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5.6 Analyses of T-cell subsets in the aged and young mice following vaccination. 
 
5.6.1 Analyses of senescence and exhaustion markers in SIINFEKL specific 
CD8 T-cells 
 
Figure 5.10 Analysis of subset of SIINFEKL specific CD8 T-cells: After 2 rounds 
of vaccination, SIINFEKL specific CD8+ T-cells were analysed for senescence and 
exhaustion markers. a) Representative plots of SIINFEKL specific CD8+ T-cells for 
KLRG-1 and PD-1 from each group. b) Percentage of PD-1+ in SIINFEKL specific 
CD8+ T-cells. c) Percentage of KLRG-1+ in SIINFEKL specific CD8+ T-cells. Mean 
± SEM percentages shown. (n=3-5, Student T-test analysis showed no statistically 
significant data) 
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To determine if the SIINFEKL specific CD8+ T-cells generated show differences in 
the expression of senescence and exhaustion markers, the percentages of KLRG-1+ 
and PD-1+ cells following CASAC vaccination with or without IRX-2 treatment was 
assessed. Analysis at day 10 after the second round of vaccination showed the 
majority of SIINFEKL specific CD8+ T-cells expressed PD-1 and KLRG-1 in both 
young and aged mice and for all vaccine regimens. No significant differences were 
found. This result was similar to the results shown by Kao et al., where an acute 
LCMV infection generated antigen specific CD8 T-cells expresses high percentage 
PD-1 and KLRG-1. After an infection has been cleared, KLRG-1 and PD-1 act to 
regulate the T-cell responses generated111. Therefore high expression of PD-1 and 
KLRG-1 in SIINFEKL specific CD8+ T-cells does not necessarily indicate 
exhaustion or senescence because these studies were carried out 10 days after the 
second round of vaccination. If antigen specific CD8 T-cell responses had been 
tested after a resting period, more informative data might have been provided. 
Higher level of PD-1+ and KLRG-1+ SIINFEKL specific CD8+ T-cells in the aged 




5.6.2 Analysis of memory T-cells subsets generated in vaccinated mice 
In chapter 4, effector memory SIINFEKL specific CD8+ T-cells were shown to be 
predominantly generated with CASAC in the presence or absence of IRX-2. Effector 
memory CD8+ T-cells can have potent cytolytic activity while central memory CD8+ 
T-cells have the ability to renew and convert to effector memory T-cells57, 129. 
Percentage of effector and central memory CD8 T-cells in the SIINFEKL specific 
CD8+ T-cell population in young and aged mice were analysed (Figure 5.11). No 
significant differences were seen between both CASAC and CASAC plus IRX-2 
vaccination either in the young or the aged. The majority of SIINFEKL specific CD8 
T-cells were of the effector memory phenotype. This data is similar to results in 
chapter 4, where effector memory T-cells were predominantly generated in the 
CASAC or CASAC plus IRX-2 vaccination.  




Figure 5.11 Analysis of memory subsets: Percentage of effector memory in 
SIINFEKL specific CD8+ T-cells generated in a) cohort 1 and b) cohort 2 of the 
young and aged C57Bl/6 mice after 2 rounds of vaccinations. Percentage of central 
memory in SIINFEKL specific CD8+ T-cells generated in c) cohort 1 and d) cohort 2 
of the young and aged C57Bl/6 mice after 2 rounds of vaccination. Mean ± SEM of 
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5.6.3 Increased percentage of Tregs in aged mice correlated with lower CD8+ T-
cell in-vivo lytic activity induced by CASAC vaccination but was overcome by 
inclusion of IRX-2 
In one of the two experiments, vaccination of aged mice using CASAC plus IRX-2 
produced significantly increased in vivo lysis of antigen positive targets compared to 
CASAC alone (Figure 5.7). This effect was not due to qualitative differences in 
SIINFEKL specific CD8+ T-cells generated by CASAC alone compared to CASAC 
with IRX-2 (Figure 5.9). The possible involvement of Tregs was therefore examined.  
In the experiment where CASAC alone induced maximum lytic activity and hence 
no benefit from addition of IRX-2 was seen, no significant differences in percentage 
of Tregs present in unvaccinated young or aged mice and vaccination did not induce 
any significant changes (Figure 5.12 a). However, in the experiment where CASAC 
alone did not stimulate maximum SIINFEKL specific lysis in aged mice, the 
percentage of Tregs in the unvaccinated aged mice was significantly higher than the 
unvaccinated young mice (12.9 ± 0.8 % and 7.7 ± 0.3% respectively; p=0.0048) 
(Figure 5.12 b). The unvaccinated group is indicative of the percentages of Tregs 
present at the start of the vaccination regimen for the other groups. Higher 
frequencies in the aged mice at the beginning of this experiment may explain why 
maximum stimulation of lytic activity by CASAC vaccination could not be achieved. 
In this setting, inclusion of IRX-2 improved the killing potency significantly in the 
CASAC plus IRX-2 vaccinated aged mice. 
 




Figure 5.12 Percentages of Tregs after vaccination: Percentages of Tregs after the 
second vaccination in two independent experiments (a and b). Percentages of Tregs 
were analysed in the blood on day 21, after 2 rounds of vaccination. Mean ± SEM 
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5.6.4 Percentages of co-stimulatory receptors on T-cells showed no significant 
changes 24 hours post vaccination 
The percentages co-stimulatory receptor CD28 and the inhibitory receptor CTLA-4, 
24 hours after each rounds of vaccination was investigated. A previous study by 
Krummel et al., has established that CD28 is constitutively expressed on T-cells but 
CTLA-4 expression is induced on T-cells between 0 and 48 hours after stimulation 
of CD28 but down-regulated at 72 hours148. The data showed no significant 
differences either in the CD8 or CD4 T-cell expression of CD28 and CTLA-4 
(Figure 5.13).   
 
 
Figure 5.13 Analysis of CD28 and CTLA-4: Percentage of CD28+ on CD8 T-cells 
(a) and CD4 T-cells (b). Percentage of CTLA-4+ in CD8 T-cells (c) and CD4 T-cells 
(b) 24 hours after the second vaccination. 24 hours after the first round of 
vaccination were not shown as results were similar. Mean ± SEM percentages and 
geometric MFI shown. (n=3-5) 
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5.6.5 Predominant Th1 cytokine production by the CD4 T-cells after CASAC 
vaccination in both aged and young mice 
In the CASAC vaccination regimen, the class II presented ISQ peptide was used to 
stimulate CD4 T-cells that provide help to CD8 T-cells. In a model suggested by 
Wherry, (2011), inclusion of T-helper peptides  provides the necessary help in order 
to reduce exhaustion of CD8+ T-cell responses109.  Therefore, the type of help that 
was provided by the use of the T-helper peptide was investigated to further elucidate 
the nature of responses generated by CASAC vaccination and to see if addition of 
IRX-2 altered help for generation of improved SIINFEKL specific CD8+ T-cell 
responses. Splenocytes harvested for the in vivo CTL assay performed on day 23 
after 2 rounds of vaccination were used for evaluation of cytokine production by 
CD4 T-cells. Splenocytes were stimulated with PMA/Ionomycin (positive control), 
TEWT (negative control - an irrelevant T-helper peptide) or ISQ (T-helper peptide 
used for vaccination). CD4+ T-cells were then analysed for TNF-α, IL-4, IFN-γ and 








Figure 5.14 Gating strategy for cytokines analysis: a) Lymphocytes were gated 
and b) separated those cells which are non-DDAOSE (DDAOSE is a dye used for in 
vivo CTL assay) labelled. c) These cells were then gated for singlet cells before d) 
gating for CD4+ T-cells. CD4+ gated cells were then gated for e) TNF-α, f) IL-4, g) 
IFN-γ and h) IL-17 using irrelevant peptide stimulated cells to form the negative gate 
and confirmation of positively stained cells with PMA/Ionomycin stimulated cells. 
 
Analysis of IFN-γ producing CD4+ T-cells showed a significant increase in CASAC 
vaccinated mice both in the aged (1.2%) and the young (0.7%) cohorts compared to 
the unvaccinated aged (0.8%) and young mice (0.3%). CASAC plus IRX-2 
vaccination did not induce responses above those seen with CASAC alone (Figure 
5.15).  




Figure 5.15 Analysis of IFN-γ producing CD4 T-cells: a) Dot plots representative 
of IFN-γ produced by TEWT stimulated splenocytes (irrelevant peptide) and ISQ 
stimulated splenocytes (helper peptide used in vaccination) b) Percentage of  IFN-γ 
producing CD4+ T-cells between different vaccination regimen after stimulating 
splenocytes for 4 hours with 25µg/ml of ISQ peptide. Mean ± SEM percentages 
shown (n=3-7, *p<0.05 compared to unvaccinated groups) 
 
Analysis of Th2 cytokines showed no differences in the production of IL-4 between 
vaccinated and unvaccinated mice. When comparing the aged and the young mice, 
the background production of IL-4 (Figure 5.16) in the unvaccinated mice was found 
to be significantly increased in the aged population. Likewise, TNF-α producing 
CD4+ T-cells (Figure 5.16) were shown to be significantly increased in the 
unvaccinated aged mice compared to young mice. There were also significantly high 
percentages TNF-α producing CD4+ T-cells in the CASAC vaccinated young mice 
(0.4%) compared to unvaccinated mice (0.2%) (p<0.001). A similar trend was found 
in the aged population for CASAC (0.7%) and CASAC plus IRX-2 
(0.61%)vaccination when compared to the unvaccinated mice (0.1%) (p<0.05).  
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Figure 5.16 Analysis of IL-4 and TNF-α producing CD4 T-cells: a) Dot plots 
representative of IL-4 production by TEWT stimulated splenocytes (irrelevant 
peptide) and ISQ stimulated splenocytes (helper peptide used in vaccination). b) 
Percentage of IL-4 producing CD4+ T-cells between different vaccination regimens 
post 4 hours stimulation with ISQ peptide. c) Dot plots representative of TNF-α 
produced by TEWT stimulated splenocytes (irrelevant peptide) and ISQ stimulated 
splenocytes (helper peptide used in vaccination). d) Percentage of  TNF-α producing 
CD4+ T-cells between different vaccination regimens after stimulating splenocytes 
for 4 hours with 25µg/ml of ISQ peptide. Mean ± SEM percentages shown.  (n=3-7, 
*p<0.05, Student T-test analysis) 
 




No production of IL-17 by CD4 T-cells from any vaccination group was above the 
background levels seen in unvaccinated mice. This shows that CASAC vaccination 
does not stimulate help via IL-17 (Figure 5.17). 
 
Figure 5.17 Analysis of IL-17 producing CD4 T-cells: a) Dot plots representative 
of IL-17 produced by TEWT stimulated splenocytes (irrelevant peptide), ISQ 
stimulated splenocytes (helper peptide used in vaccination) with PMA/Ionomycin 
stimulated splenocytes induced as positive control to show the CD4 T-cell 
population contains IL-17 producing cells. b) Percentage of IL-17 producing CD4+ 
T-cells between different vaccination regimens after 4 hours stimulation with 
25µg/ml ISQ peptide. Mean ± SEM percentages shown. (n=3-7, Student T-test 












In one of the two experiments, vaccination of aged mice by CASAC plus IRX-2 was 
found to produce superior SIINFEKL specific CD8+ T-cell lytic activity compared to 
CASAC alone. The enhancing effect of IRX-2 in the one experiment was found to 
correlate with higher percentage of Tregs in this group of aged mice at the start of 
the experiment. Comparison of expression of senescence and exhaustion markers 
and the central/effector memory composition of SIINFEKL specific CD8+ T-cells 
generated by CASAC alone or CASAC plus IRX-2 in young or aged mice did not 
show any differences. Expression of co-stimulatory molecules by CD4 and CD8 T-
cells after vaccination was similar for all regimens and in both young and aged mice. 
Analysis of the type of CD4 T-cell help induced by CASAC showed a predominant 
Th1 phenotype (IFN-γ and TNF-α) with no differences detected by addition of IRX-























In this chapter, we investigated the potency of CASAC in the presence or absence of 
IRX-2 in generating CD8 T-cell responses in the aged mice.  
 
a) Expression of senescence and exhaustion markers in T-cell subsets of 
young and aged mice. 
In the data obtained, we demonstrated increased expression of senescence/exhaustion 
marker (KLRG-1, PD-1, PD-L1 and LAG-3) in the CD8+ T-cells isolated from the 
aged C57Bl/6 mice (>18 months old). Although previous studies have indicated the 
presences of a higher percentage of CTLA-4 expressing T-cells in the aged mice149, 
the data obtained in our study here showed no changes in the percentage of CTLA-4 
or CD28 expressing cells. A major difference in the aged mice was reduced number 
of lymphocytes, almost one half of the numbers in young mice. Previous studies 
have demonstrated the reduced ability of aged mice to respond to a range of 
vaccination strategies120, 143-145, 147. This was clearly reflected in the CFA 
vaccinations in the present study where cytolytic activity of the SIINFEKL specific 
CD8 T-cells generated was much reduced in the aged population.  
 
 
b) The ability of young and aged mice to generate functional antigen specific 
T-cell responses following vaccination with CASAC.  
CASAC was much more efficient than CFA in the vaccination mediated stimulation 
of antigen specific cytolytic activity in the aged mice. Use of CASAC as an adjuvant 
for vaccination mediated generation of SIINFEKL specific CD8+ T-cells improves 
the cytolytic activity of CD8 T-cells in the aged mice to a similar level to that 
achievable by CASAC vaccination in the young mice. However, when vaccination 
was conducted in aged mice with increased Tregs percentages, the in vivo cytolytic 
activity was reduced. In this setting, inclusion of IRX-2 enhanced the responses to 
CASAC vaccination resulting in increased cytolytic activity of the SIINFEKL 
specific CD8+ T-cells generated. This could be attributed to the ability of IRX-2 
protecting the stimulated T-cells from apoptosis as well as improving the production 
                                                                                                     CHAPTER 5 
200 
 
of inflammatory cytokines which are crucial for generation of good CD8 T-cell 
responses100, 101.  
 
c) Changes in expression of exhaustion, senescence and activation markers 
by T-cells and changes in Treg percentages after vaccination. 
Understanding of responses to CASAC and IRX-2 mediated peptide vaccination was 
improved by the analysis of expression of senescence and exhaustion markers by 
antigen specific T-cells, changes in Treg frequencies, expression of co-stimulatory 
receptors by T-cells and T helper subtypes. In the present study, we did not to see 
differences in senescence and exhaustion markers on the SIINFEKL specific CD8+ 
T-cells. This however, could possibly have been more informatively investigated if 
the aged mice were left to rest for a period of time after vaccination as shown by 
other groups examining responses to chronic LCMV infection150. There were also no 
differences seen in the co-stimulatory receptors, CD28 and CTLA-4. Although no 
significant differences were found between the vaccination regimen in terms of T 
helper cytokine production, we were able to elicit CASAC (in the presence or 
absence of IRX-2 promotes skewing towards Th1 as there were IFN-γ and TNF-α 
positive CD4 T-cells after splenocytes from vaccinated mice were stimulated with T-
helper peptide, ISQ. Wells. et al., (2008), showed similar findings where CASAC 





In conclusion, the data presented here shows that CASAC is a very potent adjuvant 
for peptide vaccinations to generate antigen specific CD8 T-cells with cytolytic 
activity in both aged and young mice compared to CFA. In cases where a weaker 
immunological response is generated with CASAC alone, the combination of 
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5.9 Future studies 
 
In the present studies, generation of antigen specific CD8 T-cells in aged mice was 
evaluated very close to the vaccination when the response is likely at its peak. It will 
be important to assess whether the potent T-cell responses generated by CASAC in 
aged mice are maintained. This would require re-challenge after a prolonged period 
of time after vaccination. Furthermore, the OVA peptide used in the present studies 
is a very immunogenic foreign antigen. It will be important to test efficacy of 
CASAC in vaccinations to self antigens such as WT-1 to see if tolerance to self 
antigens can be broken in aged mice. This could have major therapeutic implications 
for development of therapeutic vaccinations in the treatment of cancer which 
predominantly affects older people.  
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Peptide vaccination has the potential to play an important role in immune therapies 
especially in cancer and chronic infectious diseases. The use of specific peptide 
sequences from TAA found in cancer, and antigens derived from viruses, enables the 
immune system to be activated in a targeted manner, thus leading to generation of 
specific responses. These short sequences were also safer compared to full length 
antigen, as cross reactivity against off-target antigens could be reduced.  However, 
the use of short sequences of peptides reduces the immunogenicity of the antigen. 
Additional help in the form of adjuvants and T-helper peptides to boost the targeted 
responses is required for improved efficacy of peptide vaccination.  
The initial aim of this study was to evaluate and improve CASAC vaccination. In a 
previously published study by our colleagues (Wells et al., 2008), CASAC has been 
shown to generate strong CD8 T-cell responses against both foreign (OVA) and self-
antigens (e.g. TRP-2) after just 2 doses of vaccination. CASAC vaccination induced 
high percentages of antigen specific CD8 T-cells, produced high levels of IFN-γ 
producing CD8 T-cells and achieved greater than 90% in vivo lysis of antigen 
positive target cells. CASAC vaccination against TRP-2 also induced rejection of 
B16 tumours which were inoculated 3 days prior to vaccination52.  
Despite the significantly improved CD8 T-cell response in CASAC vaccinated mice, 
there were several other issues that need to be addressed prior to introducing it into 
the clinic. In the studies conducted, only 2 doses of vaccine were administered. 
However, peptide vaccination has often been shown to require more than 2 doses of 
vaccine. Solares et al. has shown that 4 rounds of HPV16 (E7 epitope) peptide 
vaccination was required to obtain clearance of human papillomavirus in 3 out of 7 
patients151. In another study conducted by Schwartzentruber et al., a complete cycle 
of 12 doses of gp100 peptide vaccination, in combination with IL-2, was 
administered to melanoma patients, for up to 3 cycles152. However, one of the 
implications of multiple rounds of vaccination is the activation of regulatory T-cells 
(Tregs). Tregs were previously shown to be induced with antigen persistence68, 
causing a variety of suppressive reactions against the cytolytic T-cells by inducing 
the production of factors such as IL-10 and TGF-β, as well as increased levels of 
CTLA-4 expression153. Therefore, in this study we investigated the effect of 
vaccination regimens involving the use of alternating T-helper peptides.  These 
studies have shown to suggest that the alternating T-helper peptide regimen was able 
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to generate significantly improved percentage and numbers of antigen specific CD8 
T-cells with improved in vivo cytolytic activity. Ten rounds of vaccinations with the 
alternating T-helper peptides  resulted in no expansion of Tregs.  The level of Tregs 
at the end of this vaccination regimen was lower than the level in the standard 
vaccination with either one or two T-helper peptides administered repeatedly (Figure 
3.18 and Figure 3.20 a). However, an additional experiment repeating the same 
vaccination protocol would be required to provide conclusive evidence of 
observations. Although an improved cytolytic activity was seen in our studies, 
further studies should be conducted in order to verify that the data obtained is 
reproducible. CASAC vaccination involving the use of T-helper peptides could 
benefit from these findings especially when vaccinating against tumour-associated 
antigens, which are in fact self-antigens. Other colleagues in the laboratory have 
found that CD8 T-cell responses mediated by CASAC vaccination against WT-1 can 
be improved with 4 doses of vaccine, compared to 2, as quantified by in vivo 
cytolytic activity (data yet to be published.  Wilms Tumour 1 (WT1) is a TAA that is 
up-regulated in acute myeloid leukaemia135 and a range of solid tumours, currently 
receiving attention for therapeutic vaccinations in leukaemia and solid cancers21, 154, 
155. 
Cancer immunoediting is an important issue to consider when designing vaccination 
regimens. Patients in the clinic would have lived with the cancer for a long period of 
time before the development of symptoms. Tumours evolve in the face of a 
proficient immune system in a number of steps, including immune surveillance-
mediated “elimination" through a phase of "equilibrium" in which immune 
surveillance succeeds in keeping the tumour growth in check, to "escape” from 
immune surveillance.  In the first 2 phases, symptoms of the disease would have 
been unnoticed but upon reaching the "escape" phase, patients present with tumours 
that are poorly immunogenic, possibly immunoevasive3, 156. Schreiber et al.  suggest 
that effective immunotherapies will require to increase both the quality and the 
quantity of immune effector cells and to break tumour induced immune tolerance. 
Therefore the use of CASAC which has already been shown to increase CD8 T-cell 
responses could be an effective strategy for therapeutic vaccination against cancer. In 
order to further enhance the efficacy of CASAC, we then studied the combination of 
CASAC and IRX-2. 
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IRX-2 is a combination of biological agents generated by PHA activation of human 
PBMC, under GMP conditions, by IRX Therapeutics96. Previous studies by Naylor 
et al., have shown that IRX-2 is capable of inducing T-cell responses against target 
antigens by the administration of IRX-2 in combination with other adjuvants such as 
IFA or KLH conjugated peptides98. Pre-treatment of activated T-cells with IRX-2 
was shown in another study to prevent apoptosis induced by tumour microvesicles. 
The activation of Fas/FasL pathway leads to apoptosis of the activated T-cells when 
tumour microvesicles (FasL +ve) were co-cultured with activated T-cells (Fas +ve) 
in the absence of IRX-2100. The protection conferred by IRX-2 has been shown to act 
directly by down-regulation of Fas in the activated T-cells101. This is crucial 
especially for vaccinations against cancer cells, which have evolved to escape 
immune surveillance as previously discussed. Melanoma and HNSCC cells have 
been shown to upregulate FasL102 and IRX-2 is currently being studied to see if this 
"escape" mechanism could be overcome by IRX-2 therapy96, 157, 158.  
In terms of vaccination, we hypothesized that the inclusion of IRX-2 in CASAC 
vaccination could improve the CD8 T-cell responses.  For instance on the activated 
T-cells Fas could be down-regulated, leading to longer lasting CD8 responses. 
Previous studies by Schilling et al. have shown that IRX-2 can promote the 
expansion of effector T-cells in favour of Tregs, thus leading to an improved potency 
of CD8 responses. In our studies, the combination of CASAC and IRX-2 vaccination 
in young C57Bl/6 did show a marginal improvement in the CD8 T-cell responses. 
The in vivo cytolytic activity generated was near maximal in the CASAC vaccination 
alone, thus masking an increase in the cytolytic potency. In order to further 
investigate the benefits of IRX-2, CD8 responses of a 100 fold diluted CASAC in the 
presence or absence of IRX-2 were compared. The data obtained suggests that 
despite a similar level of antigen specific CD8 T-cells, IRX-2 inclusion significantly 
increased the in vivo cytolytic activity of antigen specific CD8 T-cells. 
Immune senescence and exhaustion play important roles in determining the efficacy 
of peptide vaccination. The aging process causes involution of the thymus, thus 
decreasing lymphocyte output139, leading to a decline in T-cell repertoire, reduced 
responsiveness towards newly encountered antigen and impaired generation of 
memory T-cells107. Constant exposure to an antigen (TAA or antigen from chronic 
infectious diseases) causes exhaustion, loss of cytolytic activity, proliferation 
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potential and finally apoptosis of the antigen specific T cell clones109. These 
conditions mirror the immune status of most patients in the clinic who are suffering 
from cancer and chronic infectious diseases (e.g. chronic HBV or HIV infection). 
Even with respect to sporadic infections such as influenza, immunosenescence has 
been closely related to the increased infection associated deaths in the older 
individuals compared to young159. 
With tumour and age associated immune senescence in mind we were interested in 
investigating the effects of vaccination in aged (>18 months old) compared to young 
C57BL/6 mice (6-8 weeks old). Preliminary investigation showed that there were 
significantly increased percentages of KLRG-1 and PD-1 expressing T cells in the 
aged mice, indicating the increased presence of immune senescent and exhausted T 
cells in these compared to young mice. We also found reduced numbers of 
lymphocytes in the aged mice compared to young mice.  This too has been shown to 
be the case by other investigators139. We then investigated the efficacy of OVA 
vaccination with the CFA adjuvant. The results indicated poorer in vivo cytolytic 
activity in the aged mice compared to the young mice. Vaccination against OVA 
with CASAC ± IRX-2 generated high levels of in vivo cytolytic activity (>90% lysis 
of antigen positive cells) in both the young and the aged mice, suggesting that 
CASAC is a superior adjuvant compared to CFA for these applications (Figure 5.6). 
However, in another batch of aged mice, CASAC vaccination did not produce the 
previously detected maximum in vivo cytolytic activity. The inclusion of IRX-2 in 
this second CASAC vaccination of the aged mice produced a significant increase in 
the in vivo cytolytic activity, suggesting an enhancement by IRX-2 (Figure 5.7). 
Upon investigation, we found that the percentage of Tregs in this batch of aged mice 
was significantly increased compared to the young mice (Figure 5.12 b). In the batch 
of aged mice that responded equally well to CASAC and CASAC plus IRX-2, the 
percentage of Tregs in the aged mice were not significantly different from the 
percentages found in the young mice (Figure 5.12 a). Therefore, we conclude that the 
increase in Tregs reduces the efficiency of in vivo cytolytic activity mediated by 
CASAC vaccination. This however is rescued by the inclusion of IRX-2 in the 
vaccination. IRX-2 has the potential to enhance in vivo cytolytic responses in peptide 
vaccination without significantly changing the number or ratio of antigen specific T-
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cells. This suggests that IRX-2 has the potential of enhancing the cytolytic activity of 
CD8 T-cells generated in response to vaccination. 
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In summary the data presented in this thesis has shown that peptide vaccination 
could be enhanced by use of alternating T-helper peptides in repeated rounds of 
vaccination, in order to avoid vaccination induced expansion of regulatory T cells. 
This however would require a repeat of the experiment with similar conditions. 
Groups of unvaccinated, SIINFEKL only, SIINFEKL plus ISQ, SIINFEKL plus ISQ 
plus TEWT and SIINFEKL plus alternating T-helper peptide vaccination should be 
included in the vaccination. Based on the data obtained in previous experiments for 
the in vivo CTL lysis assay (this assay showed the clearest outcome to the efficacy of 
alternating T-helper peptide vaccination),  a power calculation to obtain sample size 
was conducted using the mean value and standard deviation that has been 
recalculated for the alternating T-helper peptide vaccination group (83 ± 8%). Power 
and Sample size calculator (http://www.statisticalsolutions.net/pss_calc.php), a free 
sample size calculator generated a required sample size of 8 mice per group (with a 
power of 0.8 and a p<0.05). Previous studies and our results show that CASAC 
vaccination generates strong CD8 T-cell responses. However, in conditions where 
CASAC was unable to induce maximal responses, the inclusion of IRX-2 could 
enhance these effects. 
Based on the studies conducted, one could suggest additional studies to enable better 
understanding of vaccination induced responses to chronically experienced antigens.  
Such studies would include: 
1. Breaking of tolerance caused by cancer and chronic infectious diseases: Cancer 
cells have been shown to be able to induce tumour tolerance by what Schreiber and 
others have called “cancer immunoediting”.  It would be interesting to investigate 
the possibility of vaccinating against self-antigens such as WT-1.  Such studies 
would seek to determine whether inclusion of IRX-2 in CASAC based vaccination 
can promote easier breakdown of tolerance to tumour-associated self-antigens. 
Vaccinating against antigens from infectious agents such as hepatitis B virus could 
also be conducted, for instance in transgenic animals that constitutively express viral 
antigens, or possibly even are chronic carriers of the infection.  Such studies could 
have great implications for peptide vaccination.   Based on the CD8 T-cell responses 
generated in the present study, it would be expected that CASAC, either in the 
presence or absence of IRX-2, would be able to break tolerance to such chronically 
experienced antigens. Vaccination against tumour stem cells such as leukemic stem 
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cells would also be an area very much worth pursuing. This is because tumour stem 
cells are much more resistant to traditional therapies, such as chemotherapy, and thus 
immune therapies like vaccination could possibly play an important role in tumour 
clearance160, 161. 
2. Vaccination against models of spontaneous disease formation: In experimental 
models of tumour or infections in mice, there is usually insufficient interactions with 
the immune system to allow an adequate representation of the conditions prevailing 
in the normal pathogenesis of cancer or the establishment of chronic infections162. 
However, the use of animal models of spontaneous disease formation, for instance 
aflatoxin induced development of hepatocellular carcinoma in a hepatitis B virus 
transgenic mouse model (HBV-Tg)163 would allow for the disease to progress along 
a more natural course of development, including prolonged interactions between the 
tumour and the immune system, prior to vaccination.  
These “more natural” models of disease development and progression, allowing the 
establishment of chronic interactions between the immune system and the disease 
may provide better representation of the normal pathogenesis of the disease.  These 
models are therefore likely to be better informative of the potential clinical efficacy 
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